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Abbreviations 
 
ADAM  a disintegrin and metalloprotease 
AIP  autoimmune pancreatitis 
APC  antigen presenting cell 
APRIL  a proliferation-inducing ligand  
BAFF   B-cell activating factor 
CNS  central nervous system 
CRD   cystein-rich domain 
DR3   death receptor 3 
EAE  experimental autoimmune encephalomyelitis 
EBV  Epstein-Barr-Virus 
ECM   extracellular matrix 
EDA   ectodermal dysplasin  
EDAR  ectodermal dysplasin receptor  
FACS   fluorescence-activated cell sorting  
FADD  Fas associated death domain  
FcγR   Fc γ receptor  
FDC   follicular dendritic cell 
GC  germinal center 
GFAP  glial fibrillary acidic protein 
HEV   high endothelial venule 
HVEM herpes virus entry mediator 
iBALT inducible bronchus-associated lymphoid tissue 
ICAM-1 intracellular adhesion molecule 1 
IDDM  diabetes mellitus type 1 
IKK  inhibitor of κB kinase  
IKKα   inhibitor of κB kinase-α 
IκB  inhibitor of κB  
JNK   Jun N-terminal kinase  
Lck   leukocyte-specific protein tyrosine kinase 
LIGHT  homologous to lymphotoxins, exhibits inducible expression,  
and competes with HSV glycoprotein D for HVEM on T cells  
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LT   lymphotoxin  
LTβR   lymphotoxin beta-receptor 
LF  lactoferrin 
MadCAM-1 mucosal addressin cell adhesion molecule 1 
MBP   myelin basic protein 
MHC  major histocompatibility complex 
mLN   mesenteric lymph node 
MOG  myelin oligodendrocyte glycoprotein 
MS  multiple sclerosis  
MZ  marginal zone 
NALT  nasal associated lymphoid tissue 
NF-κB  nuclear factor-κB  
NIK   nuclear factor-κB inducing kinase 
NK  natural killer cells 
PLP  myelin proteolipid protein 
PP  Peyer’s patch 
PSTI   pancreatic secretory trypsin inhibitor 
RA   rheumatoid arthritis 
RANKL  receptor activator of nuclear factor-κB ligand  
RF  rheumatic factor 
SLE  systemic lupus erythematosus 
SLO  secondary lymphoid organ 
sLTβR-Ig  soluble LTβR immunoglobulin fusion protein 
THD  TNF homology domain 
TIM   TRAF interacting motif 
TLO  tertiary lymphoid organ  
TNF   tumor necrosis factor  
TNFR   tumor necrosis factor receptor  
TNFSF TNF superfamily 
TRADD  TNFR associated death domain  
TRAF   TNFR associated factors 
TWEAK  TNF-like weak inducer of apoptosis  
VCAM-1  vascular cellular adhesion molecule-1  
VEGI   vascular endothelial cell-growth inhibitor 
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Summary 
 
 
Autoimmune diseases are the consequence of an inappropriate immune response directed 
against self-antigens and as such they can affect most organs of the body including liver, 
heart, the endocrine system, the musculoskeletal apparatus and the central nervous system 
(CNS). They commonly start off at a young age and last throughout life, often resulting in 
severe disability. Collectively, autoimmune diseases affect up to 6% of the population and 
represent the 3rd greatest health issue after heart diseases and cancer. Therefore, much 
research is directed towards understanding the mechanisms associated with the development 
and pathology of autoimmune diseases. Aetiologically relevant preclinical animal models, 
preferably with spontaneous disease initiation are indispensable for studying disease 
pathogenesis and discovering new treatment strategies for human autoimmune diseases. 
The inflammatory cytokines LTα and LTβ  (LT) have been implicated in the context of a 
variety of autoimmune diseases (e.g. rheumatoid arthritis, Sjögren’s syndrome, multiple 
sclerosis). The mechanisms attributed to LT during autoimmune diseases stem from their 
ability to trigger the development of secondary lymphoid organs, their involvement in the 
formation of ectopic lymphoid structures and their capability to control aspects of the 
organization of lymphoid microenvironments. During the past 20 years several transgenic 
mouse models have been generated, some of them by our research group (AlbLTαβ, 
lckLTαβ). However, none of these models so far were shown to develop an organ specific or 
a systemic autoimmune disease.  
In my thesis I have analyzed serum and pancreatic tissue samples from human autoimmune 
pancreatitis (AIP) patients and I concluded that patients suffering of AIP display high 
expression of LT and downstream targets such as homeostatic chemokines. Interestingly, 
mice with acinar-specific LT expression Tg(Ela1-LTa,b) that I describe in my thesis, display 
spontaneous development of autoimmunity, reminiscent of AIP, including anti-nuclear 
antibodies (ANA), auto-antibodies against pancreatic self-antigens and renal immune-
complexes, causally linking pancreatic LTαβ expression with AIP. Furthermore, in this novel 
mouse model I assessed the contribution of monocyte and lymphocyte cell populations 
towards inflammation and autoimmunity. Absence of lymphocytes (Ela-1LTab/Rag1-/-) 
abrogated AIP, while lack of pro-inflammatory monocytes (Ela-1LTab/Ccr2-/-) decreased 
early pancreatic tissue damage but failed to prevent AIP. Current treatment options for human 
AIP are limited, mostly administering corticosteroids, which frequently results in relapses. 
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The Tg(Ela1-LTa,b) mouse model can also serve as a useful tool to test potential new 
therapies: I compared prednisolone treatment with inhibitors of the CD40L-CD40 or the 
LTα1β2-LTβR-signalling pathway in Tg(Ela1-LTa,b) mice. Corticosteroid treatment reduced 
pancreatitis but did not hamper auto-antibody production. Inhibition of the CD40-CD40L 
pathway failed to reduce the extent of AIP in Tg mice, although a decrease in serum IgG 
levels confirmed treatment efficacy. In contrast, inhibition of LTβR-signalling dampened 
auto-antibody production, chemokine expression, renal immune-complex deposition and fully 
abrogated AIP. Thus, suppression of LTβR-signalling might become a viable alternative or 
combinatorial treatment option for AIP.     
A controversial role is attributed to LT in autoimmune reactions and demyelination in the 
CNS. To elucidate the role of astrocyte derived LT induced cytokine production and tissue 
destruction in CNS autoimmunity, I have generated a transgenic mouse model with targeted 
overexpression of Ltα and β on astrocytes under the control of the glial fibrillary acid protein 
promoter (GFAP-Lta,Ltb). Transgenic mice developed early onset of astrogliosis concomitant 
with increased expression of lymphoid chemokines and adhesion molecules. EAE was 
induced in age matched transgenic and wild type animals to assess the contribution of LT to 
EAE pathogenesis. Tg(GFAP-Lta,Ltb) mice showed a significantly earlier disease onset, more 
severe disease manifestation and relapse compared to age matched wild type littermates. As a 
next step, I intercrossed Tg(GFAP-Lta,Ltb) with mice bearing myelin oligodendrocyte 
glycoprotein (MOG)-specific TCR transgenic T-cells (2D2/GFAP-LT). These double 
transgenic mice developed spontaneous inflammatory demyelinating disease - mainly 
localized in the spinal cord and cerebellum - with a 100% incidence. The inflammatory 
infiltrates in the spinal cord resembled ectopic lymphoid follicles, mainly consisting of CD4+ 
T-cells and B220+ B-cells. We hypothesize that the spontaneous disease development resulted 
from the attraction of myelin autoimmune T-cells via the inflammatory milieu in the CNS 
created by LT overexpressing astrocytes. This is the first study to our knowledge that 
describes the role of local CNS immunity in attracting myelin specific T-cells, facilitating to 
study the initiation and pathogenesis of a complex spontaneous demyelinating autoimmune 
disease.    
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Zusammenfassung  
 
Autoimmunerkrankungen sind die Folge fehlgeleiteter Immunantworten gegenüber 
Eiweissmolekülen des eigenen Körpers (sogenannte Selbstantigenen) und können als solche 
nahezu alle Körperorgane unter anderem Leber, Herz, endokrine System, Muskelapparat und 
das zentrale Nervensystem (ZNS) betreffen. Gewöhnlich treten sie bereits im jungen 
Lebensalter auf und halten ein Leben lang vor, was häufig zu schweren körperlichen 
Einschränkungen führt. Autoimmunerkrankungen betreffen bis zu 6% der Bevölkerung und 
bilden nach Herz- und Krebs-erkrankungen das drittgrößte Gesundheitsproblem. Aus diesem 
Grund werden große Bemühungen in der Forschung unternommen, um die zugrunde 
liegenden Mechanismen der Entstehung und Pathologie von Autoimmunerkrankungen zu 
verstehen. Relevante prä-klinische Tiermodelle, bevorzugt mit spontaner 
Krankheitsentstehung, sind unerlässlich zur Untersuchung der Krankheitsverläufe und zur 
Entwicklung neuer Therapieansätze für humane Autoimmunerkrankungen.  
Die Entzündungsmediatoren LTα und LTβ konnten in Verbindung mit einer Vielzahl 
verschiedenster Autoimmunerkrankungen gebracht werden u.a. Rheumatoide Arthritis, 
Sjörgren’s Syndrom und Multipler Sklerose. Die Rolle von Lymphotoxinen in 
Autoimmunerkrankungen beruht auf ihrer Eigenschaft die Entwicklung sekundärer 
lymphoider Organe zu induzieren, der Mitwirkung an der Enstehung ektoper lymphoider 
Strukturen und ihrer Fähigkeit verschiedene Aspekte der Organisation des lymphoiden 
Microenvironment zu beeinflussen. Innerhalb der letzten 20 Jahre wurden verschiedenste 
transgene Mausmodelle entwickelt, einige davon durch unsere Arbeitsgruppe. Jedoch zeigt 
keines der bisher generierten Modelle Anzeichen einer Organ-spezifischen oder einer 
systemischen Autoimmunerkrankung. 
Im Rahmen meiner Doktorarbeit habe ich Serumproben und Gewebematerial von Patienten 
mit Autoimmunpankreatitis (AIP) untersucht und feststellen können, dass Patienten, die an 
AIP leiden, eine hohe Expression von LT and seinen Zielgenen wie zum Beispiel 
homöostatische Chemokine aufweisen. Mäuse mit einer Azinar-spezifischen LT Expression 
(Ela1-LTa,b), welche ich im Rahmen meiner Doktorarbeit beschreibe, zeigten eine spontane 
Autoimmunerkrankung mit Merkmalen von AIP wie anti-nukleäre Antikörper, 
Autoantikörper gegen Pankreas spezifische Selbstantigene und renale Immunkomplexe. Dies 
deutet auf einen kausalen Zusammenhang zwischen der pankreatischen LT Expression und 
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der Enstehung von AIP hin. Zusätzlich untersuchte ich mit Hilfe dieses neuen Mausmodels 
die Rolle von Monozyten und Lymphozyten in Entzündung und Autoimmunität. Das Fehlen 
von Lymphozyten verhinderte die Enstehung einer AIP vollständig während in der 
Abwesenheit pro-inflammatorischer Monozyten nur eine Abschwächung der frühen 
pankreatischen Gewebeschädigung erfolgte jedoch keine Verhinderung der AIP möglich war. 
Derzeit sind die Behandlungsmethoden für humane AIP Patienten stark begrenzt und in den 
meisten Fällen erfolgt eine Behandlung mit Corticosteroiden, welche häufig zu Rückfällen 
führt. Dieses Mausmodel kann als Hilfsmittel zur Entwicklung neuer Therapieformen dienen: 
Zu diesem Zweck habe ich im Tg(Ela1-LTa,b) Mausmodel die Behandlung mit Prednisolon, 
mit Inhibitoren des CD40L-CD40 sowie des LTα1β2-LTβR Signalweges verglichen. Eine 
Behandlung mit Corticosteroiden reduzierte die Entzündung, nicht jedoch die Produktion von 
Autoantikörpern. Die Inhibition des CD40L-CD40 Signalweges konnte zwar nicht den Grad 
der Gewebeentzündung senken, jedoch konnte über die Absenkung des Serum IgG Spiegels 
die Effektivität der Behandlung nachgewiesen werden. Im Gegensatz dazu resultierte die 
Inhibition des LTβR Signalweges in einer Verringerung der Autoantikörper und 
Chemokinproduktion, der Ablagerung renaler Immunkomplexe und führte zu einer 
vollständigen Unterdrückung der Gewebeentzündung. Die Inhibition des LTβR könnte daher 
eine neue Alternative oder Ergänzung in der Behandlung von AIP darstellen. 
Die Rolle von Lymphotoxinen in Autoimmunprozessen und Demyelinierung in ZNS wird 
kontrovers diskutiert. Um die Rolle Lymphotoxin induziert Zytokinproduktion und 
Gewebschädigung in Astrozyten in Autoimmunerkrankungen des zentralen Nervensystems 
(ZNS) genauer zu untersuchen, habe ich ein transgenes Mausmodel mit gewebespezifischer 
Überexpression von LTα und β in Astrozyten unter der Kontrolle des glial fibrillary acid 
protein (GFAP) Promotors generiert. Tg(GFAP-LTa,LTb) Mäuse entwickelten eine frühe 
Astrogliose einhergehend mit der Expression lymphoider Chemokine und verschiedener 
Adhäsionsmolekülen. Um die Rolle von LT in der Pathogenese von EAE zu untersuchen 
wurde EAE in transgenen und Wildtyptieren gleichen Alters induziert. Im Vergleich zu den 
gleichaltrigen Kontrolltieren zeigten die transgenen Tiere ein signifikant früheres Auftreten 
der Erkrankung, eine schwerer Ausprägung der Erkrankung und Rückfälle nach Ausheilung 
der Erkrankung. Im nächsten Schritt wurden die transgenen Tiere mit Mäusen verpaart, 
welche einen transgenen T-Zell Rezeptor tragen, der spezifisch für das myelin-
oligodendrocyte Glykoprotein ist. In doppelt transgenen Tieren entwickelte sich mit einer 
Inzidenz von 100% eine spontane, entzündliche, demyelinisierende Erkrankung, welche sich 
hauptsächlich auf Rückenmark und Kleinhirn begrenzte. Die entzündlichen Infiltrate im 
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Rückenmark ähneln ektopen Lymphfollikeln und bestehen hauptsächlich aus CD4+ T-Zellen 
und B220+ B-Zellen. Wir vermuten, dass die spontane Erkrankung auf die Rekrutierung der 
autoreaktiven T-Zellen in das ZNS aufgrund des inflammatorischen Milieus zurückgeht, 
welches durch die Überexpression von LT in Astrozyten verursacht wird. Dies ist nach 
unserem Wissen die erste Studie welche eine Rolle des lokalen ZNS Immunsystems in der 
Rekrutierung Myelin-spezifischer T-Zellen beschreibt und somit die Analyse der Entstehung 
und Pathogenese einer komplexen demyelinisierenden Autoimmunerkrankung ermöglicht. 
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1. Introduction 
 
1.1 Autoimmunity 
 
Autoimmunity is the failure of an organism to recognize its own proteins as self, which can 
consequently trigger an immune response against the own cells and tissues. Any disease that 
results from such an aberrant immune response is termed an autoimmune disease. 
Autoimmune diseases affect approximately 6% of the population and therefore they are the 
third largest disease burden after heart disease and cancer (Siatskas et al., 2006). Autoimmune 
diseases can affect most organs of the body including liver, heart, endocrine system, the 
musculoskeletal apparatus and the central nervous system (CNS). Autoimmune diseases can 
be broadly divided into organ-specific and systemic autoimmune diseases. Systemic 
autoimmune diseases include diseases such as systemic lupus erythematosus (SLE), 
scleroderma and polymyositis. The feature of these diseases is that the targeted antigens are 
located throughout the body. As the name implies, organ-specific autoimmune diseases 
involve specific organs of the body in which the target auto-antigen is found. Prominent 
examples of organ-specific autoimmune diseases include type 1 diabetes (insulin secreting 
cells of the pancreas), thyroiditis (thyroid), multiple sclerosis (myelin sheath of neurons), and 
as a recently accepted entity autoimmune pancreatitis (exocrine pancreas). They commonly 
start at a young age and then last throughout life, often resulting in severe disability (Pollinger 
et al., 2009). 
Autoimmune diseases may arise by different mechanisms; genetic factors are important, but 
are not the only explanation for development of an autoimmune disorder. Its risk is also 
affected by environmental factors and by infections as well (Doan, Melwold et al., 
Immunology). The factors triggering the onset and modulating the course of the autoimmune 
diseases have remained obscure, a deficit of knowledge which sets limits to the design of 
specific and efficient therapies (Pollinger et al., 2009).  Cytokines play a pivotal role in the 
pathogenesis of autoimmune diseases. The precise triggers for the breakdown of self-
tolerance and the subsequent events leading to the induction of pathogenic autoimmune 
responses remain to be defined for most of the naturally occurring autoimmune diseases. 
Studies conducted in experimental models of human autoimmune diseases and observations in 
patients have revealed a general scheme in which pro-inflammatory cytokines contribute to 
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the initiation and propagation of autoimmune inflammation, whereas anti-inflammatory 
cytokines facilitate the regression of inflammation and recovery from acute phase of the 
disease (Moudgil and Choubey, 2011). Until recently, the pathogenesis of autoimmune 
diseases was examined and analysed largely in the context of the T helper 1 and 2 (Th1/Th2) 
cytokine balance, with the two T-cell subsets mutually cross-regulating each other (Abbas et 
al., 1996) (Mosmann et al., 1986) (Coffman, 2006). Interestingly, over the past decade, the 
interleukin (IL)-17/IL-23 axis has rapidly emerged as the new paradigm, attributing an 
important role for IL-17 in the development of various autoimmune diseases such as RA 
(Lubberts et al., 2001)  and MS (Cua et al., 2003) (Komiyama et al., 2006).  
To date, however, it is still elusive how auto-antigens drive the pathogenesis of autoimmune 
disease, particularly how they interact with the triggers that initiate inflammation and hence, 
the clinical onset of disease. Animal models are indispensable for studying disease 
pathogenesis and discovering new treatments for human organ-specific autoimmune diseases, 
and developing better diagnostic tools (Wekerle et al., 2012). Although animal models make 
it possible to identify and manipulate certain autoimmune pathogenic mechanisms, they are 
limited by other factors.  
First, the mode of disease initiation is usually highly artificial. This is particularly true for the 
models of MS and RA, which are usually induced by active immunization with an auto-
antigen emulsified in aggressive immune adjuvants (Billiau and Matthys, 2001) or by transfer 
of in vitro–activated autoimmune lymphocytes (Ben-Nun et al., 1981). Second, the treatment 
in these therapy studies is often administered very early in the course of the induced 
autoimmune disease and is even sometimes given as a prophylactic, in which case it precedes 
the onset of clinical disease. In contrast, any therapy given to patients with autoimmune 
disorders is usually administered to counter a mature, often chronic disease (Wekerle et al., 
2012). In my thesis I will describe two novel transgenic mouse models, to elucidate the role of 
the pro-inflammatory cytokines, Lymphotoxin (LTα and LTβ) in the course of autoimmune 
pancreatitis (AIP) and an autoimmune disease of the central nervous system (CNS). 
 
1.2 The Lymphotoxin signalling 
 
1.2.1. The TNF superfamily – receptor and ligand interactions 
 
The Lymphotoxin β receptor (LTβR) signalling axis belongs to a complex gene family of 
cytokines and their corresponding receptors, which is called the tumor necrosis factor (TNF) –
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superfamily (TNFSF). At present, TNFSF is composed of 19 different ligands, including, for 
example, TRAIL, RANKL, BAFF, and CD40. The ligands mediate their cellular response 
through 29 type I transmembrane receptors, which contain an extracellular cysteine-rich 
domain  and in some cases (for example, TNFR1, TRAIL R1, TRAIL R2, Fas) a death 
domain (Figure 1) (Schneider et al., 2004) (Aggarwal, 2003). Activation of the TNFR 
members via their ligands affects cell proliferation, survival, differentiation and apoptosis of 
responding cells. 
 
Figure 1. Interactions between TNF superfamily ligands and their known receptors. Ligands and receptors 
are shown in a diagrammatic form. Many ligands bind more than one receptor indicated with arrows. Ligands for 
RELT, TROY and DR6 have not been discovered yet. A common motif of all TNF-superfamily receptors is the 
cysteine-rich domain in the extracellular portion (blue circles). Red boxes in the cytoplasmic part of the receptors 
indicate the presence of a death domain. (Adapted from Aggarwal et al., 2003)  
 
                                                                                                                        INTRODUCTION           
15 
 
Except for lymphotoxin alpha (LTα) and vascular endothelial cell-growth inhibitor (VEGI), 
which are secreted, all TNFSF ligands are type II transmembrane proteins (intracellular N-
terminus) which are biologically active as self-assembling, non-covalently bound trimers  
(Hehlgans and Pfeffer, 2005). In the membrane bound form they can initiate signalling by 
activating cell surface receptors on adjacent cells (juxtacrine signalling) or on the producing 
cell (autocrine signalling). The soluble ligands consequently can act also on distant cells. The 
C-terminal extracellular domain contains a TNF homology domain (THD).  This trimeric 
domain is responsible for receptor binding and its amino acid homology between family 
members is 20-30%. The THD is present in the form of an antiparallel β-sheet that allows the 
ligands to assemble trimeric tertiary structure with three exposed receptor-binding sites  
(Bodmer et al., 2002) (Aggarwal, 2003). Although these ligands are generally synthesized as 
membrane bound proteins, soluble forms can be released from the cell surface by limited 
proteolysis. Distinct proteases are involved in this process, depending on the ligand: TNF and 
receptor activator of nuclear factor-κB ligand (RANKL) are cleaved by members of the a 
disintegrin and metalloprotease (ADAM) family of metalloproteases (Black et al., 1997) 
(Lum et al., 1999); matrilysin acts on Fas ligand (FasL) (Powell et al., 1999); and B-cell 
activating factor (BAFF), ectodermal dysplasin (EDA), TNF-like weak inducer of apoptosis 
(TWEAK) and a proliferation-inducing ligand (APRIL) is cleaved by proteases of the furin 
family (Schneider et al., 2004).  
Most of the TNF receptor family members are type I transmembrane proteins. Their hallmark 
is a cystein-rich domain (CRD) in the extracellular portion. The CRDs are pseudo-repeats 
typically containing six cysteine residues engaged in the formation of three disulfide bonds  
(Bodmer et al., 2002).  The number of CRDs can range from one partial motif (BAFF-
receptor) up to 6 found in CD30 (Aggarwal, 2003). Based on their intracellular sequences the 
members of the TNFR superfamily can be classified into three major groups.  
1. The first group, including FAS (CD95), TNFRI, TNF related apoptosis inducing ligand 
receptor 1 (TRAIL-R1) (DR4), TRAIL-R2 (DR5), TRAIL-R4 (DcR2), TNF-like receptor 
apoptosis mediating protein (TRAMP) (DR3), Ectodysplasin (EDA) receptor (EDAR) 
contains so called death domains (DD) in their cytoplasmic domains.  
Binding of TNF superfamily ligands to their DD containing receptors mediate signalling 
through intracellular death domain containing adaptors, such as FAS-associated death domain 
(FADD) and TNFR associated death domain (TRADD). These molecules activate the caspase 
cascade and subsequently induce apoptosis (Dempsey et al., 2003).  
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2. The second group of receptors, including TNFR-II, CD27, CD 30, CD40, LTβR, OX40, 4-
1BB, BAFFR, BCMA, RANK, GITR, TACI, Fn14, HVEM, RELT, XEDAR and TROY 
contain one or more TNF-receptor associated factor (TRAF)- interacting motifs (TIMs) in 
their cytoplasmic domain. Activation of TIM containing TNFR family members leads to the 
recruitment of TRAF family members and the subsequent activation of downstream signal 
pathways like nuclear-factor κB (NF-κB) and Jun N-terminal kinase (JNK) pathways, p38, 
extracellular signal-related kinase (ERK) and phosphoinositide 3-kinase (PI3K) (Hehlgans 
2005). 
3. The third group of receptors including TRAIL-R3 (DcR1), DcR3 and osteoprotegerin 
(OPG) does not contain intracellular signalling domains or motifs. This group of receptors can 
effectively compete with the other two groups of receptors for their corresponding ligands. 
These decoy receptors therefore function by impeding the activation of signal transduction 
pathways of other TNF receptors (Dempsey et al., 2003).  
The majority of the TNF superfamily ligands are expressed by cells of the immune system, 
including B-cells, T-cells, NK cells, monocytes and dendritic cells. The only exception is 
VEGI, which is expressed mainly by endothelial cells. However, the TNF receptors are 
expressed by a wide variety of cells that have both hematopoietic and non-hematopoietic 
origins. Thus, numerous activities are assigned to TNF superfamily members, in particular, 
their profound role in regulation of both normal and pathogenic immune responses (Grewal, 
2009).  
 
1.2.2. The history of LT and TNF – the prototypic members of the TNF 
superfamily 
 
In the 1960s and early 1970s, two distinct molecules were described based on their ability to 
promote cell death in target cells (for example, murine fibrosarcoma L-929 cells L cells) 
(Ruddle and Waksman, 1967) (Granger and Williams, 1968). In 1967, Ruddle and colleges 
first described a “cytotoxic factor” in an experiment where isolated lymph node cells from 
rats showed toxicity on fibroblasts in the presence of specific antigens. One year later in 1968, 
a molecule with cytotoxic activity produced by lymphocytes was reported and named 
lymphotoxin (LT)  (Granger and Williams, 1968) (Granger et al., 1969). In 1975, a substance 
was depicted causing efficient necrosis in various tumor types in vivo throughout a cytotoxic 
activity and was thus denominated ‘tumor necrosis factor’ (TNF) (Carswell et al., 1975). 
These molecules subsequently caught attention of several research groups using these 
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cytotoxic, tumor necrotizing capabilities for their therapeutic potential in the treatment of 
human cancer. In 1984, human LT was the first cytokine to be purified from a B-
lymphoblastoid cell line (Aggarwal et al., 1984) and thereafter its amino acid sequence and 
structure was determined (Aggarwal et al., 1985) (Nedwin et al., 1985a). Neutralization of LT 
activity by LT-specific antibodies led to the isolation of a second cytotoxic factor from a 
human myeloid cell line, already known as TNF. The determination of the amino acid 
sequence of TNF revealed its close relationship to LT, leading to a renaming of LT into 
TNFβ. Due to the discovery of similarities in amino acid sequence of LT and TNF, and 
cloning their complementary DNA, it eventually became evident that these two cytokines are 
the prototypic members of the TNF superfamily (TNFSF) (Hehlgans and Pfeffer, 2005).  
Genes encoding these two TNF proteins have been cloned from mouse and man, and in both 
cases they are found in close proximity to each other (in mouse on chromosome 17 
(Nedospasov et al., 1986) in man on the short arm of chromosome 6 (Nedwin et al., 1985b)) 
within the major histocompatibility complex (MHC) region. Roughly a decade later a third 
ligand was found in the same locus and named lymphotoxin β (LTβ, TNFSF3) (Pokholok et 
al., 1995) while subsequently TNFβ was termed LTα or TNFSF1B (tumor necrosis factor 
super family member 1B). 
 
1.2.3. Signalling in the core TNF family 
 
Under physiological conditions, LTα and LTβ are expressed by activated lymphocytes, a 
subset of resting B-cells, natural killer (NK) - and lymphoid tissue-inducer (LTi) cells. The 
LTβR is expressed mainly by non-haematopoietic and myeloid cells (Gommerman and 
Browning, 2003), thus facilitating a crosstalk between immune cells and the stroma. Although 
LTα mRNA expression was shown to be inducible in B-cells, LTβ mRNA is constitutively 
produced (Browning et al., 1993) (Worm and Geha, 1994).  
The immediate TNF family is defined by four closely related ligands, which include LTα, 
LTβ, TNF and LIGHT and their cognate receptors TNFR1, TNFR2, LTβR and HVEM 
(Figure 2).  LTα and LTβ can form 3 different ligands (Schneider et al., 2004). As secreted 
homotrimeric molecule, LT (LTα3), like TNF, signals via TNFR1 (p55), TNFR2 (p75), and 
herpes virus entry mediator (HVEM). Unlike LTα, LTβ has not been detected in a secreted 
form, rather as a type II transmembrane protein which binds  LTα to form 2 distinct 
membrane anchored heterotrimers: LTα1β2 (predominant form) and LTα2β1 (Browning et al., 
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1995). LTα1β2 triggers LTβR, whereas LTα2β1 was reported to bind TNFR1 and TNFR2, but 
this is a minor form expressed by T-cells (< 2%) with an undefined biological role (Ware, 
2005). LIGHT (TNFSF14), the most recently described member is an alternative ligand for 
the LTβR but also interacts with HVEM (Schneider et al., 2004).  
 
 
Figure 2.  Ligand and receptor interactions of the tumor necrosis factor core family. Solid lines indicate 
high affinity interactions; dashed line refers to weak interactions. Two fundamental pathways can be defined. 
The TNF pathways are activated by TNF or LTα homotrimer (LTα3), signalling through the two TNF receptors 
(TNFR1, TNFR2). The LTβR signalling is triggered by two ligands, the LTαβ heterotrimer (LTα1β2) and 
homotrimeric LIGHT (adapted from Ware et al 2005). 
 
TNFR and LTβR-signalling pathways lead to the activation of NF-κB through different 
mechanisms (Figure 3). The NF-κB signalling is a major regulator of innate and adaptive 
immune responses, cell survival or apoptosis, cellular stress responses, development and 
maintenance of lymphoid organs. In mammals, the NF-κB family consists of five structurally 
conserved members: NFκB1 (p50 and its precursor p105), NFκB2 (p52 and its precursor 
p100), Rel A (p65), Rel B and c-Rel. These NF-κB proteins can form different homo- and 
heterodimeric complexes and are tightly controlled by several inhibitory proteins, belonging 
mostly to the IκBα family (Bonizzi and Karin, 2004). So far, two different signalling 
pathways are characterized: the canonical (classical) and the non-canonical (alternative) 
pathway (Dejardin et al., 2002).  
Activation of the canonical NF-κB pathway mainly occurs in response to inflammatory 
cytokines such as TNF, and IL-1, engagement of the T-cell receptor and in response to 
bacterial infection (for example, lipopolysaccharide). NF-κB1 is kept in the cytosol by 
inhibitors such as IκB (inhibitor of κB). Upon a wide variety of stimuli the IKK (IκB kinase) 
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complex (IKKα, IKKβ and the regulatory subunit IKKγ, also called NEMO) gets 
phosphorylated, which results in the ubiquitination and degradation of IκB by the proteasome 
allowing the NF-κB1/RelA heterodimer to translocate in the nucleus.  
 
 
 
Figure 3. TNFR and LTβR signalling pathways lead to the activation of NF-κB through different 
pathways.  (Left) The canonical pathway of NF-κB activation is induced by a large number of agonists, 
representatively, TNF and LTα3 are shown. Stimulation of the TNF receptor (TNFR) leads to the activation of 
the TAK1 complex through TRAF proteins. This leads to the activation of the IKK complex by phosphorylation 
of NEMO/IKKγ and IKKβ, which results in the phosphorylation of IkBα, its subsequent ubiquitylation and 
proteasomal degradation. Finally, the heterodimeric p50-RelA complex translocates to the nucleus, where it 
binds to specific kB-sequences and induces the expression of target genes, including pro-inflammatory cytokines 
or genes involved in cell survival, cell proliferation and pro-carcinogenesis.  
(Right) The non-canonical pathway becomes activated by membrane-bound LTα1β2 heterotrimers, which 
results in the activation of  NF-κB-inducing kinase (NIK). This leads to the phosphorylation and activation of the 
homodimeric IKKα complex. As a consequence, the precursor p100 becomes phosphorylated and proteasomally 
processed to the p52 subunit establishing now the RelB-p52 heterodimeric complex that translocates to the 
nucleus and induces the expression of target genes. Besides, LTβR was shown to activate the canonical NF-κB 
signalling pathway (Adapted from Wolf et al. Oncogene). 
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Activation of the classical NF-κB pathway predominantly induces expression of inflammatory 
genes, such as VCAM1, CCL14 (MIP-1β) and CXCL2 (MIP-2) (Dejardin et al., 2002) 
(Schneider et al., 2004). Interestingly, LTβR activation (through LIGHT or LTαβ 
heterotrimers) can also activate the canonical NF-kB (Dejardin et al., 2002) (Haybaeck et al., 
2009). 
Stimulation of a subset of TNFR family members, such as LTβR and CD40, can activate the 
non-canonical NF-κB pathway (Coope et al., 2002) (Pomerantz and Baltimore, 2002). These 
stimuli appear to converge upon NF-κB -inducing kinase (NIK) (Xiao et al., 2001), which is 
required for IKKα phosphorylation (Ling et al., 1998). In this pathway, IKKα is thought to 
exist as a homodimer, independent of NEMO/IKKγ and IKKβ (Senftleben et al., 2001). 
Activated IKKα phosphorylates p100, thereby inducing its proteasome dependent processing 
to p52. The p52/RelB dimer then translocates into the nucleus to induce gene expression 
through NF-κB activation by the LTα1β2, LTβR, NIK, IKKα pathway. This pathway is 
crucial for development and maintenance of spleen architecture, follicular dendritic cell 
maturation, lymph node, Peyer’s patch and NALT organogenesis as well as regulation of B-
cell survival (Weih and Caamano, 2003) (Wolf et al., 2010). The alternative pathway activates 
genes implicated in secondary lymphoid organogenesis and homeostasis such as CCL21 
(SLC), CCL19 (ELC), CXCL13 (BLC), CXCL12 (SDF-1) and BAFF (Dejardin et al., 2002). 
 
1.3 Lymphotoxin in health and disease 
 
1.3.1. The biological functions of LT 
 
Initially, LTα and TNFα were thought to play similar biological functions. However, targeted 
gene deletion of several members (LTα, LTβ, LTβR, TNFR1, TNFR2 and TNFα) of the 
immediate TNF family altered this view, and allowed the dissection of various biological 
functions attributed to LT. 
 
1.3.2. LTβR-signalling and lymph node organogenesis 
 
The first evidence that LT is involved in the development of lymphatic tissues was provided 
by generation of a mice model lacking LTα (De Togni et al., 1994; Liepinsh et al., 2006).  
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LTα-/- mice (which are deficient in membrane bound LTα1β2, LTα2β1 heterotrimers and LTα 
homotrimer) are devoid of all peripheral and mesenteric lymph nodes (mLNs) as well as 
Peyer’s patches (PPs). Of note, it has been reported that certain number of LTα-/- mice 
develops lymph node like mesenteric structures (1-3 % according to (Fu et al., 1997) and up 
to 20% according (Banks et al., 1995)). Since LT-deficient mice produce normal levels of 
TNFα, it is apparent that this function in lymphoid organogenesis is peculiar to LT (Kratz et 
al., 1996).  
To elucidate the distinct role of LTα and LTβ in the lymphoid organogenesis a mice deficient 
in LTβ expression were generated (Alimzhanov et al., 1997) (Koni et al., 1997). LTβ-/- mice, 
devoid of heterotrimeric LTα1β2 (and LTα2β1) that binds LTβR, but continue to express LTα, 
exhibit a similar phenotype to LTα-/- mice except that the cervical (cLNs) and mLNs are 
retained (Ngo et al., 1999). This data suggested that LTα can function independently from 
LTβ during lymphoid organogenesis (Wolf et al., 2011).  
Generation of LTβR-/- mice enabled to define the role of LTβR in lymphoid development, 
micro-architectural organization and lymphoid neogenesis; and to dissect whether these 
processes require heterotrimeric LT (via LTβR) or LTα3 homotrimer (via TNFR1 or TNFR2). 
LTβR-/- mice have a phenotype very similar to LTα deficient animals concerning splenic 
microarchitecture. In contrast to LTα and LTβ deficient mice histological studies revealed 
that mLNs, cLNs and inguinal lymph nodes as well as PPs are completely undetectable in 
LtβR-/- mice, and at the putative locations of LNs, cavernous spaces with endothelial linings 
could be found, indicating that LN development is completely arrested (Futterer et al., 1998). 
Thus it can be concluded that LTβR-signalling is crucial for the organogenesis of the 
peripheral LN system. 
Notably, similar to LTα-/- mice, LTβR-/- mice show inflammation in the liver, lung, pancreas, 
and kidney mainly composed of activated lymphocytes. It is believed that this possibly 
reflects a state of autoimmunity or an in vivo situation in which immune cells have started to 
colonize new niches in non-lymphoid organs due to the lack of various secondary lymphoid 
organs (Futterer et al., 1998) (Chin et al., 2003). The generation of LTβR-Ig, a fusion decoy 
protein which enables a functional inhibition of LTβR-signalling, helped to study the role of 
surface LTαβ complexes in the development of peripheral lymphoid organs. By varying the 
gestational day of LTβR-Ig injection (by specifically blocking signalling through LTβR), the 
genesis of LNs and PPs appeared to proceed in an anteriorto-posterior order (mesenterics, 
brachials, axillaries, inguinals, and poplietals, PPs) (Rennert et al., 1996). Postgestational 
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LTβR-signalling during the first 6 weeks after birth is shown to be critical for the 
development of intestinal lamina propria B cells and isolated lymphoid follicles of the 
intestine (Lorenz et al., 2003). 
 
1.3.3. LTβR-signalling and splenic micro-architecture 
 
Both LTα-/- and LTβR-/- mice lack an organized splenic microarchitecture, germinal centers 
(GC), follicular dendritic cell (FDC) networks from the B-cell follicles, compartmentalization 
into T- and B-cell areas, display size reduction of white pulp follicles and are devoid of a 
distinct marginal zone (MZ) (Wolf et al., 2011) (De Togni et al., 1994).  Of note, in LTβ-/- 
mice splenic architecture is somewhat less disturbed than in LTα-/- mice (Ngo et al., 1999). 
To dissect cell type-specific LT contribution in the complex LT-deficient phenotype, LTβ 
deficient mice were generated by conditional gene targeting (Tumanov et al., 2003). The 
obtained results imply that LT complex expressed by B-cells plays a major role in the 
maintenance of spleen structure, while surface LT expressed by T-cells provides a 
complementary but distinct signal.  
The spleens of LTα-/- and LTβ-/- mice exhibit a dramatic reduction in the expression of 
homeostatic chemokines (CCL19, CCL21, and CXCL13) (Ngo J.exp med. 1999). In the 
spleen CXCL13 (or B lymphocyte chemoattractant) is primarily expressed by FDCs to attract 
B-cells into the splenic follicle. CXCL13 signals through its cognate receptor CXCR5 on the 
surface of B-cells, resulting in sustained LTαβ expression (McCarthy et al., 2006). LTβR-
signalling also controls the level of CCL19 and CCL21, chemokines that serve to attract T-
cells and dendritic cells (DCs) (Ngo et al., 1999). Likewise, CXCL13 maintains the 
positioning of B-cells in the follicle, whereas CCL19/CCL21 draws T-cells into the T-cell 
zone. Thus, the mechanism whereby LTβR-signalling controls lymphoid tissue development 
is at least partially explained by the deregulation of the expression of homeostatic chemokines 
such as CXCL13, CCL19, and CCL21, which recruit immune cells to the developing 
lymphoid anlage (Mebius, 2003) (Muller and Lipp, 2003). In addition to lymphocyte 
organization in white pulp of the spleen, LTβR-signalling also influences the marginal zone. 
The marginal zone separates the red and white pulp regions of the spleen and it is important 
for sampling antigens from the blood. Expression of adhesion molecules, such as intracellular 
adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1) and mucosal 
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addressin cell adhesion molecule 1 (MAdCAM-1) is induced by LTβR-signalling, and they 
play an important role in retaining MZ-resident cells (McCarthy et al., 2006). 
 
1.3.4. The role of Lymphotoxin in regulation of the immune responses 
 
Humoral immune responses result in the migration of a subset of antigen specific B-cells into 
the germinal center, within the B-cell follicles of secondary lymphoid tissues. GCs are 
specialized microenvironments where antigen-specific B-cells proliferate, undergo class 
switch, somatic hypermutuation and affinity maturation in order to generate high affinity 
antibodies. FDCs form tight networks within the GC where they provide survival factors to 
rapidly dividing centroblast B-cells and present antigen-antibody complexes to B-cells 
(McCarthy et al., 2006) (Park and Choi, 2005). In order to study the contribution of LT in 
mounting of a proper immune response, LTα-/-, LTβ-/- and LTβR-/- mice were immunized. A 
normal IgM response was observed in all mice, but only minimal amounts of IgG production 
was measured, which indicates a defect in class switch (Koni et al., 1997) (Futterer et al., 1998). 
In LTβ deficient mice, which lack all FDC networks, GC formation is diminished but they do 
form, furthermore high-affinity antibody production is not completely absent but is delayed 
by a few weeks (Koni and Flavell, 1999). In addition, affinity maturation leading to high-
affinity antibodies is impaired in LTβR deficient mice (Futterer et al., 1998). Recently, 
somatic hypermutation was shown to occur outside the germinal centers in extrafollicular 
compartments, perhaps explaining the observations in LT-deficient animals (Gommerman and 
Browning, 2003) (William et al., 2002). Reconstitution experiments in which wild type mice 
received primed splenocytes from LTα-/- mice, Fu and colleagues demonstrated a substantial 
impairment in the formation of memory B-cells in LTα-/- mice (Fu et al., 2000). Of interest, 
functional memory T-cells could be recovered from LTα-/- donors. As previously mentioned 
mice deficient in LTα, LTβ or LTβR are born with impairment of LN and PPs biogenesis and 
disturbed splenic microarchitecture. Most likely these structural disturbances are associated 
with impaired high affinity isotype-switched Ig responses following immunization (Fu et al., 
2000). Further, an important role of LTβR-signalling was recently shown in dendritic cell 
function (Summers-DeLuca et al., 2007). The absence of LTαβ expression on helper T-cells 
results in compromised T-cell priming by DCs ex vivo, and LTβ-/- CD4+ T-cell responses 
were impaired in vivo. This shows that CD4+ T-cell derived LT is a critical participant in 
mediating full DC maturation and stimulatory function. 
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1.3.5. The role of Lymphotoxin in pathological processes  
 
Members of the LT/TNF family can not only contribute to the development and maintenance 
of secondary lymphoid organs, but they also play an important role in inflammatory 
processes. In the course of chronic inflammation or autoimmune disease new lymphoid 
tissues, so called tertiary lymphoid organs (TLOs) develop ectopically in non-lymphoid 
organs (Ruddle, 1999). These structures mimic secondary lymphoid organs (SLOs) 
anatomically, and also share functional characteristics, such as germinal center reactions. 
Further, they are critical for B-cell isotype class switching and affinity maturation (Henry and 
Kendall, 2010). However, unlike lymph nodes, TLOs are not encapsulated, suggesting an 
intimate interaction with the inflamed tissues. The presence of TLOs is thought to allow 
antigen presentation at the local mucosal tissue with high efficiency and reduce the possibility 
of disseminating infection (Zhang and Lu, 2012). The process by which highly organized 
TLOs arise de novo during chronic inflammation has been referred to as lymphoid neogenesis 
(Kratz et al., 1996).  For the induction of TLOs LT activates endothelial cells to express 
adhesion molecules (e.g., V-CAM, I-CAM) (Cuff et al., 1999) (Cuff et al., 1998) and 
regulates the induction of homeostatic and a variety of pro- and anti-inflammatory 
chemokines (e.g., CXCL13, CCL19, CCL21, CCL5, CCL2, CXCL10). These TLOs display 
cells or structures known to depend on LTβR-signalling (e.g., FDCs; high endothelial venules 
(HEVs) (Browning, 2008) (Drayton et al., 2006). HEVs are postcapillary vessels of secondary 
lymphoid organs composed of endothelial cells with a characteristic cuboidal morphology.  
Lymphocytes selectively adhere to and migrate across HEVs to initiate immune responses 
(Kawashima et al., 2009). Interestingly, HEVs were also observed in chronically inflamed 
non-lymphoid tissues (Drayton et al., 2006), and at the same time a direct role of LTβR-
signalling as a requirement for the homeostatic control of HEV differentiation and function 
was described (Browning et al., 2005). A recent study shows that dendritic cells, which are 
well known for their role in antigen presentation to T lymphocytes, control the entry of naive 
lymphocytes to lymph nodes by modulating the phenotype of HEVs. The effect of DCs on 
HEV endothelial cells is direct and requires LTβR-dependent signalling  (Moussion and 
Girard, 2011). 
Several human inflammatory (e.g., hepatitis B and C virus-induced chronic hepatitis, 
Helicobacter pylori-induced gastric inflammation (Drayton et al., 2006) (Haybaeck et al., 
2009) and autoimmune diseases (e.g. rheumatoid arthritis, Sjögren’s syndrome, multiple 
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sclerosis (Hjelmervik et al., 2005) (Serafini et al., 2004) (Takemura et al., 2001) are 
associated with LT upregulation and TLO formation. It is likely that immune responses to 
self-antigens expand in these de novo lymphoid organs, as they allow co-localization of 
antigen specific T-and B-cells with antigen presenting cells (APCs) (Spahn et al., 2005). 
Various animal models were generated to recapitulate inflammation, accompanied by 
lymphoid neogenesis in the context of development of these autoimmune and inflammatory 
disorders. These models either utilize immunization with self-antigens, or transgenic 
expression of TNFSF members and its target genes (Summarized in Table 1). 
 
Table 1. Mouse models of inflammation that are accompanied by lymphoid neogenesis (Adapted from Drayton 
et al., 2006 and Aloisi et al., 2006). 
 
LTα or LTαβ expression under the control of the rat insulin promoter II (RIP) induces 
chemokine expression and follicular lymphocytic infiltrations (CD4+, CD8+ T-cells, B220+ B-
Disease Target tissue TLO characteristic References 
Autoimmune 
diseases:    
Prediabetic NOD 
mice 
pancreatic islets, 
salivary  glands 
Lymphoid aggregates with CCL21+ stromal cells 
and MADCAM1+ HEVs 
(Faveeuw et al, 
1994) 
Collagen induced 
arthritis Joints B-cell follicles with GL7+ GCs 
(Zheng B. et al. 
2005) 
Experimental 
autoimmune 
encephalomyelitis CNS 
Intrameningeal B-cell follicles with FDCs and 
GCs 
(Magliozzi et al. 
2004) 
Ectopic 
expression    
RIP-TNF 
pancretic islets, 
kidney 
T cell–B cell compartments, HEVs (MAdCAM-
1,  PNAd), FDCs, DCs, plasma cells with IgG 
and IgM, CCL21, CXCL13 
(Kratz. et al. 
1996) 
RIP-LTa, RIP-
LTb 
pancretic islets, 
kidney 
T cell–B cell compartments, CCL19, CCL21, 
CXCL13 FDCs, DCs, HEVs (MAdCAM-1, 
PNAd) 
(Drayton et al. 
2003) 
RIP-SLC 
(CCL21) Pancreatic islets 
T cell–B cell compartments, naive T cells, DCs, 
HEVs (MAdCAM-1, PNAd), FDCs 
(Fan L. et al. 
2000, Chen SC et 
al. 2002) 
RIP-BLC 
(CXCL13) Pancreatic islets 
T cell–B cell compartments, DCs (no FDCs), 
HEVs (PNAd, HEC-6ST, MAdCAM-1) CCL21 
(Bistrup A. et al. 
2004) 
RIP-ELC 
(CCL19) Pancreatic islets 
Small infiltrates, T cell–B cell compartments, 
HEVs (PNAd) 
(Luther SA et al. 
2002) 
RIP-CXCL12 Pancreatic islets 
Small infiltrates, mainly naive B cells, few T 
cells, DCs, plasma cells 
(Luther SA et al. 
2002) 
Alb-LTab Liver 
B cells, FDCs, IgD+ and IgG1+ cells, DCs, 
PNA+ clusters 
(Haybaeck et al. 
2009) 
Ela1-Lta,b Exocrine pancreas 
T cell–B cell compartments, FDCs, HEVs 
(PNAd), Germinal Centers (CD21/35) (Seleznik et al.) 
Tg-CCL21 Thyroid 
T cell–B cell compartments, CD62L+ T cells, 
CD11c+ DCs, HEVs (PNAd) 
(Martin, A.P. et 
al. 2004 
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cells, F4/80+ macrophages, CD11c+ dendritic cells) with GCs, HEVs and mature FDC 
networks in the kidney and pancreas (Picarella et al., 1992) (Kratz et al., 1996) (Drayton et 
al., 2003). Although insulitis was found in the case of many but not all pancreatic islets, 
RIPLTα mice did not progress to diabetes until the age of 8–12 months (Picarella et al., 
1993). Notably, in RIPLTα kidneys pathological changes were observed, including mesangial 
proliferation and mesangiolysis within the glomeruli. Subsequent studies also demonstrated 
that overexpression of lymphoid homeostatic chemokines such as CCL21 or CXCL13 under 
the RIP promoter resulted in lymphotoxin dependent lymphoid neogenesis (Chen et al., 2002) 
(Luther et al., 2000) 
Recently, - as a new paradigm in the TLO formation - IL-17, produced by T-cells was 
identified as being required for the formation of inducible bronchus-associated lymphoid 
tissue (iBALT), a type of TLO that forms in the lungs during chronic inflammation and 
infection (Rangel-Moreno et al., 2011). Using various knockout mice, the authors also 
showed that LTα and homeostatic chemokines, such as CXCL13, CCL19 and CCL21a, were 
required for the further organization of iBALT. Blockade of IL-17 reduced the number and 
size of iBALTs but did not affect their architecture. Thus, IL-17 is proposed to be important 
in TLO induction, while the maintenance and structural organization of iBALTs is LT 
dependent (Zhang and Lu, 2012). Of note, a recent study showed the generation of iBALT in 
IL-17 knock out animals, claiming that the general conclusion reached by Rangel-Moreno et 
al. that iBALT formation depends on IL-17 is inappropriate (Fleige et al., 2012).  
Overexpression of LTαβ under the liver-specific albumin promoter (AlbLTαβ) led to chronic 
hepatitis in transgenic mice with an incidence of 100% at the age of 9 month. The 
pathological changes in this mouse model include organized portal and lobular lymphocytic 
infiltrates, proliferating hepatocytes and oval cells, presence of FDCs and GCs leading to 
mild, chronic liver damage. Interestingly, in approximately one-third of the mice at an age of 
>12 months (hepatocellular carcinoma) HCC can be detected (Heikenwalder et al., 2005) 
(Haybaeck et al., 2009). 
Mice expressing LTα and LTβ under the control of the distal leukocyte-specific protein 
tyrosine kinase (lck) promoter were generated, resulting in LT expression on developing 
thymocytes within the thymus and on peripheral T cells in various lymphoid organs 
(Heikenwalder et al., 2008). In this case transgene expression on thymocytes led to their 
activation accelerated thymic involution, aberrant T cell development, and an altered thymic 
microarchitecture. Thymic involution, caused by massive apoptosis of thymic epithelial cells, 
was rescued by the removal of either TNFR1 or LTβR in the stromal compartment, but not by 
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depletion of overall TNFR2, LTα, or LTβ expression. Therefore, ectopic thymic LTαβ 
expression induces toxicity on thymic stromal cells, which is mediated by two non-redundant 
pathways: LTα3 signalling through TNFR1 and LTα1β2 signalling through LTβR (Wolf et 
al., 2011). 
1.3.6. Therapeutic potential of modulating LTβR signalling in inflammatory and 
autoimmune diseases 
 
As mentioned, LTβR is a TNFSF member best known for its role in lymphoid organogenesis 
and maintenance of lymphoid tissue organization. However, in addition to the well described 
function, a number of reports identify the involvement of LTβR-signalling in inflammatory 
processes, infectious diseases and carcinogenesis; conversely they may involve distinct 
mechanisms in the various in vivo paradigms tested so far. Manipulation of LTβR-signalling 
has revealed numerous aspects of their function in both health and disease, particularly in 
autoimmune diseases. There are various approaches to manipulate LTβR-signalling; one is 
stimulation with an agonistic receptor-specific monoclonal antibody (ACH6) or blocking with 
a soluble chimeric protein that efficiently inhibits LTβR-signalling (LTβR-Ig) (Force, W.R JI. 
1995). LTβR-Ig has been so far the primary pharmacological tool to inhibit LTβR-signalling 
and HVEM. The construct binds to both LTαβ and LIGHT with a high affinity, consequently 
blocking the interactions of LTαβ with LTβR and LIGHT with both LTβR and HVEM, as 
outlined in Figure 2 (Browning, 2008). Analysis of the effects of genetic or pharmacological 
disruption of the LTβR pathway in rodent models of inflammatory diseases and more recently 
in carcinogenesis has been extensively performed in the last years. Table 2 lists the animal 
models where LTβR-Ig administration was efficacious.  
Recent reports convincingly show an involvement of LTβR-signalling in inflammatory 
processes and carcinogenesis. For example LTβR-Ig treatment in TRAMP mice interrupted 
clonal T-cell deletion, reduced the size of the primary prostate cancer (CaP) and prevented 
further metastasis (Zhou et al., 2009) - suggesting a role of LT in controlling anti-tumor T-cell 
selection and primary cancer development. Moreover, depletion of LT expression on B-cells - 
not on T-cells - delayed CR-CaP (castration-resistant CaP) recurrence (Ammirante, 2010), 
pointing towards a therapeutic application of LTβR-signalling inhibition even as a tool to 
fight cancer re-emergence (Wolf et al., 2010). The chronic and relapsing course of many 
autoimmune diseases calls for new biological agents capable of suppressing the underlying 
inflammatory disorders. Recent studies indicate that inhibition of LTβR-signalling in adult 
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animals can prevent and relieve autoimmune diseases such as colitis, uveitis, Sjögren’s 
syndrome, rheumatoid arthritis, insulin-dependent diabetes mellitus and experimental 
autoimmune encephalomyelitis EAE) (Gommerman and Summers deLuca, 2011). 
 
Target Disease  Model References 
LT signalling in 
cancer 
Prostate cancer  TRAMP (SV40-Tag) (Ammirante, 2010) 
Colon carcinoma Syngeneic colon carcinoma 
tumor xenograft model 
(Lukashev et al., 2006) 
 Fibrosarcoma LTβR-Ig expression on tumor 
cells 
(Hehlgans et al., 2002) 
 Hepatocellular carcinoma AlbLTαβ mice (Haybaeck et al., 2009) 
 Nasopharyngeal carcinoma Transplantation of tumors with 
amplification 12p13.3 
(Or et al., 2009) 
 Prostate cancer  TRAMP (SV40-Tag) (Zhou et al., 2009) 
LT signalling in 
infectious 
diseases 
Prion disease Scrapie infection (Montrasio et al., 2000) 
Viral shock LCMV infection (Puglielli et al., 1999) 
LT signalling in 
autoimmune 
diseases 
Arthritis Classical CIA (Fava et al., 2003) 
 Adjuvant arthritis (Fava et al., 2003) 
Hepatitis Con A hepatitis (An et al., 2006; Anand et al., 
2006)  
  AlbLTαβ mice (Haybaeck et al., 2009) 
 Inflammatory Bowel Disease Inflammatory CD45RB
hi  (Mackay et al., 1998) 
  CD3εTg26 (Mackay et al., 1998) 
  DSS (Stopfer et al., 2004) 
  TNBS (An et al., 2005) 
 Autoimmune pancreatitis  Tg(Ela1-LTa,b)  (Seleznik et al. ) 
 Multiple sclerosis PLP_SJL EAE (Columba-Cabezas et al., 
2006; Gommerman et al., 
2003 ) 
  MBP-rat acute EAE (Gommerman et al., 2003) 
  Cuprizone (Plant et al., 2007) 
 Sjögren’s syndrome Male NOD (Gatumu et al., 2009) 
 Systemic Lupus Erythematosis Adeno-IFN BWFI Biogen Idec, unpublished 
  Pristane SNFI Biogen Idec, unpublished 
  GVHD skin (Wu et al., 2004) 
  GVHD chronic (Tamada et al., 2000; Tamada 
et al., 2002) 
 Type I diabetes Female NOD (Ettinger et al., 2001 ; Lee et 
al., 2006 ; Wu et al., 2001) 
 Uveitis R16 immunization (Shao et al., 2003) 
LTα or LTαβ 
expressing T-
cells 
Arthritis CIA (Chiang et al., 2009) 
Delayed type hypersensitivity KLH/CFA (Chiang et al., 2009) 
Multiple sclerosis EAE (MBP-TCR Tg mice) (Chiang et al., 2009) 
Table 2: Summary of experiments leading to disease regression in rodent models due to conditional interference 
with LTβR signalling (Adapted from Wolf et al. 2010) 
 
 
 
 
   
   
                                                                                                                        INTRODUCTION           
29 
 
There are three principal mechanisms for the potential mode of action in LTβR blockade. 
Figure 4 summarizes the changes in the lymphoid microenvironment observed in mice 
following LTβR-Ig treatment (Spahn et al., 2005).  
  
 
Figure 4. Proposed biological effects of LTβR pathway inhibition via LTβR-Ig. Three biological 
mechanisms (circles) have been described: loss of CXCL13 gradient in follicular dendritic cell networks, loss of 
adhesion molecule expression, and loss of proper and timely positioning of T cells in lymphoid organs. These 
mechanisms contribute to changes in secondary lymphoid organ formation, and loss of ectopic lymphoid organs, 
as indicated by the four boxes (Adapted from Spahn et al., 2005).  
 
(1) Interruption of the positive feedback loop between LT and homeostatic chemokines, 
especially CXCL13. LTβR-signalling is required to maintain a CXCL13 chemokine gradient, 
which attracts CXCR5+ B cells to the lymphoid follicle and to sustain the differentiation 
status of the recruited B-cells and the FDCs in the network. (2) Prevention of adhesion 
molecule (MadCAM-1, V-CAM1) expression, causing the absence of marginal zones. 
Similarly, LTβR engagement is required for continued expression of V-CAM1 by the FDC 
network (Gommerman and Browning, 2003) (Husson et al., 2000). Furthermore, by reducing 
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adressin expression, it can lead to diminished cell entry into LNs or TLOs (Browning, 2008) 
(3) Anti-LTβR treatment is able to impair immune function by preventing proper homing of 
T-cells, B-cells, and APCs in secondary lymphoid organs, thus preventing the induction of 
appropriate antigen-specific immune responses.  
Hence, the observed pathological changes in mice treated with LTβR-Ig include the absence 
of discreet B-cell follicles, lack of FDC networks and the absence of marginal zones in the 
spleen. Furthermore, germinal centers did not form in these mice upon immunization.  
As many autoimmune diseases are accompanied by the formation of pathological ectopic-
lymphoid structures, TLOs, the inhibition of LTβR pathway has a potential to be used as an 
alternative or supplementary approach in treatment of autoimmune diseases.   
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2.1 Abstract 
 
The mechanisms triggering autoimmune pancreatitis (AIP), an increasingly recognized, 
immune mediated form of chronic pancreatitis, remain elusive. Current treatment options are 
limited, frequently resulting in disease relapse. Here we report upregulation of lymphotoxin 
(LTαβ) in pancreata of AIP patients concomitant with elevated pancreatic and serum 
chemokine levels - a signature unaffected by corticosteroid treatment and contributing to 
relapse. Acinar-specific LT expression in mice (Ela1-LTa) induced autoimmunity reminiscent 
of human AIP, including ANA, auto-antibodies against pancreatic self-antigens and renal 
immune-complexes, causally linking pancreatic LTαβ expression with AIP. Notably, chronic 
inflammation initially and exclusively arising in the pancreas sufficed to induce a systemic 
autoimmune disease. Disease mechanisms of AIP development and potential therapies were 
tested in Ela1-LTab mice. Absence of lymphocytes (Ela-1LTab/Rag1-/-) abrogated AIP, while 
lack of pro-inflammatory monocytes (Ela-1LTab/Ccr2-/-) eliminated early pancreatic tissue 
damage but failed to prevent AIP. Adoptive transfer of transgenic splenocytes into Rag1-/- 
mice suggested that acinar cell damage in Ela1-LTab mice is T-cell mediated. Corticosteroid 
treatment reduced pancreatitis but did not hamper auto-antibody production. In contrast, 
inhibition of LTβR-signalling dampened chemokine expression, renal immune-complex 
deposition and fully abrogated AIP. Thus, suppression of LTβR-signalling might become a 
viable alternative or combinatorial treatment option for AIP.    
2.2 Introduction 
 
Chronic pancreatitis (CP) is an inflammatory disease of the exocrine pancreas leading to 
irreversible and progressive tissue damage resulting in severe exocrine and endocrine 
insufficiency (Braganza et al., 2011). Chronic destruction of acinar cells usually coincides 
with inflammation, metaplasia and fibrosis. Various aetiologies induce CP e.g. chronic 
alcohol intake, smoking and drug abuse (Talamini et al., 1996; Yadav and Whitcomb, 2010). 
Notably, chronic pancreatitis is believed to increase the risk to development of pancreatic 
ductal adenocarcinoma (PDAC) (Guerra et al., 2011). Autoimmune pancreatitis (AIP) is a 
distinct form of CP with so far unknown aetiology, but with characteristic clinical and 
histological features (Kloppel et al., 2003). It is speculated that 11-15% of all CP cases 
develop in an autoimmune context (Finkelberg et al., 2006). Two distinct types of AIP have 
been described: (1) Type 1 AIP, with lobular and interlobular inflammation, germinal center 
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formation, prominent lymphoplasmacytic inflammation and vasculitis, in which the pancreas 
is involved in a systemic IgG4-positive disease. (2) Fibroinflammatory duct-centric type (type 
2 AIP) with granulocyte epithelial pancreatic lesions and destruction of the pancreatic duct 
without IgG4-positive cells or systemic involvement (Park et al., 2009). 
In the clinic, elevated IgG4 levels are currently the most sensitive serum parameter used for 
diagnosis (Hamano et al., 2001). However, about half of all AIP patients have normal serum 
IgG4 levels, and elevated IgG4 levels were also reported in non-autoimmune pancreatitis and 
pancreatic cancer (Choi et al., 2007). Recently, B-cell activating factor (BAFF) was identified 
as a novel serum marker for diagnosis and treatment response of AIP in combination with 
total serum IgG and IgG4 or anti-nuclear antibodies (ANA) (Yamanishi et al., 2011). 
However, the identification of further selective diagnostic markers remains a challenge.  
Auto-antibodies detected in human AIP, are anti-carbonic anhydrase II (anti-CA-II), anti-
lactoferrin (anti-LF), and more recently, anti-trypsinogen antibodies (Lohr et al., 2010). 
Current studies revealed that approximately 40% of AIP patients suffer from extra-pancreatic 
manifestations involving liver, salivary glands, retro-peritoneum or kidneys (Kamisawa et al., 
2006), (Raina et al., 2009). Thus, AIP is a systemic autoimmune disease, which responds well 
to conventional steroid treatment (Finkelberg et al., 2006); however relapses are frequent (~ 
40%) and are associated with a more severe disease course (Kalaitzakis and Webster, 2011). 
Hence, novel therapeutic strategies and a better understanding of the underlying disease 
mechanisms are needed.  
Major regulators of immunity under both normal and pathological conditions include the 
cytokines LTα, LTβ and their receptor (LTβR), members of the tumor necrosis factor (TNF) 
superfamily. Under physiological conditions, LT is expressed mainly by immune cells. Under 
pathological conditions, parenchymal cells - like hepatocytes - are also capable of expressing 
LT in mice and humans (Haybaeck et al., 2009), (Lowes et al., 2003). LTβR-signalling serves 
pleiotropic functions including control and maintenance of lymphoid organ development 
(Gommerman and Browning, 2003), development of high endothelial venules (HEVs) 
(Browning et al., 2005) and control of lipid homeostasis (Lo et al., 2007). LT is crucial for the 
generation and maintenance of tertiary lymphoid organs (TLOs), frequently arising during 
chronic inflammation (Haybaeck et al., 2009), (Drayton et al., 2003), (Kratz et al., 1996). 
TLOs are found in many human autoimmune diseases (e.g. rheumatoid arthritis, Sjögren’s 
syndrome, Multiple sclerosis) (Takemura et al., 2001),(Hjelmervik et al., 2005),(Serafini et 
al., 2004). TLOs upregulate LT, express chemokines and adhesion molecules (e.g. CXCL13, 
CCL21; V-CAM) and contain cells or structures known to depend on LTβR-signalling (e.g. 
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follicular dendritic cells (FDC), HEVs) (Browning et al., 2005),(Browning, 2008; Drayton et 
al., 2006; Drayton et al., 2003; Heller et al., 2007). The consequences of ectopic LT 
expression were previously investigated in several transgenic animal models, such as RIP-
LTα (Picarella et al., 1992), AlbLTαβ (Haybaeck et al., 2009) and lckLTαβ (Heikenwalder et 
al., 2008). Although these models display chronic inflammation and TLOs in the respective 
organs, they did not develop detectable organ-specific or systemic autoimmune disease.   
Characterization of human AIP tissue revealed strong up-regulation of the cytokines LTαβ 
and its target genes but not IL17 as recently proposed to be important in TLO induction in 
non-lymphoid organs (Rangel-Moreno et al., 2011). Based on this data and on the known role 
of LTβR-signalling in immunity and disease, we aimed to test the potential role of LT in AIP 
pathology. To this end, we created transgenic mice expressing LT under the control of the 
acinar-cell specific elastase promoter (Tg(Ela1-LTa,b). Strikingly, Tg(ELa1-Lta,b) mice 
reproduced a number of key pathological hallmarks of human AIP, demonstrating for the first 
time that chronic inflammation which initially develops exclusively in the pancreas suffices to 
induce AIP and a systemic autoimmune disease. Moreover, Tg(ELa1-Lta,b) mice serve as a 
novel mouse model to study disease development, pathogenesis and potential treatment 
interventions for AIP. Here, we have utilized Tg(Ela1-LTa,b) mice to investigate AIP disease 
mechanisms, determine the source of AIP relapse after corticosteroid treatment, and to 
explore novel therapeutic strategies for AIP. 
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2.3 Results  
 
2.3.1. Distinct expression patterns of TNFR-superfamily members and 
chemokines in non-AIP versus AIP patients  
 
We first investigated whether particular subsets of cytokines or chemokines are deregulated in 
pancreata of patients suffering from pancreatitis. We analyzed frozen material derived from 
inflammation-unaffected patients (n=6), patients with pancreatic inflammation with different 
degrees of fibrosis (n=6), as well as patients with AIP (n=5) by qPCR analysis. Identical 
tissue specimens used for mRNA expression were pre-screened histologically by 
Hematoxilin-Eosin (H&E) staining to verify the respective pancreatic pathology (Figure 5).  
 
 
Figure 5. Characterization of human autoimmune pancreatitis and non-autoimmune pancreatic 
inflammatory diseases. (A) LT−alpha LT-beta and Cxcl13 transcripts were analysed in pancreatic tissue 
samples of patients with non-AIP of different fibrosis degree (light (stage I), medium (stage II) and severe 
fibrosis (stage III)) and compared to unaffected pancreatic tissues. The staging of fibrosis was carried out based 
on the amount of syrius red positive areas in the tissue sample. (B) Histological analysis of representative human 
pancreatic tissues from a healthy control patient (scale bar: 100 µm), a patient with pancreatic inflammatory 
disease with severe fibrosis (scale bar: 200 µm) and an autoimmune pancreatitis (AIP) case (scale bar: 100 µm). 
H/E staining shows typical features of pancreatic inflammation (fibrosis) and autoimmune disease (inflammatory 
infiltrates, vasculitis). 
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mRNA expression analysis revealed strong and significant upregulation of LTα, LTβ, 
CXCL13, CCL19, CCL21, CCL17 and BAFF in AIP patients when compared to controls and 
patients with severely fibrotic non-autoimmune pancreatic inflammation. A possible 
candidate cytokine that was recently proposed to be crucial for autoimmune disease 
development, (e.g. rheumatoid arthritis, psoriasis, multiple sclerosis, and inflammatory bowel 
diseases (Yamada, 2010)) as well as for TLO generation in non-lymphoid organs of mice (e.g. 
iBALT) is IL17 (Rangel-Moreno et al., 2011). However, we could not detect a significant 
induction of IL17 in pancreata of human AIP patients.  In contrast, increase in CCL20, TNFα, 
CCL2, IL6, IL17 and α-SMA transcripts were found in fibrotic, non-AIP pancreata when 
compared to healthy controls or AIP patients (Figure 6). This reveals distinct transcriptional 
signatures in pancreata of AIP and non-AIP patients with remarkably high expression of LT 
and homeostatic chemokines (e.g. CXCL13, CCL19, CCL21), especially in AIP. 
 
 
Figure 6. Distinct transcriptional signature in AIP and CP patients. qPCR analysis of human cryo-material 
from pancreatic tissues for LTa and LTb transcripts, homeostatic chemokines and LT target genes (e.g. CXCL13, 
CCL19, CCL21, CCL17, CCL20) as well as inflammatory mediators (BAFF, TNFα, CCL2, IL6,, IL17). 
2.3.2. LT expression is found on infiltrating lymphocytes and metaplastic acinar 
cells 
 
We next aimed to identify the cells expressing LT in the pancreata of CP and AIP patients. 
Immunohistochemistry of pancreatic tissue sections derived from non-AIP patients with 
fibrotic pancreatitis (n=12), from AIP patients (n=16) compared to unaffected control tissue 
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(n=6) revealed strong LTβ protein expression on infiltrating lymphocytes and acinar cells 
(Figure 7). In most cases, the latter were undergoing acinar-to-duct-metaplasia. Double-
staining with lymphocytic markers CD3 (T-cells), CD20 (B-cells) as well as amylase (acinar 
cells) supported this finding. Furthermore, the frequency of LTβ+CD20+ B-lymphocytes 
appeared to be strongly increased in AIP patients compared to patients suffering from fibrotic 
pancreatitis, which primarily display LTβ expression on T-cells.  
 
 
Figure 7. Pancreatic lymphotoxin expression of healthy individuals, CP and AIP patients . (A) Human LTβ 
expression on inflammatory cells as well as on acinar cells - especially that undergoing acinar-to-duct metaplasia 
(insets). Size of scale bars: Upper row: Control: 200µm. Severe fibrosis and AIP: 100 µm. Lower row: Control, 
severe fibrosis and AIP: 50 µm. (B) LTβ is expressed on CD3+ T-cells, CD20+ B-cells and on amylase+ acinar 
cells in pancreatitis from both autoimmune and non-autoimmune origin. Of note, whereas more T cells and a 
sub-fraction of B cells express LTβ in pancreatic inflammatory disease with severe fibrosis (non-AIP), AIP 
patients express LTβ to high degree on almost all B cells and less on T cells (scale bar: 50 µm). 
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2.3.3. Serum analysis of healthy individuals and AIP patients 
 
The observed induction of various cytokine and chemokine transcripts was also detectable in 
serum of AIP patients (Figure 8). We found homeostatic chemokines (CXCL13, CCL19, 
CCL21) and pro-inflammatory cytokines (TNFα, IL6) strongly elevated in sera of AIP 
patients when compared to healthy individuals. We next investigated whether these 
chemokines are modulated upon corticosteroid treatment in AIP patients (n=10). Application 
of standard corticosteroid treatment for 12 weeks did not lead to significant reduction of the 
investigated cytokines and chemokines. Therefore, although corticosteroid-treatment 
significantly reduced some indicators of inflammation (IgG, IgG4), levels of important 
inflammatory mediators remained insignificantly changed, indicating a possible cause of 
disease re-emergence.  
 
 
Figure 8. Serum analysis of healthy individuals and AIP patients. Serum from healthy controls and AIP 
patients - before and after corticosteroid treatment – was analysed for the presence of CXCL13, CCL19, CCL21, 
TNFα and IL6 proteins. Serum IgG and IgG4 is significantly decreased in AIP patients treated with 
corticosteroids for 12 weeks. 
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2.3.4. Generation and molecular characterization of Tg(ELa1-Lta,b) mice 
 
Data presented above indicate a distinct cytokine/chemokine signature in fibrotic pancreatitis 
and AIP patients. Moreover, focal LT expression on metaplastic acinar cells and the 
correlation between LT upregulation suggested a link between LT expression and AIP. 
Hence, we aimed to test whether ectopic LTαβ expression in the murine exocrine pancreas 
would induce tissue damage and AIP in mice. 
 
Figure 9. Generation of transgenic mice. (A) Schematic representation of the transgenic LTα and LTβ 
constructs controlled by the rat elastase 1 promoter, co-injected into C57BL/6N zygotes. (B) TaqMAN-PCR 
analysis revealed Tg(ELa1-Lta,b) line #58 as the higher and Tg(ELa1-Lta,b) line #40 as the lower expresser 
double transgenic line. LTαβ expression is highly specific to the pancreas. No or very little (>100 fold) elevated 
LTαβ mRNA expression was found in lung, liver or kidney compared to C57BL/6 tissues. (C) Analysis of 
transgene specific LTαβ mRNA expression in pancreas, spleen, liver, kidney, lung, thymus, duodenum and 
jejunum of transgenic mice and negative littermates. PCR was performed on cDNA isolated from 8 week-old 
mice using primers specific for transgenic Ela1-Lta Ela-Ltb constructs. Similar to TaqMan data, no transgenic 
mRNA expression was detected by this method in other organs than pancreas. 
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We therefore generated double transgenic mice expressing LTα and LTβ in the pancreas 
under the control of the rat elastase 1 promoter (Swift et al., 1984). Upon PCR analysis, we 
selected two double transgenic, LTab expressing lines, denoted as line #40 and #58, for 
further experiments. Southern blot analysis confirmed the integration of two copies of LTα 
and β for line #58 or one copy of each construct per haploid genome for line #40. After 
thorough Real-time PCR analysis of various organs derived from lines #40 and 58, we 
verified that transgene expression is restricted to the pancreas, and no significant LT 
expression could be detected in the spleen, thymus, lung, liver, kidney, jejunum or duodenum 
(Figure 9). 
Transgene expression on mRNA and LTα protein level differed between the two transgenic 
lines, thus line #40 was classified as the low expressing and line #58 as the high expressing 
(Figure 9B and Figure 10). Tg(ELa1-Lta,b) henceforth refers to the high expressing line #58, 
however, we have corroborated the observed phenotypes also in mice of line #40. 
 
 
2.3.5. Chronic pancreatitis and altered amylase, lipase levels in Tg(ELa1-Lta,b) 
mice 
 
We first analysed whether ectopic LT expression in acinar cells would lead to tissue damage 
indicated by increased pancreatic enzyme levels (e.g. amylase; lipase) in sera of transgenic 
mice. Tg(ELa1-Lta,b) mice showed strongly and significantly elevated levels of both amylase 
and lipase already by the age of one month (Figure 11A).  
To investigate macroscopic changes, pancreas to body weight ratio was calculated in three, 
six and twelve month-old mice (Figure 11A). Pancreas size was significantly smaller (30-
40%) in Tg(ELa1-Lta,b) mice compared to wild type mice at all time-points. This finding 
Figure 10. Protein expression level of LTα in 
pancreata. Lymphotoxin alpha protein levels of Tg(ELa1-
Lta,b) line #58 and #40 measured by ELISA confirmed 
transcription analysis. 
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could be explained by the prominent accumulation of inflammatory cells persisting at later 
time points.  
 
 
Figure 11.  Description of inflammatory phenotype in Tg(Ela1-Lta,b) mice. (A) Pancreatic enzyme levels of 
lipase and amylase in serum were elevated starting from the age of two months in Tg(ELa1-Lta,b) mice. Changes 
in size and weight of the pancreas as visualized by pancreas to body weight ratio shows significant decrease in 
transgenic mice compared to wild type mice. (B) Development and progression of pancreatic inflammation as 
visualized by H/E staining from 3, 6, 12, 18 and 22 months old Tg(ELa1-Lta,b) line #58 mice compared to 
negative littermates (scale bar: 100 µm). (C) Typical features of chronic pancreatitis like acinar to duct 
metaplasia (scale bar: 20 µm), goblet cell metaplasia (Scale bar: 50 µm) and vasculitis (scale bar: 100 µm) were 
found in Tg(ELa1-Lta,b) mice.  
 
Based on the early acinar cell damage reflected by elevated pancreatic serum enzyme levels, 
we addressed whether ectopic LT expression on acinar cells induces inflammation and tissue 
damage (Figure 11B). In both transgenic lines, first focal infiltrating immune cells (T, B 
lymphocytes and F4/80+) accumulated in the pancreas already by eight weeks of age 
accompanied by an early onset acinar-to-duct-metaplasia.  
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Figure 12. Immunohistochemical analysis of lymphocytes, macrophages and proliferative cells in 
Tg(ELa1-Lta,b) pancreata over time. (a) B220+ B-cells, (b) CD3+ T-cells, (c) F4/80+ macrophages (see also 
inset) (d) and Ki67+ proliferating inflammatory cells and acinar cells (see also inset, arrow heads) were stained in 
Tg(ELa1-Lta,b) mice compared to negative littermate controls. Ki67+ proliferating inflammatory and acinar cells 
are indicated (arrow heads). Scale bar: 200 µm.  
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Pancreatitis progressed over time, with a strong influx of inflammatory cells and concomitant 
proliferation of Ki-67+ acinar cells to pronounced tissue damage at 12-22 months of age 
(Figure 12).  
The constantly rising number of immune cells led to development of organized B- and T-cell 
zones after 6 months, indicative of the formation of tertiary lymphoid organs. Sporadic acinar-
to-goblet cell metaplasia and vasculitis were also observed - two histo-pathological features 
commonly found in human CP and AIP (Figure 11C). Inflammation was restricted to the 
exocrine part of the pancreas; in contrast pancreatic islets remained unaffected (Figure 11B 
and Figure 13 B). The body weight of transgenic mice did not differ significantly from wt 
littermates at any time point (Figure 13A). Based on the comparable patterns of pancreatic 
inflammation observed in both independent transgenic lines (Figure 13B), the phenotype of 
Tg(ELa1-Lta,b) mice is unlikely to be due to a positional effect of randomly integrated 
transgenes. 
 
Figure 13. Characterization of both transgenic lines. (A) Body weight was measured from both males and 
females in Tg(ELa1-Lta,b) line #58 and Tg(ELa1-Lta,b) line #40 at 2, 3, 6, 12 and 18 months of age. No 
significant difference was found either for male or female transgenic mice when compared to age matched wild 
type controls. (B) Development and progression of pancreatic inflammation in the Tg(ELa1-Lta,b) line #40 
visualized with H/E staining at the age of 3 months, 6 months, 12 months and 18 months. Lower LT expression 
leads to less infiltrating inflammatory cells, but the formation of tubular complexes after 18 months is 
comparable to the higher expresser transgenic line. Scale bar: 100µm.  
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2.3.6. Tg(ELa1-Lta,b) mice display a transcriptional signature reminiscent of 
human AIP 
 
Next, we investigated mRNA and protein expression of chemokines and cytokines in 
pancreata of three- and twelve-month-old transgenic mice compared to negative littermates 
(Figure 14A). Not only a rise in endogenous Lta and Ltb transcripts over time but also an 
induction of the homeostatic chemokines Cxcl13, Ccl19, Ccl21, Ccl17, Ccl20, the adhesion 
molecule Vcam, the inflammatory chemokines Cxcl1, Cxcl10, Ccl2, the inflammatory 
cytokines Baff, Il6, Il1β, Il7 and Tnfα  was detected.  
 
 
Figure 14. Cellular and molecular characterization of Tg(ELa1-Lta,b) mice. (A) Quantitative RT-PCR 
analysis of pancreatic Lta, Ltb, Cxcl13, Ccl19, Ccl21, Ccl17, Ccl20, Vcam, Cxcl1, Cxcl10, Ccl2, Il6, Il1β, Baff 
(Tnfsf13b), Il7 and Tnfα, transcripts in 3 and 12 month-old Tg(ELa1-Lta,b) pancreata compared to negative 
littermates (3 and 12 months pooled). (B) Elisa for CXCL13, CXCL10, CXCL1, IL6 and IL1β in pancreas 
homogenates of C57BL/6 and Tg(ELa1-Lta,b) mice. (C) Serum CXCL13 levels are elevated in 12 month-old 
Tg(ELa1-Lta,b) (n=10) mice compared to age matched C57BL/6 (n=10) mice. (D) Quantification of CD4+, 
CD8+, B220+ and CD11b+ infiltrating cells at the age of 3 and 6 months in transgenic and wild type mice. 
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This resembles the development of a progressive inflammatory response concomitant with the 
formation of a homeostatic environment favourable to the development of TLOs. 
Transcriptional data were corroborated by pancreatic protein expression of CXCL13, 
CXCL10, CXCL1, IL6 and IL1β (Figure 14B). Similar to human AIP patients, serum protein 
levels for CXCL13 were elevated in transgenic mice (Figure 14C). 
To gain a quantitative and qualitative overview of the immune cell populations in transgenic 
mice at the age of three and six months, we performed flow cytometry on isolated white blood 
cells from pancreata of C57BL/6 and Tg(ELa1-Lta,b). Consistent with the histological 
evaluation, a drastic increase in CD4+, CD8+ and B220+ lymphocytic cells in transgenic 
pancreata was shown at both time-points (Figure 14D). In contrast, control littermates 
displayed almost no detectable CD4+, CD8+ and B220+ cells. 
Moreover, we found a strong increase in CD45hiCD11bmi (R1) and CD45hiCD11bhi (R2) cells 
in pancreata of Tg(ELa1-Lta,b) mice compared to negative littermates. Further analyses 
revealed that the CD45hiCD11bmi population contained primarily granulocytes (Ly6ChiLy6Ghi 
cells) (approx. 73%) and to a lower degree inflammatory monocytes (Ly6Chi Ly6Glo) (approx. 
27%). The CD45highCD11bhigh cells were mainly composed of Ly-6Clow and Ly-6G- cells, 
which are most likely resident macrophages (Figure 15).  
 
 
 
Although β-pancreatic islets were not directly affected by the inflammatory process, 
pancreatic inflammation can lead to endocrine insufficiency. Therefore, we tested whether Tg 
mice are diabetic. Even though Tg(ELa1-Lta,b) mice remained tolerant in response to glucose 
load during an intraperitoneal glucose tolerance test (IPGTT,; (Khasawneh et al., 2009) 
Figure 16A), they had to secrete ~ 2-3 fold more insulin than their control littermates in order 
Figure 15. Characterization of myeloid 
cells in Tg(ELa1-Lta,b) mice. Two CD11b+ 
populations were found in pancreata of 3 
months old transgenic mice: R1 depicts 
CD11bhigh and R2 CD11blow cells. Gated on 
the R1 population in average 73% are Ly6C+ 
Ly6G+ granulocytes and 27% Ly6C+ 
inflammatory monocytes. In the R2 
population Ly6Clow Ly6Gneg cells were 
identified as resident macrophages. 
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to support the same glucose clearance. Further, qPCR analysis of genes involved in glucose 
and lipid metabolism revealed deregulation of transcripts involved in lipolysis, fatty acid 
oxidation, gluconeogenesis and insulin signalling were indicative of alterations in the 
endocrine compartment (Figure 16B). Overall, glucagon- and insulin-producing α and β cells 
in pancreatic islets appeared normal arguing against a functional deficit that could give rise to 
diabetes in Tg(ELa1-Lta,b) mice (Figure 16C). 
 
 
Figure 16. Analysis of the endocrine function of the pancreas in Tg(ELa1-Lta,b) and control mice (A) 
Intraperitoneal glucose tolerance test (IP-GTT) of 12 month-old Tg(ELa1-Lta,b) and C57BL/6 mice shows no 
signs of diabetes in Tg(ELa1-Lta,b) mice, however plasma insulin levels are significantly higher throughout IP-
GTT. (B) Analysis of pancreatic Cpt1a, Acc, Mttp, Glut1, Glut2, Gluko, insulin receptor (Ir) and insulin 
transcripts by Real-time PCR of 12 month-old Tg(ELa1-Lta,b) mice compared to negative littermates.  (C) 
Immunohistochemical analysis of pancreatic islets in 12 months old Tg(ELa1-Lta,b) mice and in age matched 
C57BL/6 mice. No difference in insulin or glucagon expression can be seen on pancreatic islets of transgenic 
mice compared to control. Magnification: 20x.   
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2.3.7. Germinal center formation and increased regulatory T-cells in Tg(ELa1-
Lta,b) mice 
 
To characterize the inflammatory cell populations in Tg(ELa1-Lta,b) pancreata in more detail 
we performed additional flow cytometry experiments, analysing CD62L, CD69 and CD44 
positive cell populations (Figure 17). A drastic increase in the activation of memory and 
effector CD4+ and CD8+ T-cells in Tg(ELa1-Lta,b) pancreata was observed at the age of 12 
months when compared to C57BL/6 controls.  
Additionally, we found substantially enhanced recruitment of FoxP3+CD25+ regulatory T-
cells (Treg) in Tg(ELa1-Lta,b) pancreata compared to negative littermates. This phenomenon 
of elevated Treg cells in inflamed tissues was already described in several autoimmune 
diseases like rheumatoid arthritis, multiple sclerosis and Crohn’s disease (Campbell and 
Koch, 2011) (Cao et al., 2003) (Kumar et al., 2006) (Maul et al., 2005) (Uhlig et al., 2006). 
Furthermore, these changes could be seen in the draining lymph node of the pancreas, the 
mesenteric lymph node and the spleen - albeit at much lower level - suggesting that the 
primary locus of auto-reactive immune activation is within the pancreas. 
Next, we evaluated the T-helper cell subsets (Th1/Th2/Th17) on mRNA level, based on their 
distinct cytokine production profile (Figure 18). Strong upregulation of Ifnγ and Tnfα and the 
transcription factor T-bet in 12-month-old Tg mice indicates the presence of predominantly 
Th1-type cells. Although, the expression of Gata3 is known to control the development of 
Th2 lineage, recently a stable Gata3+/T-bet+ cell subset was described (Hegazy et al., 2010). 
Cytokines secreted by Th2 cells such as Il4 and Il10 were also slightly upregulated. Cytokines 
produced by Th17 cells, Il17A, Il17F, as well as some Th2 cytokines (Il5 and Il13), were 
undetectable in the pancreata of Tg(ELa1-Lta,b) mice compared to controls (data not shown), 
which correlates to our analyses of human AIP pancreata.  Of note, in peripheral blood of 
human AIP patients, Th1 cells but not Th17 cells are predominant over Th2-type cells 
(Okazaki et al., 2010).  
To macroscopically identify organised inflammatory follicles within the pancreata of 
Tg(ELa1-Lta,b) mice we performed immunohistochemical stainings. By the age of three 
months transgenic pancreata contained high endothelial venules (HEV) (Figure 19). The 
above described follicles developed into tertiary lymphoid organs (TLOs) characterized by the 
presence of distinct T- and B-cell areas containing clusters of proliferating lymphocytes, 
CD21/35+ germinal center B-cells as well as FDC-M1+ follicular dendritic cell networks. 
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Figure 17. Flow cytometry of chronically inflamed Tg(ELa1-Lta,b) pancreata. (A) Gating strategy for 
activated CD4+, CD8+ T cells as well as (B) regulatory T cells (FoxP3+CD4+) in pancreata and mesenteric lymph 
nodes (mLN) of 12 month-old Tg(ELa1-Lta,b) and C57BL/6 control mice. (C) Quantification of activated CD4+, 
CD8+  T-cells and regulatory T-cells in pancreata  and mesenteric lymph nodes (mLN)) of 12 month-old 
Tg(ELa1-Lta,b) and C57BL/6 control mice. 
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Figure 18. mRNA transcript analysis of T-helper cell subsets. Quantitative RT-PCR analysis of pancreatic 
Tnfα, Ifnγ, T-bet, Gata3, Il4 and Il10 transcripts in 3 and 6 month-old Tg(ELa1-Lta,b) pancreata compared to 
negative littermates (3 and 6 months pooled).  
 
Figure 19. Characterization of tertiary 
lymphoid organs in Tg(Ela1-LTa,b) 
mice. Between 3 and 12 months of age 
Tg(ELa1-Lta,b) develop high endothelial 
venules, whereas HEVs are absent from 
age matched C57BL/6N mice (PNAd 
staining) (scale bar: 100 µm).  After 6 
months of age inflammatory infiltrates are 
found with distinct CD3+ and B220+ T- and 
B-cell compartments (scale bar: 200 µm). 
The cluster of Ki67+ proliferating 
inflammatory cells (scale bar: 200 µm) is 
indicative of a germinal center, which is 
supported by the presence of CD21/35+ 
germinal center B-cells (scale bar: 100 
µm). Of note, follicular dendritic cell 
networks (FDC-M1+) (scale bar: 100 µm) 
can be found in the inflammatory 
infiltrates of 12 months old Tg(ELa1-Lta,b) 
mice. 
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2.3.8. Analysis of total immunoglobulins in Tg(ELa1-Lta,b) and wild-type mice 
 
TLOs with germinal centers and an auto-inflammatory, activated lymphocytic environment in 
the exocrine part of Tg(ELa1-Lta,b) pancreata are reminiscent of an autoimmune disease. 
Thus, we investigated whether transgenic mice display increased immunoglobulins and/or 
auto-antibodies.  
Serum IgG4 is known to be elevated in 50% of AIP patients; however, IgG4 does not exist in 
mice. We therefore analyzed total IgG (including subtypes IgG1, IgG2a and 2b, IgG3), IgM 
and IgA levels at twelve-month-old Tg(ELa1-Lta,b) mice and negative littermates. We found 
a significant increase in total IgG (1.56 fold, P=0.0148), IgG1 (1.79 fold, P=0.0128), IgG2b 
(2.99 fold, P =0.0073), and IgM (1.65 fold, P=0.0050) of Tg(ELa1-Lta,b) mice when 
compared to C57BL/6 mice. The observed increase in immunoglobulins parallels the hyper-γ-
globulinemia found in human disease (Figure 20). 
 
 
Figure 20. Serum immunoglobulin measurement. Serum analysis of 12 month-old Tg(ELa1-Lta,b) shows 
significantly elevated total IgG, IgG1, IgG2b, IgM and IgA (n.s.) levels compared to age matched negative 
littermates. 
2.7.9. Development of auto-antibodies in transgenic mice 
 
The increased serum immunoglobulin levels and the presence of TLOs in the pancreas 
suggest that Tg(ELa1-Lta,b) mice had developed an autoimmune phenotype. Therefore, we 
investigated whether anti-nuclear antibodies (ANA) are present in sera of transgenic mice. 
Sera from six-, twelve- and eighteen-month-old mice were subjected to an indirect 
immunofluorescent microscopy assay (Figure 21). Although we could not detect auto-
antibodies at the age of six months in transgenic or wild-type mice, ANA were present in sera 
of Tg(ELa1-Lta,b) mice with an incidence of around 66% at the age of twelve months (Table 
3). To assess the specificity of ANA, we measured plasma concentrations of anti-nucleosome 
and anti-dsDNA antibodies. Levels of both antibodies were increased in twelve-month-old Tg 
mice (anti-Nucleosome P=0.1003; anti-dsDNA: P=0.0440; Figure 5C). Rheumatic factor 
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(RF) is elevated in sera of AIP patients (Okazaki and Chiba, 2002). Similarly, transgenic mice 
showed an almost four-fold increase in serum RF compared to negative littermates (P=0.029). 
We also identified an increase in anti-Smith IgG, indicating systemic autoimmune disease 
(P=0.028, Figure 5C). Thus, auto-antibodies seen in human AIP, as well as indicators of 
systemic autoimmune disease are present in the sera of Tg(ELa1-Lta,b) mice. 
As the inflammatory process started in the pancreas we investigated whether Tg(ELa1-Lta,b) 
mice developed auto-antibodies against pancreatic self-antigens, as observed in human AIP. 
(Asada et al., 2006) (Okazaki et al., 2010). Thus, we measured anti-PSTI, anti-LF and anti-
Lipase antibodies in twelve-month-old Tg mice (Figure 5D). We found significantly elevated 
levels of auto-antibodies against PSTI, LF, and the Lipase in Tg(ELa1-Lta,b) mice (PSTI: 
P=0.0003; LF: P=0.036; Lipase: P=0.028).  
 
Figure 21. Detection of antinuclear antibodies (ANA) and auto-antibodies against pancreas-specific 
proteins. (A) Detection of antinuclear antibodies (ANA) on Hep-2 cells with sera obtained from 6, 12 and 18 
month-old C57BL/6 and Tg(ELa1-Lta,b) mice (scale bar: 20µm). (B) Transgenic mice possess elevated serum 
anti nucleosomes and anti dsDNA antibodies, as well as Rheumatic factor and anti-Smith IgG levels which are 
indicative of a systemic autoimmune disease. (C) Detection of anti-PSTI, anti-Lactoferrin and anti-Lipase 
antibodies in sera from 12 months old C57BL/6 and Tg(ELa1-Lta,b) mice. 
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 Table 3. Incidence of AIP in Tg(ELa1-Lta,b) transgenic lines #58 and #40. Incidence and percentage of 
ANA is indicated for both lines and C57BL/6 mice. 
2.3.10. Tg(ELa1-Lta,b) T-cells cause acute pancreatic damage in Rag1-/- mice 
 
To examine the immune cells contributing to pancreatic damage in AIP pathogenesis, we 
transferred C57BL/6 and Tg splenocytes into Rag1-/- recipients. 7 days post splenocyte 
transfer Tg donor CD3+ cells, but not Tg donor B220+ B-cells (data not shown) were found in 
pancreata of Rag1-/- recipient mice. Concomitantly, significant elevation of serum amylase 
levels was observed (Figure 22). In contrast, adoptive transfer of C57BL/6 splenocytes 
neither led to influx of immune cells into the pancreas nor to detectable pancreatic damage. 
These experiments suggest that Tg T-cells are capable of damaging acinar cells in Tg(ELa1-
Lta,b) mice. 
 
 
Figure 22. Representative pathological findings from Rag1-/- pancreata after spleen cell transfer with cells from 
12 months old Tg(ELa1-Lta,b) and C57BL/6N mice. Presence of CD3+ T cells in Rag1-/- tissue indicates that the 
autoimmune disease is transferable (scale bars from left to right: 100 µm, 200 µm, 200 µm). The transferred 
immune cells from Tg(ELa1-Lta,b) mice into Rag1-/- pancreas led to pancreatic tissue damage shown by elevated 
amylase values compared to cells from C57BL/6 mice. 
2.3.11. Glomerulonephritis in Tg(ELa1-Lta,b) mice  
 
Extra-pancreatic pathologies are recognized as important manifestations of IgG4-related 
systemic disorders during AIP. Since increased immunoglobulin levels were found in sera of 
Tg(ELa1-Lta,b) mice, we investigated possible involvement of other organs. Indeed, 
                                               LYMPHOTOXIN DRIVEN AUTOIMMUNE PANCREATITIS           
53 
 
transgenic mice developed glomerular lesions, which became apparent at the age of twelve 
months and were more prominent after eighteen months of age. The mesangial matrix of 
Tg(ELa1-Lta,b) kidneys was broadened, resulting in narrowed peripheral capillaries as 
demonstrated by light- and electron microscopy. Immunohistochemistry demonstrated IgG 
deposits in the mesangium, but only occasionally in peripheral capillary walls. Quantification 
of immune deposits showed a significant increase after one year of age (Figure 23).  
 
 
Figure 23. Extrapancreatic manifestation of AIP in Tg(ELa1-Lta,b) mice. (A) Representative pathological 
findings in kidneys of Tg(Ela1-LTa,b) mice. Prominent IgG deposits, indicated with white arrow in the 
mesangium of Tg(Ela1-LTa,b) kidneys compared to age matched C57BL/6 controls. Accumulation of Mac2+ 
macrophages is observed in the capillaries of transgenic mice but not in negative littermates. The silverstain 
illustrates accumulation of mesangial matrix (black arrow), and the reduced number of open glomerular 
capillaries as compared to the control (scale bar: 20 µm). (B) Electronmicroscopy demonstrates mesangial 
matrix expansion (white arrows) and narrowing peripheral capillaries (white arrow heads) in transgenic mice 
compared to C57BL/6 mice. Thickening of the capillary wall and narrowing of the glomerular capillary by 
cellular interposition is illustrated in the lower right panel (white arrow) (scale bar: 5µm in upper row, 1 µm in 
C57BL/6 and 2 µm in Tg(ELa1-Lta,b) mice, lower row).  (C) Quantification of IgG deposits in mesangium and 
macrophage accumulation in capillaries in 3, 6, 12, 15 and 18 months old Tg(Ela1-LTa,b) (n=4-5) compared to a 
pool (n=8) of all representative age groups from C57BL/6 mice. *: P>0.05; **: P<0.01, ***: P<0.001.  
 
Increased accumulation of Mac-2+ macrophages in glomeruli correlated with age. Electron 
microscopy confirmed the mesangial matrix expansion and some electron dense immune 
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deposits were found predominantly in the mesangium. Occasionally interposition of cellular 
protrusions into the wall of peripheral capillaries was present. Podocyte foot processes were 
well preserved and comparable to the wild-type controls. The described renal lesions resemble 
an immune-complex glomerulonephritis, which is associated with AIP in some patients. 
2.3.12. Autoantibodies against commensal bacteria in Tg(ELa1-Lta,b) animals 
 
In wt, specific pathogen free (SPF) mice, high-affinity IgG responses specific for microbiota 
cannot be detected in serum (Slack et al., 2009). However, gut microbiota can contribute to 
autoimmune diseases, e.g. Crohn’s disease and rheumatoid arthritis (Tiwana et al., 1997) 
(Newkirk et al., 2010). 
To determine whether the observed hyper-γ-globulinaemia may be partly driven by increased 
systemic exposure to the intestinal microbiota, we used flow cytometry to quantify the serum 
titers of IgG1, IgG2b and IgM directed against the surface of live bacteria (Figure 24). 
Twelve-month-old Tg(ELa1-Lta,b) mice display increased IgG1, IgG2b and IgM titers against 
both bacterial strains when compared to wild type littermates.  
 
Figure 24. Autoantibodies against commensal bacteria. 12 month-old transgenic mice show an elevated 
serum IgG1, IgG2b and IgM titer against two of their own commensal bacterial strains (two facultative aerobic 
bacteria isolated from the fecal microbiota of Tg(ELa1-Lta,b) mice: Lactococcus gravieae and Lactobacillus 
murinus) compared to negative littermates. Pure cultures of the indicated bacteria were stained with dose-
titrations of serum from Tg(ELa1-Lta,b) or C57BL/6N mice. Serum antibody coating of bacteria was visualised 
using monoclonal PE-conjugated anti-mouse IgG1, FITC-conjugated anti-mouse IgG2b, APC-conjugated anti-
mouse IgM and quantified per bacterium by flow cyotmetry. Resulting MFI was plotted against total IgG1, 
IgG2b and IgM added to the assay as determined by ELISA.  
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The timecourse of anti-microbiota IgG appearance suggests that at least a portion of observed 
hyper-γ-globulinaemiea in Tg(ELa1-Lta,b) mice is due to intestinal mucosal damage resulting 
in an increased systemic exposure to gut bacteria. 
2.3.13. The role of monocytes and lymphocytes in the initiation and progression of 
AIP 
 
To define the cellular and molecular mechanisms of AIP development we crossed Tg(ELa1-
Lta,b) mice to mice lacking B- and T-lymphocytes (Rag1-/-) or pro-inflammatory monocytes 
(Ccr2-/-) (Mildner et al., 2009) (Kuziel et al., 1997).  
Crossing to Rag1-/- mice resulted in early pancreatic injury, based on serum lipase levels 
(similar to Tg(ELa1-Lta,b) mice) and acinar to duct metaplasia formation (Figure 25B). 
Furthermore Tg(ELa1-Lta,b) x Rag1-/- mice showed increased F4/80+ macrophage infiltration. 
On the contrary, lack of pro-inflammatory monocytes rescued the early onset of pancreatic 
tissue damage and concomitant lipase elevation; however, modest lymphocytic infiltration 
was observed. This suggests that proinflammatory monocytes support the initiation of 
pancreatic tissue damage in transgenic mice (Figures 25A and B).  
Altered transcriptional expression at 8 weeks corroborated this difference. Tg(ELa1-Lta,b) x 
Ccr2-/- mice displayed an increase in homeostatic chemokines, while in the absence of B and 
T-cells, genes involved in macrophage activation, e.g. Tnfα, Il6 and Ccl2 are significantly 
increased (Figure 25C). Between three and six months, B and T cells also seem to contribute 
to pancreatic inflammation, as serum lipase levels show similarly reduced levels in both 
Tg(ELa1-Lta,b) x Rag1-/- and Tg(ELa1-Lta,b) x Ccr2-/- mice (Figure 25B).  At later time 
points (twelve months), chronic tissue damage appeared to be driven by lymphocytes, as 
Tg(ELa1-Lta,b) x Ccr2-/- show organized T and B-cell infiltrates concomitant with 
significantly elevated serum lipase levels compared to Tg(ELa1-Lta,b) x Rag1-/- mice. In 
contrast to Tg(ELa1-Lta,b) x Rag1-/-, 12  months old Tg(ELa1-Lta,b) x Ccr2-/- mice displayed 
elevated anti-PSTI antibody levels (Figure 26), and immune deposits in the kidneys (Figure 
27). Thus, lack of pro-inflammatory monocytes protects from early pancreatic damage, but it 
does not affect the extent of AIP. From three months onwards, lack of lymphocytes resulted in 
reduced tissue damage and failed to induce AIP, suggesting that lymphocytes are directly 
involved in sustaining tissue damage and AIP in Tg(ELa1-Lta,b) mice.   
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Figure 25. CCR2+ macrophages aggravate the initiation phase of chronic pancreatitis whereas 
lymphocytes contribute to late damage and autoimmunity. (A) Immunohistochemical characterization of   2 
and 12-month-old Tg(ELa1-Lta,b) x Rag1-/- and Tg(ELa1-Lta,b) x Ccr2-/- mice. H/E, F4/80+ macrophages, Ki67+ 
proliferating inflammatory cells and acinar cells, CD3+ T-cells and B220+ B-cells are indicated (scale bar: 200 
µm). (B) Serum lipase levels  of 1, 3, 6 and 12 month-old C57BL/6; Tg(ELa1-Lta,b); Tg(ELa1-Lta,b) x Rag1-/-; 
Tg(ELa1-Lta,b) x Ccr2-/- mice. (C) Quantitative real-time PCR results from 8 weeks old mice show difference of 
pro-inflammatory chemokines (CXCL1, CXCL9, CXCL10) and genes involved in macrophage activation 
(TNFα, MCP-1, IL-6). Data are shown in fold changes. 
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Figure 26. Detection of auto-antibodies in serum transgenic mice. Lack of proinflammatory monocytes could 
not rescue the development of anti-PSTI antibodies in Tg(Ela1-LTa,b) mice. 
 
 
Figure 27. Detection of renal immune complexes in Tg(Ela1-LTa,b) x Ccr2-/- mice.  IgG deposits in kidneys 
from mice of various genotypes illustrates prominent IgG1 deposits in Tg(ELa1-Lta,b) x CCR2-/- mice. Scale bar 
50µm. In contrast, Tg(ELa1-Lta,b) x Rag1-/- lack glomerular IgG1 deposits (data not shown).  
2.3.14. Corticosteroid treatment is anti-inflammatory but not anti-autoimmune in 
Tg(ELa1-Lta,b) mice 
 
We next tested whether corticosteroid treatment, an established therapy for treating 
autoimmune disorders including AIP (Kamisawa et al., 2004), would be effective in Tg(ELa1-
Lta,b) mice. Prednisolone was administered four weeks long through the drinking water to 
twelve-month-old transgenic and wild type mice. Indeed, prednisolone treatment in mice with 
established AIP significantly reduced histological signs of inflammation, the number of 
infiltrating B- and T-cells, macrophages and also acinar cell proliferation. The treatment 
effectively reduced acinar-to-duct metaplasia lesions as well (Figures 28A and B). However, 
the systemic autoimmune reaction was not affected, indicated by the persistence of auto-
                                               LYMPHOTOXIN DRIVEN AUTOIMMUNE PANCREATITIS           
58 
 
antibodies (anti-PSTI) and immune complex deposition in the kidneys (Figure 28D, E and 
F). Severe side effects of long-term steroid treatment and in addition frequent relapses 
(approx. 40 %) are well-documented in patients (Kalaitzakis and Webster, 2011).  
Therefore, we compared prednisolone treatment with inhibitors of the CD40L-CD40 or the 
LTα1β2-LTβR signalling pathway. CD40 is a cytokine receptor expressed mainly on B-cells 
and antigen presenting cells (APCs). CD40 activation by its ligands CD40L or CD154, which 
is secreted by activated CD4+ T lymphocytes, stimulates APCs, namely dendritic cells, 
monocytes and macrophages to produce TNF, IL-1β, and IL-6. This signalling is essential for 
the induction of affinity maturation, and class switch recombination in response to T-
dependent antigen. Antibodies against CD40L were shown to prevent TH1 mediated 
autoimmune diseases (e.g. with preventing expansion of germinal center B-cells or activation 
of monocytes) in mouse models of diabetes, SLE, RA and MS ((Mohan et al., 1995) (Balasa 
et al., 1997) (Durie et al., 1993). Treatment with anti-CD40L antibody in Tg(Ela1-LTa,b) 
mice failed to reduce the extent of AIP, although a decrease in serum IgG levels confirmed 
treatment efficacy (Figure 29).  
In contrast, LTβR-Ig (a soluble chimeric protein that efficiently inhibits LTβR signalling) 
(Force et al., 1995) abrogated pancreatic inflammation as well as acinar-to-duct metaplasia 
upon four weeks of treatment (Figures 28A and B). Moreover, LTβR-Ig treatment 
significantly reduced the expression of chemokines and cytokines compared to prednisolone 
treatment (Figure 28C). Importantly application of LTβR-Ig also led to a remarkable 
reduction of auto-antibodies (e.g. against PSTI), and strongly reduced the deposition of 
immune complexes in the glomeruli. This suggests that in Tg(ELa1-Lta,b) mice, prednisolone 
acts rather as an anti-inflammatory than anti-autoimmune therapy (Figures 28D-F). 
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Figure 28. Corticosteroid treatment as well as blocking the LTβR signalling axis reduced the severity of 
inflammation. (A) Immunohistochemical characterization of pancreatic tissue from 12 months old mice treated 
with 10 mg/kg prednisolone (second row) and mice injected weekly with 100 µg LTβR-Ig fusion protein (third 
row), compared to age matched untreated Tg(ELa1-Lta,b) mice (first row) (scale bar: 200µm). H/E, CD3+ T-
cells, B220+ B-cells, Ki67+ proliferating inflammatory cells and acinar cells and F4/80+ macrophages are 
indicated (scale bar: 200 µm). (B) Both steroid and LTβR-Ig treatment reduces the number of acinar to duct 
metaplasia. H/E staining of 12 months old Tg(ELa1-Lta,b) mice untreated, treated with corticosteroid and LTβR-
Ig respectively (scale bar: 100 µm). Number of acinar to duct metaplasia was quantified and normalized to the 
total surface of pancreas. (C) Detection of CXCL10 and CXCL13 protein expression in pancreata of treated and 
control mice. (D) Detection of anti-PSTI antibodies before and after prednisolone or LTβR-Ig treatments 
compared to wt controls. (E) Quantification of IgG1 deposits in the glomeruli after four week-long treatments 
with either prednisolone or LTβR-Ig compared to age matched Tg(ELa1-Lta,b) and C57BL/6 animals. (F) 
Representative images of IgG1 deposits in kidneys after LTβR-Ig and prednisolone treatment. Scale bar: 50µm.  
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Figure 29. Anti-CD40L treatment did neither reduce pancreatic inflammation nor the level of anti-
lactoferrin auto-antibodies. (A) Immunohistochemical characterization of pancreatic tissue from 12 months 
old mice treated with 100 µg anti-CD40L antibody for 4 weeks. B220+ B-cells, CD3+ T-cells, F4/80+ 
macrophages and Ki67+ proliferating inflammatory cells and acinar cells are indicated. Scale bars: 200 µm. (B) 
Visualization of IgG1 deposits in the glomeruli after 4 week-long treatment with α-CD40L antibody compared 
to untreated 12-month-old Tg(ELa1-Lta,b) and C57BL/6 animals. Scale bars: 50 µm.  (C) Detection of anti-
lactoferrin antibodies after 4 week-long treatments with aCD40L antibody compared to Rag1-/- controls. 
Comparison of total serum IgG levels before and after aCD40L treatment. 
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2.4. Discussion 
 
The underlying mechanisms inducing and maintaining AIP remain elusive, thus far. Here, we 
show that patients suffering from AIP display high pancreatic LTαβ and chemokine 
expression. Of note, AIP and chronic pancreatitis with severe fibrosis each displayed unique 
expression signatures. Not only could we detect a strong upregulation of LT on infiltrating 
lymphocytes, but also on acinar cells that have undergone metaplasia.  
Recently, IL17 was proposed to be crucial for autoimmune disease development as well as for 
TLO generation in non-lymphoid organs, stimulating stromal CXCL13 and CCL19 
expression (Rangel-Moreno et al., 2011). However, we could not find significant changes in 
pancreatic IL17 mRNA expression in human AIP patients compared to healthy controls, nor 
could we find IL17 transcripts in Tg(Ela1-Lta,b) mice, suggesting that autoimmunity and 
TLO development during AIP are IL17-independent.    
Existing mouse models for AIP all rely on inducing pancreatitis via experimental means i.e. 
by immunization with self-antigens, injection of pathogens (Haruta et al., 2010) or via 
adoptive transfer of auto-reactive cells or Tregs (Uchida et al., 2002),(Nishio et al., 
2011),(Asada et al., 2010),(Meagher et al., 2008). Such models can be highly variable. 
Though spontaneous development of AIP has been reported previously in various genetic 
backgrounds prone to develop autoimmunity (Freitag et al., 2010), a genetic model of AIP 
with robust penetrance and phenotypic reproducibility on a C57BL/6 background was 
previously unavailable.  
Based on our data derived from human AIP patients we have established a novel transgenic 
mouse model of AIP by expressing LTαβ specifically on acinar cells. This led to a 
transcription profile of inflammatory chemokines and cytokines (e.g. in pancreas and serum) 
reminiscent of human AIP causally linking ectopic LT expression in the pancreas to the 
development of AIP. At approximately six months of age, ectopic LT expression led to the 
generation of TLOs - as frequently found in AIP. Surprisingly, localized inflammation in the 
pancreas developed into AIP and systemic autoimmune disease over time. This coincided 
with a rise in pancreatic expression of endogenous Lta and Ltb transcripts, most likely 
produced by infiltrating immune cells.  
AIP in Tg mice was characterized by (1) the development of antibodies against pancreatic 
self-antigens, (2) the presence of ANA, (3) the rise in total serum IgG, (4) antibodies against 
commensal bacteria as well as (5) extrapancreatic manifestation - mainly in the kidney. 
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Formation of pancreatic TLOs, T-cell polarization (mainly towards Th1), systemic 
autoimmunity and involvement of other organs (e.g. kidney) in Tg mice suggests a disease 
profile consistent with Type 1 human AIP. Importantly, the degree of Lta and Ltb transcript 
upregulation in transgenic pancreata (50 to 500 fold) was comparable to pancreata of human 
AIP patients (100 to 200 fold). 
Flow cytometry analysis demonstrated a strong shift in the activation of effector and memory 
T-cells in pancreata of Tg(ELa1-Lta,b) mice. Further, as in other autoimmune diseases, an 
increase in Treg cells in the pancreas was observed (Cao et al., 2003) (Kumar et al., 2006) 
(Maul et al., 2005) (Uhlig et al., 2006).  TNF was shown to have the capacity to expand the 
functional Tregs, representing a negative feedback loop to counteract TNF-induced pro-
inflammatory effects (Chen and Oppenheim, 2011). This implies that the significantly 
elevated TNF levels in 12-month-old transgenic mice could explain the increase in the Treg 
subset. However, decreased functionality of Tregs, or Teff resistance on Treg-mediated 
suppression has been described in various human autoimmune diseases (Long and Buckner, 
2011), which could contribute to AIP development in Tg(ELa1-Lta,b) mice.  
The autoimmune phenotype in Tg(ELa1-Lta,b) mice could be prevented by genetic depletion 
of B- and T-lymphocytes. In contrast, absence of pro-inflammatory (Ly-6Chi) monocytes due 
to CCR2-deficiency pinpointed these cells to be important in initiating early acinar cell 
damage. However, lack of these Ly6Chi cells did not ablate development of autoimmunity 
which is in contrast to autoimmune models of the CNS (Mildner et al., 2009). Of note, 
adoptive transfer of transgenic splenocytes into Rag1-/- recipients resulted in the influx of T-
cells, but not B-cells in the pancreata in parallel with acute pancreatic damage. These data 
suggest that, in contrast to the early pancreatic damage mediated by innate immune cells (e.g. 
pro-inflammatory monocytes), subsequent damage in Tg(ELa1-Lta,b) mice is mediated by 
cells of the adaptive immune system, particularly T-cells. This is corroborated by the strong 
reduction of pancreatic tissue damage (e.g. serum lipase) in Tg(ELa1-Lta,b) x Rag1-/- mice 
between 6-12 months of age. In contrast, Tg(ELa1-Lta,b) x CCR2-/- mice display a similar 
amount of pancreatic tissue damage when compared to Tg(ELa1-Lta,b) mice within the same 
time-frame. 
Thus, acinar cell-specific expression of LT leads to two independent reactions: (1) Early onset 
of pancreatitis attracting innate immune cells (e.g. pro-inflammatory monocytes) and 
activating tissue macrophages, presumably to remove non-viable pancreatic cells. (2) 
Recruitment of lymphocytes to the pancreas results in further increase in cytokine and 
chemokine expression contributing to an inflammatory milieu sustaining pancreatitis, 
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metaplasia and enabling germinal center and TLO formation. This environment fosters 
activation, clonal selection and expansion of auto-reactive lymphocytes - as corroborated by 
antibodies against pancreatic self-antigens found in Tg(ELa1-Lta,b) mice.  
Currently, treatment options for AIP are limited. AIP patients respond well to corticosteroid 
treatment; however disease relapses upon treatment discontinuation are very frequent. 
Interestingly, neither pro-inflammatory cytokines nor homeostatic chemokines were reduced 
upon steroid treatment in sera of human AIP patients, which is likely responsible for the 
disease relapse. Therefore, a complementary treatment which could additionally down-
regulate inflammatory mediators is very likely to benefit patients. 
Tg(ELa1-Lta,b) mice were also responsive to corticosteroid treatment, which failed to revert 
the autoimmune repertoire (e.g. anti-PSTI antibodies). In contrast, treatment with LTβR-Ig 
led to a strong decrease of inflammation and also ablated AIP in Tg mice (e.g. reduction in 
auto-antibodies, abrogation of renal immune deposits and decrease of pancreatic CXCL13). 
We also depleted germinal center B-cells using a CD40L antibody (Heikenwalder et al., 
2007). Although IgG levels were reduced, the load of pancreatic inflammation and the course 
of AIP remained unchanged upon treatment in Tg(ELa1-Lta,b) mice. This could possibly be 
explained by the presence of long-lived plasma cells in the pancreas that do not respond to 
anti-CD40L treatment.  
This indicates that corticosteroid treatment acts as an anti-inflammatory, whereas LTβR-Ig 
treatment has additional anti-autoimmune effects. Surprisingly, we also found that 
suppression of LTβR-signalling in mice with established AIP protects against peripheral 
pathologies caused by AIP (e.g. immune-complex glomerulonephritis). Therefore, inhibition 
of the LTβR-signalling pathway could be a viable alternative or supplementary approach for 
the treatment of AIP. 
In summary, increased local LT expression in the pancreas is sufficient to drive chronic 
pancreatitis, to reproduce various clinical features of human AIP and to induce systemic 
autoimmunity. Tg(ELa1-Lta,b) mice will facilitate the study of AIP-specific pathogenic 
mechanisms and allow testing potential treatment interventions. 
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2.5. Outlook 
 
Human AIP is believed to be a T-cell mediated autoimmune disease. In Tg(ELa1-Lta,b) 
mouse model we could show with adoptive transfer of splenocytes into Rag1-/- recipients, that 
T-cells can directly damage acinar cells.  
(1) Based on this we would first like to analyse if the CD3+ T-cells we found infiltrating the 
Rag1-/- pancreata from Tg donor cells, belong to the group of CD4+ or CD8+ T-cells.  Further, 
we plan to investigate the mechanisms of the caused acinar cell damage with a cytotoxic T-
lymphocyte killing assay. Although, isolating and culturing viable immune cells from the 
pancreas is experimentally difficult, a trend towards the activation of CD8+ lymphocytes in 
the mesenteric lymph nodes was observed.  
(2) Secondly, to delineate the role of B-cells in the pathogenesis of AIP and in acinar cell 
damage in Tg(ELa1-Lta,b) mice, I already initiated an intercrossing with JH-/-  mice (targeted 
deletion of the gene responsible for immunoglobulin heavy chain production provides a 
mouse model devoid of mature  B-cells). I plan to monitor the changes in serum amylase and 
lipase, and follow up the composition and number of infiltrating immune cells on histology, 
as well as investigate the polarization of Th-cell subsets over time. Since JH mice lack both 
surface immunoglobulins and secreted IgG and IgM, we cannot use the conventional ANA 
assay and the above described anti-PSTI or anti-LF Elisa systems to assess the role of B-cells 
in autoimmunity. Therefore, I plan to deplete B-cells with anti-murine CD20 (rituximab) 
antibody from Tg(ELa1-Lta,b) mice with established AIP and analyse auto-antibody 
production, cytokine and chemokine expression and renal immune-complex deposition.  
(3) Our results indicate, that in Tg(ELa1-Lta,b) mice CD4+ T-cell polarization mainly occurs 
towards Th1 phenotype, based on elevated Tnfα, Ifnγ and Tbet levels. Therefore, I would like 
to test the efficacy of an anti-TNF treatment in Tg mice. The activity of TNF can be inhibited 
in vivo by injection of a recombinant fusion protein consisting of the mouse p55 TNFR-IgG.  
(4) There is now emerging evidence implicating gut microbiota in the starting phase of human 
autoimmune diseases. Besides inflammatory bowel disease, in which bacteria may act on 
local tissue directly as well as indirectly, inflammatory diseases with remote tissues affected 
seem to be modulated by the gut environment (e.g. in rheumatoid arthritis, type 1 diabetes 
mellitus or in the animal model of MS (EAE) (Berer et al., 2011). Interestingly, Tg(ELa1-
Lta,b) mice develops auto-antibodies against their own commensal bacteria. Thus, I would 
like to assess whether modification of the commensal microflora would influence the 
induction and development of AIP in Tg(ELa1-Lta,b) mice. Tg mice will be treated with an 
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antibiotic cocktail, that has been shown to effectively reduce the gut intestinal bacterial 
burden (Ochoa-Reparaz et al., 2009). Alternatively, although cumbersome it would be 
feasible to generate germ free Tg mice to thoroughly investigate the role of commensal 
microflora in autoimmune pancreatitis.  
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2.6. Material and Methods 
 
Human samples: Human pancreas biopsies and serum samples were obtained from the 
University Hospitals Zurich and Bern, the University of Graz and Ehime University. All 
samples were registered in the respective biobanks and kept anonymous. The research project 
was authorized by the Ethics Committees of the University Hospital Zurich and the Canton of 
Zurich (Ref. Nr.StV 26-2005), local ethics committee Bern, Graz (Ref. Nr 20-492 ex 08/09), 
and the Ehime University Graduate School of Medicine (#1001003).The study protocol was 
in accordance with the ethical guidelines of the Helsinki declaration.  
 
PCR specific for Tg(ELa1-Lta,b) mice: For transgenic LTa the following primers were used: 
Forward primer: (Prp 5’): 5’-CTG AGT ATA TTT CAG AAC TG-3’. Reverse primer: (LTa 
rev): 5’-CAG AGA AAA CCA CCT GGG AG-3’. For transgenic LTb the following primers 
were used: Forward primer (Prp 5’): 5’-CTG AGT ATA TTT CAG AAC TG-3’. Reverse 
primer: (LTb rev): 5’- GAG TCT CTG AGA GGC TAG AG-3’. The following PCR 
conditions were established on a Gene Amp® PCR System 9700 PCR machine (Applied 
Biosystems): 95°C 60 sec denaturation; 55°C 50 sec annealing; 72°C 50 sec elongation; 35 
cycles. 
 
Real-time polymerase chain reaction: For mRNA expression analysis Real-time PCR was 
performed using Fast Start SYBR Green Master Rox (Roche) or specific TaqMan® Gene 
Expression assays (Applied Biosystems, AB). Primers were custom made by Microsynth or 
purchased from ABI. (Primer sequences and probes are listed in supplemental table 2) Real-
time PCR was performed: (1) On an ABI PRISM 7900 HT Fast Real-Time PCR System 
(AB). Data were generated and analyzed using SDS 2.4 and RQ manager 1.2 software. The 
mRNA expression levels were normalized to the housekeeping gene Gapdh, primer sequences 
used are listed in the supplemental material. Identical cryo-blocks used for mRNA-expression 
analysis of human samples were controlled on histological level by Hematoxilin-Eosin (H/E) 
staining to verify the respective pancreatic pathology. Specimens that did not meet the 
respective pathological criteria were not included. (2) Real-time PCR was run on a Taqman 
7000 or 7500 FAST (Applied Biosystems, Switzerland) under standard conditions. Transcript 
levels were quantified using 18S rRNA (TaqMan® Ribosomal RNA Control Reagents, 
Applied Biosystems) as a reference and normalized.  
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Flow cytometry: Pancreata from Tg(ELa1-Lta,b) and wt mice were harvested immediately 
after sacrifice and dissected free of contaminating lymph nodes or fat pads. Pancreata from 
two mice were pooled for the analysis. Tissues were macerated with scalpels in a petri dish 
and transferred in a 2 ml tube containing 2 ml Collagenase D solution (Roche 2 mg/ml) for 30 
minutes at 37°C with agitation. DNase (2.5 mg/ml) was added and the tissue was drawn 
through an 18-gauge needle several times.  After washing, lymphocytes were isolated using 
density gradient separation (Lymphoprep) and centrifugation at 1200 rpm for 45 minutes at 
room temperature. The buffy coat, containing lymphocytes was removed and washed. Cells 
were resuspended in FACS buffer and cell populations were characterized with antibodies 
against CD45, CD4, CD8, CD11b, B220, Ly6G and Ly6C. 
 
Antinuclear antibody (ANA) detection: Sera obtained from Tg(ELa1-Lta,b) transgenic mice 
and C57BL/6 mice at the age of 6, 12 and 18 months were used to detect the presence of 
ANA using Hep2 cells (Euroimmun Lübeck, Germany). The cells were incubated with 1:60 
and 1:200 dilutions of each mouse serum sample in PBS, followed by incubation with FITC-
conjugated polyclonal goat antibody to mouse IgG-H&L (ab6785, Abcam, Cambridge, UK). 
The reaction was visualized using a LEICA DLMB immunofluorescence microscope 
equipped with FITC (absorption, 485–520 nm; emission, 520–560 nm wavelengths) filter 
sets. Staining intensity was determined visually based on independent observation of two 
experienced technicians of the routine diagnostic immunology laboratory.  
 
Serum Anti-LF, anti-lipase and anti-PSTI Antibodies: Microtiter plates (MaxiSorp; Nalge 
NUNC, Roskilde, Denmark) were coated with 20 mg/ml of LF (Sigma Chemicals), 10 mg/ml 
PSTI (Graf et al., 2002) and 10mg/ml purified pancreatic rat lipase in 50-mM sodium 
carbonate buffer (pH 9.5), and kept overnight at 40C. The coated wells were washed with PBS 
and blocked with 5% nonfat milk in PBS for 2 h at 370C. After three washes with PBS, each 
well was incubated with of mouse serum sample diluted at 1:10 with PBS containing 2% 
nonfat milk for 2 h at room temperature. The wells were then washed with PBS and incubated 
with Phosphatase-conjugated goat anti-mouse antibodies (Biosource) for 1 h at room 
temperature. After three washes with PBS, the bound antibodies were detected with 
Phosphatase substrate (Dako, Glostrop, Denmark). The plates were read at 405 nm using an 
ELISA plate reader (Vmax, Molecular Devices, Tokyo, Japan). 
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Statistical analyses and software: GraphpadPrism version 5 (LaJolla, Ca) was used to 
construct figures and diagrams. One-way ANOVA or unpaired t-tests and Mann-Whithey 
tests were used where appropriate. Differences were considered statistically significant if P < 
0.05 and marked with an asterisk. Asterisks indicate: *: P<0.05; **: P<0.01, ***: P<0.001. 
 
Animal husbandry and samples: Animals were maintained under specific pathogen–free 
conditions, and experiments were approved and conform to the guidelines of the Swiss 
Animal Protection Law, Veterinary office, Canton Zurich. C57BL/6 and Rag1-/- mice were 
purchased from The Jackson Laboratory, CCr2-/- mice were purchased from the Jackson 
laboratory (Kuziel et al., 1997).  
 
Generation of Tg(ELa1-Lta,b)  mice: The promoters from Alb-LTa  (Heikenwalder et al., 
2005) and lck-LTb (Heikenwalder et al., 2008) expression constructs were cut out by Not I, 
BamH I double digest and the remaining DNA expression vector cassettes purified (LTa-
expression cassette; LTb expression cassette). The modified rat pancreatic elastase promoter 
plasmid (deleted for the restriction site BamH I) (Swift et al., 1984) was used as template to 
amplify the promoter sequence. The fwd primer was designed with a 24 base overhang to 
create a BamH I cut site. The PCR products were inserted to pCR®2.1-TOPO® Vector by 
using TOPO TA cloning Kits (Invitrogen). The positive clones were selected and analyzed by 
sequencing (Microsynth). A clone containing the correct elastase promoter sequence was 
double digested by Not I and BamH I in order to isolate the elastase promoter and was then 
purified by using GenEluteTM HP Plasmid Midiprep Kit (Sigma). The elastase promoter - Not 
I and BamH I fragment was then ligated into the LTa and LTb expression cassettes using a T4 
DNA Ligase (New England Biolabs). Bacterial colonies containing the elastase-LTa and 
elastase-LTb constructs were then picked, cultivated and screened by digestion with BamHI 
and NotI. After sequencing plasmids, and subsequent linearization microinjection was 
performed into pronuclei of C57BL/6N zygotes with equimolar ratio of independent, 
linearized constructs harbouring each the Lta and Ltb murine cDNA.  
Upon PCR analysis, from 50 born offspring, 8 were identified as single or double transgenic. 
Some of these potential founder lines expressed the transgene(s) on mRNA level in the 
pancreas (Supplemental Figures 3B, C and 4A). After expansion of those transgenic lines and 
further analysis of the F2 and F3 generations we selected two double transgenic, LTab-
expressing lines C57BL/6N-Tg(Ela1-Lta,b)228, 229Biat (Tg228 and Tg229 denoted as line 
#40 and #58) for further experiments described. Litter size and average weight (2-18 months) 
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remained normal in both transgenic lines when compared to age matched C57BL/6N control 
mice. Moreover, #40 and #58 mice displayed no obvious behavioural changes and alteration 
of breeding efficiency when compared to non-transgenic littermates (data not shown). 
Transgene expression stayed stable up to 12 months of age in both lines (Supplemental Figure 
4C). 
 
RNA extraction: RNA was extracted and used for Real-time polymerase chain reaction 
(PCR) as described previously (Reding et al., 2006) or with a newly established method using 
the Precellys®24 Dual homogenizer with MagNA Lyser Green Beads from Roche Applied 
Science. In short, a small piece of snap frozen tissue was transferred to a tube containing 
beads, 650µl of Lysis buffer (Qiagen) was immediately added and the tube immediately 
transferred to the Precellys and homogenized once at 6000 rpm for 30 seconds. The 
homogenates were transferred to a Qiashredder and the RNA was extracted following the 
Qiagen RNeasy Mini Kit extraction protocol with an on column DNase digestion step. 
Purified RNA was reversely transcribed into cDNA using Quantitect Reverse Transcription 
Kit (Qiagen) according to the manufacturer’s protocol. For the 7500 FAST Real-Time PCR 
System, RNA was transcribed using the High Capacity cDNA Reverse Transcription Kit. 
 
Serum markers of digestive enzymes produced by the pancreas: Samples for serum 
analyses were collected in serum separator tubes (BD, Microtainer, 365951), allowed to clot 
at room temperature and centrifuged at 10000 rpm for 6 min. The serum was transferred to a 
cryo-tube and stored at -80 0C until further analysis. Amylase and Lipase levels were 
measured using a serum multiple biochemical analyzer (Ektachem DTSCII; Johnson & 
Johnson Inc., Rochester, NY, USA). 
 
Histology and Immunohistochemistry: Paraffin (2μm) sections of pancreas were stained 
with Hematoxylin/Eosin or various primary and secondary antibodies. Paraformaldehyde 
(4%) fixed and paraffin embedded tissue was incubated in Ventana buffer and staining was 
performed on a NEXES immuno-histochemistry robot (Ventana instruments, Switzerland) 
using an IVIEW DAB Detection Kit (Ventana) or on a Bond MAX (Leica) system. 
Antibodies against murine B220+ B-cells (Pharmingen; 1:400), F4/80 (Serotec, 1:50) for 
macrophages, CD3+ T-cells (clone SP7, Neomarkers; 1:300) were kindly provided by R. 
Zinkernagel (Odermatt et al., 1991). Meca-79 (Vector 1:1000), FDCM-1 (BD Biosciences cat. 
Nr. 551320 rat monoclonal 1:60), CD21/35 (BD Biosciences cat. Nr. 553817 rat monoclonal 
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(7G6) 1:2000), Ki67 staining proliferating cells was purchased form NeoMarkers (Code RM-
9106-S; 1:200). The antibody against human LTb was kindly provided by J. Browning 
(Biogen Idec.) Antibodies against human CD3 (neomarkers RM—9107-So rabbit monoclonal 
SP7 1:300) (Ventana Roche Prodiluted) CD20 (Ventana Roche Prodiluted) Amylase (Sigma 
1:1000) were used for immunofluorescent stainings. Image acquisition was performed on an 
Olympus BX53, equipped with an Olympus DP72 camera using cellSens software or on an 
Olympus SZX12, equipped with JVC digital camera (KY-F70; 3CCD) using Analysis 
software. 
Immunohistochemistry of kidneys was performed on paraffin embedded materials as 
previously described (Vielhauer et al., 2009). In brief, the sections were deparaffinized, 
rehydrated and incubated in 3% hydrogen peroxide to block endogenous peroxidases. 
Endogenous biotin was blocked by the Avidin/Biotin blocking Kit (Vector, Burlingame, CA). 
An autoclave oven (or microwave treatment) was used for heat based antigen retrieval. 
Incubation with the primary antibody was performed for 1 hour or overnight. Incubation with 
biotinylated secondary antibodies (Vector) was followed by the ABC reagent (Vector). 
3’3’Diaminobenzidine (DAB, Sigma, Taufkirchen, Germany) with metal enhancement was 
used as a detection system. Consecutive sections were stained for mouse IgG (Vector), 
macrophages using Mac-2 (Cederlane Labs, Ontario, Canada), and smooth muscle actin 
(DAKO, Hamburg, Germany). Glomerular staining was quantified for IgG deposits in the 
mesangium, IgG deposits in peripheral glomerular capillaries, monocyte/macrophage 
accumulation and the expression of smooth muscle actin using semiquantitative scores (from 
0-3).  
 
Treatment with prednisolone: 12 months old Tg(ELa1-Lta,b) and C57BL/6 mice were 
treated with 10 mg/kg per day Prednisolone (Sigma-Aldrich) for four  weeks. To deliver a 
dose of 10 mg/kg per day, 30 milligram of prednisolone was dissolved in 1ml ethanol and was 
added to 500 ml drinking water to give a final concentration of 60 g/ml. Prednisolone 
containing water was replaced every three days as this has been reported to maintain systemic 
levels of prednisolone (Biondo et al., 2006). After four weeks of treatment mice were 
sacrificed to obtain serum and pancreatic tissues. 
 
Treatment with LTβR-Ig: 12 months old Tg(ELa1-Lta,b) mice were injected 
intraperitoneally with 100 µg LTβR-Ig fusion protein (n=5) or with MOPC21 (control IgG) 
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(n=5) 4 weeks long on weekly basis. After four weeks of treatment mice were sacrificed, 
pancreas was resected and serum was obtained through cardiac puncture.  
 
Treatment with anti-CD40L antibody  
12 months old Tg(ELa1-Lta,b) mice were injected intraperitoneally with 100 g a -CD40L 
(MR-1) antibody (n=6) or with MOPC21 (control IgG) (n=5) four weeks long on weekly 
basis. After four weeks of treatment mice were sacrificed, pancreas was resected and serum 
was obtained through cardiac puncture. 
 
Adoptive spleen cell transfer: 12 months old Tg(ELa1-Lta,b) (n=3) transgenic mice and 
C57BL/6 mice (n=3)  were sacrificed and spleen cells were obtained. Spleen cells were 
filtered through a 40 µm cell strainer and 5 x 107 cells in 200 µl PBS were intravenously 
injected into Rag1-/- recipient mice (n=5). 7 days after the spleen cell transfer recipient mice 
were sacrificed and pancreatic tissues were examined for lymphoid cell infiltration 
(pathological damage). In parallel, serum amylase and lipase levels from recipient mice were 
analyzed. 
 
Anti-nuclesome, anti-histone, RF, anti-Smith IgG detection: Anti-nucleosome and anti-
dsDNA antibodies: NUNC maxisorp ELISA plates were pre-coated with poly-L-lysine 
(Trevigen, Gaithersburg, MD, USA) and PBS (ratio 1:1) for 1 hour as described  (Lech et al., 
2011)). In brief, ELISA plates were washed with 50mM Tris 0,14M NaCl buffer and 
incubated with mouse Histones (both 2µg/ml) or Nucleosome (2µg/ml) in SCC buffer 
overnight at 4°C. Anti-Smith antibodies: NUNC maxisorp ELISA plates were coated with 
Smith (Sm) antigen (Immunovision, Springdale, AR) in 0,05M carbonate-bicarbonate buffer 
overnight at 4°C. Rheumatoid factor: ELISA plates were coated with 10 µg/ml rabbit IgG 
(Jackson Immunoresearch, West Grove, PA, USA) in 0,05M carbonate-bicarbonate buffer 
overnight at 4°C. Serum samples were diluted 1:3 for all anti-DNA and anti-Nucleosome IgG 
ELISAs or 1:6 for anti-Smith and anti-RF ELISAs. C57BL/6 24-week mouse serum or 
antibody-poor serum (IRF-4 knock-out mice) was used as negative control. C57BL/6-lpr and 
MRL-lpr 24-week mouse serum was used as positive control. Specific IgGs were detected by 
horseradish peroxidase-conjugated goat anti-mouse IgG (Bethyl Labs, Montgomery, TX, 
USA).  
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Glucose Tolerance Test (GTT): After an overnight fast, GTT was performed by i.p. 
injection of 1.5 g/kg body weight of glucose (Glucosteril®, Bad Homburg, Germany). Blood 
samples were drawn at indicated time points and glucose levels were measured using a 
glucometer (Bayer Ascensia Elite XL, Leverkusen, Germany). Insulin levels were measured 
using Rat Insulin ELISA Kit (Crystal Chem Inc., Downers Grove (IL), USA). 
 
Electron microscopy: Tissue pieces of 1 mm3 were fixed in 2.5% phosphate buffered 
glutaraldehyde, post-fixed in 1% Osmium tetroxide and embedded in Epon Epoxy resin 
following routine protocols. Ultra-thin sections were cut at 70 nm, fixed on grids and stained 
with uranyl-acetate for 10 minutes and lead citrate for 10 minutes. Grids were scanned on a 
transmission electron microscope (Philips CM 100) available at the Center of Microscopy and 
Image Analysis, University of Zurich, Switzerland.  
 
Lymphotoxin alpha protein measurement: Microtiter plates (MaxiSorp; Nalge NUNC, 
Roskilde, Denmark) were coated with 5 µg/ml of anti-LTaFcm (provided by Dr. Grogan, 
Genentech), in 100 ml of 50-mM sodium carbonate buffer (pH 9.5), and kept overnight at 
40C. The coated wells were washed three times with PBS +0.05% Tween and blocked with 
5% PBS/BSA for 1 h at room temperature. After three washes, each well was incubated 
overnight at 40C with 100 ul LT standard dilutions (RnD Systems, recombinant TNFb) and 
pancreas homogenates, diluted at 1:10 with 1% PBS/BSA. The wells were then washed five 
times and incubated with the detection antibody (50 ng/ml biotinilated anti-mouse TNFb, 
RnD Systems) for 2 h at room temperature. After five washes 100 µl Avidin-HRP 
(eBioscience) was added to each well. The bound antibodies were detected with TMB 
solution (eBioscience) incubated for 15 minutes in dark. After addition of 20% sulphuric acid 
the plates were immediately read at 450 nm using an ELISA plate reader (Vmax, Molecular 
Devices, Tokyo, Japan). 
 
Cytokine Protein array and Immunoglobulin measurement: Cytokine protein and 
immunglobulin levels from mouse pancreatic tissue and serum, and human serum BLC were 
measured using a multiplexed particle-based flow cytometric cytokine assay (Vignali et al., 
2000). Human and mouse kits were purchased from BioRad (Ismaning, Germany) and R&D 
Systems (Oxon, UK) and Millipore (Zug, Switzerland). The procedures closely followed the 
manufacturer’s instructions. The analysis was conducted using a conventional flow cytometer 
(Guava EasyCyte Plus, Millipore, Zug, Switzerland) Multiplexed particle-based flow 
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cytometric assays. Protein concentration from pancreas homogenates were determined by 
BCA (explain, vendor) assay, and final cytokine concentrations were normalized to total 
protein concentrations.   
 
Bacterial FACS: Bacterial FACS analysis was performed as described previously (Slack et 
al., 2009). Two facultative aerobic bacteria were isolated from the fecal microbiota of 
Tg(ELa1-Lta,b) mice, identified as Lactococcus garvieae and Lactobacillus murinus. Briefly, 
5ml LB cultures were inoculated from single colonies of plated bacteria and cultured 
overnight at 37°C without shaking. 1ml of culture was gently pelleted for 3min at 7000rpm in 
an Eppendorf minifuge and washed 3x with sterile-filtered PBS/1%BSA/Na-Azide before 
resuspending at approximately 107 bacteria per ml. Mouse serum was diluted 1:10 in 
PBS/1%BSA/Na-Azide and heat-inactivated at 60°C for 30min. The serum solution was then 
centrifuged at 13000rpm in an Eppendorf minifuge for 10min to remove any bacteria-sized 
contaminants and the supernatant was used to perform serial dilutions. 25µl serum solution 
and 25µl bacterial suspension were then mixed and incubated for 1h at 4°C. Bacteria were 
washed twice before resuspending in monoclonal FITC-anti-mouse IgG2b or IgA, PE-anti-
mouse IgG1 and APC-anti-mouse IgM (all BD Pharmingen). After a further hour of 
incubation the bacteria were washed once with PBS/1% BSA/Na-Azide and then re-
suspended in 2% PFA/PBS for acquisition on FACSArray using FSc and SSc parameters in 
logarithmic mode. Data were analysed using FlowJo software (Treestar, USA). Total 
concentrations of antibody isotypes in mouse serum were determined by sandwich ELISA. 
Coating antibodies were goat-anti-mouse IgG1, 2b, A and M (Serotech) and detection 
antibodies were HRP-conjugated anti-mouse IgG, IgM or IgA (Sigma). Standards were 
myeloma-derived purified IgG1, IgG2b, IgM (Invitrogen) and IgA (BD Pharmingen).
                                                                  THE ROLE OF LTβR-SIGNALLING IN THE CNS           
74 
 
3. The role of LTβR-signalling in the central nervous system in 
health and disease - a novel mouse model to study chronic 
inflammation and autoimmunity in the CNS 
 
3.1. Introduction 
 
3.1.1. Multiple Sclerosis 
 
Multiple sclerosis (MS) is among the most common neurological diseases in young adults and 
is a leading cause of neurological disability in this age group. In northern Europe and North 
America, the prevalence of MS is 1 in 1000. Worldwide, an estimated number of around 1.5–
2 million people are affected (Hohlfeld, 2009).  
MS is a chronic inflammatory disease of the central nervous system (CNS) characterized by 
focal areas of demyelination, multifocal inflammation, reactive gliosis and oligodendrocyte 
and axonal loss. Increasing evidence supports an autoimmune pathogenesis, with myelin 
antigens as the most plausible targets (Magliozzi et al., 2004). Although MS is thought to be 
primarily mediated by autoreactive T-cells, humoral immune responses also appear to be 
involved (Noseworthy et al., 2000). There are four clinical forms of MS: relapsing-remitting 
(RR), secondary progressive (SP), primary progressive (PP), and progressive relapsing (PR) 
MS. Blood brain barrier damage, prominent infiltration by activated CD4+ T-cells and 
clonotypic CD8+ T-cells, the presence of macrophages with phagocytosed myelin debris, 
reactive astrocytes and proliferating oligodendrocytes are characteristic of acute plaques. In 
chronic plaques, inflammation is less pronounced and generally restricted to the rim of the 
plaque, which exhibits gliosis, while the hypocellular center exhibits axonal and 
oligodendrocyte loss, and variable demyelination (Allavena et al., 2010). 
The aetiology of MS remains elusive and its pathogenesis is only partly understood; however, 
it is assumed that both a complex genetic background and environmental factors (possibly 
including infectious agents) determine the susceptibility to develop the disease. The human γ-
herpes virus - Epstein–Barr virus (EBV) - has long been considered as a biologically plausible 
causative trigger of MS. Although, no data so far explicitly support a direct etiologic role of 
the virus, recent studies allow for the development of testable hypotheses as to how EBV 
infection potentially promotes autoimmunity and central nervous system (CNS) tissue damage 
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in MS (Lunemann and Munz, 2009). In addition respective results indicate that immune 
mechanisms play an essential role in driving the disease process (Lassmann and van Horssen, 
2011). 
3.1.2 Experimental autoimmune encephalomyelitis (EAE), the widely used animal 
model of demyelinating diseases 
 
Autoreactive T lymphocytes appear crucial in the development of demyelinating lesions. 
Their contribution has been studied extensively with the experimental autoimmune 
encephalomyelitis (EAE) model. EAE is an inflammatory demyelinating disease induced 
either by the subcutaneous administration of myelin peptide antigens (e.g., myelin basic 
protein (MBP), proteolipid protein (PLP), myelin oligondendrocyte protein (MOG)) with 
Freund's adjuvant (Keegan and Noseworthy, 2002), which is called active EAE. 
Immunization of rodents with myelin-specific proteins or peptides, leads to the generation of 
encephalitogenic, myelin-reactive, CD4+ effector T-cells. Encephalitogenic T-cells then 
mediate an immune response in the CNS with the formation of perivascular cuffs of 
mononuclear cells primarily in the spinal cord and cerebellum (Muller et al., 2010). In EAE, 
the identity of the target auto-antigen, at least in part, determines the disease phenotype and 
pattern of lesion distribution in the CNS. For example, immune responses to MBP or PLP 
induce lesions located predominantly in the spinal cord whereas immunization with MOG 
generates optic nerve and spinal cord lesions. The clinical phenotypes reported in EAE range 
from monophasic (in Lewis rats with MBP immunization) to relapsing-remitting (in SJL mice 
immunized with PLP or dark agouti rats immunized with MOG) or chronic/chronic 
progressive forms (in C57Bl/6 or NOD mice immunized with MOG) (Bettelli et al., 2003). 
EAE can also be induced by adoptive transfer of myelin-specific T-cells, termed passive EAE 
(Stromnes and Goverman, 2006). A major difference between MS and EAE is that the latter 
requires an external immunization step to develop, whereas in humans, the sensitization to 
auto-antigens is not artificially induced. Sensitization to myelin antigens in EAE typically 
occurs through the use of adjuvant, usually containing bacterial components highly capable of 
activating the innate immune system via pattern recognition receptors (Libbey and Fujinami, 
2011). In EAE, the inducing antigens are known, whereas in MS, there is no unique identified 
antigen (Constantinescu et al., 2011).    
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3.1.3. Immunopathogenesis of multiple sclerosis 
 
3.1.4. Role of the T-lymphocytes 
 
Based on animal experiments in EAE model and observation in human multiple sclerosis, 
research has mostly focused on the role of CD4+ T cells in disease pathogenesis. Figure 30 
depicts the prevailing T-cell centric view of MS pathogenesis.  
CD4+ T helper (Th) cells can be classified into subsets based on their cytokine expression 
(Figure 31). The in vivo pathogenesis of various inflammatory and autoimmune diseases as 
well as protective immune responses tend to be skewed towards specific Th lineages (Becher 
and Segal, 2011).  Major emphasis has been put on the nature of Th cell polarization pattern 
underlying MS. Th1 cells produce pro-inflammatory cytokines such as IFN-γ or TNFα that 
activates macrophages to kill intracellular pathogens. On the other hand, Th2 cells secrete 
anti-inflammatory cytokines such as IL-4, IL-5 and IL-10 which are important in clearing 
extracellular pathogens. A deregulation in the balance between Th1 and Th2 cytokines has 
long been implicated in MS immunopathogenesis (Comabella and Khoury, 2012). Th17 cells 
represent a distinct, newly discovered lineage of effector T cells. IL-23 produced by 
macrophages and dendritic cells is critical for expansion of Th17 cells that synthesize the 
cytokines IL-17A and IL-17F with highly pro-inflammatory properties. Accumulating data 
suggest that Th17-mediated immune responses are very important in host defense but also in 
promoting chronic inflammation and autoimmunity (Korn et al., 2009). 
In MS, the accumulation of IL-17 producing T cells in the circulation and CNS compartments 
correlates with disease activity (Becher and Segal, 2011). Studies in EAE have shown that 
suppression of Th17 cells is associated with a reduction of disease severity, although this is 
becoming an area of debate. Interestingly, the Th17 to Th1 ratio appears to be a critical 
determinant of CNS inflammation, and high Th17 to Th1 ratios are associated with T-cell 
infiltration and inflammation in the brain parenchyma (Comabella and Khoury, 2012).  
There is now accumulating evidence that FOXP3 expressing Treg (CD3+CD4+CD25+) cells are 
engaged in the suppression of a variety of physiological and pathological immune responses. 
Impaired generation of Treg cells or their effector activity may contribute to autoimmune 
diseases such as MS. This cell population is believed to be important in the induction of 
remission and prevention of extensive tissue damage during EAE (Korn et al., 2008). 
Studying human MS patients compared with healthy individuals, the number of circulating 
Treg cells was shown to be decreased (Khoury et al., 2000) or unchanged (Putheti et al., 2004) 
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(Haas et al., 2005). A more recent study shows that relative counts of both CD25+ T 
lymphocytes (CD3+CD25+) and Treg cells were significantly increased in whole blood of MS 
patients compared with healthy individuals. Also the relative counts of CD3+CD8+CD25+ 
lymphocytes displayed increased numbers in MS patients compared with those of healthy 
individuals (Kumar et al., 2006). One possible explanation for this discrepancy could be the 
definition of Treg cells according to the level of CD25 expression (to include only CD25high or 
additionally CD25intermediate population). Another explanation might be that different subgroups 
of MS patients were included in the studies. In vivo depletion of CD25+ Treg cells in a murine 
EAE model resulted in increased severity, both in terms of mean clinical scores and mortality 
(Stephens et al., 2005).  
 
 
 
Figure 30. Scheme of MS immunopathogenesis. Pre-existing autoreactive T cells are activated outside the 
CNS. The activated T cells traverse the blood-brain-barrier and are locally re-activated when they recognize 
‘their’ antigen on the surface of local antigen presenting cells. The activated T cells secrete cytokines that 
stimulate microglia cells and astrocytes, recruit additional inflammatory cells, and induce antibody production by 
plasma cells. Anti-myelin antibodies and activated macrophages/microglia cells are thought to cooperate in 
demyelination (Modified from Hohlfeld et al.; Brain 1997).  
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There are several lines of evidence suggesting an important role of CD8+ T-cells in MS 
immunopathogenesis: (1) CD8+ T-cells are prominent in the inflammatory infiltrate in human 
CNS lesions, and in some studies, CD8+ T-cells outnumber CD4+ T-cells; (2) infiltrating 
CD8+ T-cells are clonally expanded and may persist in the CSF for many years; (3) CD8+ T-
cells may promote CNS vascular permeability; (4) axonal damage was correlated with the 
number of CD8+ T lymphocytes infiltrating the lesion; (5) in animal models adoptive transfer 
of activated myelin-specific CD8+ T-cell clones has been shown to induce EAE, suggesting a 
role for CD8+ T-cells as effector cells in MS pathogenesis (discussed in (Comabella and 
Khoury, 2012)).  
The first hypothetical event in MS pathogenesis is the initial activation of the autoreactive T-
cells in the periphery (reviewed in (Hohlfeld, 1997)).  Based on animal experiments in EAE 
and observations in human MS patients several scenarios have emerged: (1) molecular 
mimicry, during bacterial or viral infection (2) cross-reactivity that occur at the level of TCR 
(in case two types of αβ TCR could form and appear on the cell surface) (3) stimulation of 
viral or bacterial superantigens (Fleischer, 1994) (4) high local concentrations of cytokines 
secreted in the course of unrelated inflammatory reactions. Of note, (5) CNS-reactive T-cells 
may be activated (or reactivated) within the CNS itself. Under normal physiologic conditions 
lymphocytes are able to traffic into the CNS. Resident microglial cells, both perivascular and 
parenchymal, have been identified as competent APCs, thus antigen presentation could be 
accomplished by resident cells or by invading monocytes/macrophages and dendritic cells 
(Bar-Or, 2008).  
 
3.1.5. Role of the B lymphocytes 
 
The predominant view has held that pathology and disease activity in MS is mediated by T-
cells by the peripheral activation of pro-inflammatory CD4+ (Th1, ThIL-17) and CD8+ T 
cells. However, humoral immunity is also considered to play an important role in MS 
pathogenesis as indicated by the persistent intrathecal production of oligoclonal 
immunoglobulins in the CSF from MS patients, a finding that is part of the diagnostic criteria 
for the disease. B-cells may directly participate in the demyelination process by secreting 
pathogenic antibodies that target oligodendrocytes with or without the presence of 
complement (O'Connor et al., 2005).  
 
 
                                                                  THE ROLE OF LTβR-SIGNALLING IN THE CNS           
79 
 
 
 
 
Figure 31. Upon activation, naïve CD4+ T cells differentiate into functionally distinct T cell subsets: Th1, 
Th2, Th17, and Treg under the influence of specific cytokines. These cell subsets express master transcription 
factors (shown underneath the cells) that are required for lineage commitment. Antagonistic actions of IL-4 and 
IFN-γ on Th17 development and of IL-6 on Treg cells are also shown. The fully-differentiated T cell subsets 
secrete specific cytokines that mediate their effector functions. Th1 cytokines will be important in host defence 
against intracellular pathogens such as viruses or intracellular bacteria. Th2 cytokines enhance humoral immune 
responses and will be essential for clearance of extracellular pathogens such as parasites. Th17 cells secrete 
cytokines with strong pro-inflammatory properties that will be involved in the host defence against extracellular 
pathogens such as bacteria. Finally, cytokines produced by Treg cells will play positive roles in 
immunomodulation. EC indicates extracellular; IC, intracellular (Adapted from Comabella et al., 2012).  
 
The presence of tertiary lymphoid organs with germinal centers in the meninges and cerebral 
perivascular spaces (Prineas, 1979) of some patients with secondary progressive MS suggests 
that abnormal lymphoid microenvironments can also form and can be maintained locally in an 
immune privileged site like the CNS and may contribute to the pathogenic process (Magliozzi 
et al., 2007). These lymphoid structures resemble ectopic lymphoid follicles, with FDC 
networks, CXCL13-expressing stromal cells, proliferating B-cells and plasma cells. These 
intrameningeal follicles were observed in patients with secondary progressive MS, but not in 
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relapsing remitting and primary progressive MS (Serafini et al., 2004). It has been recently 
shown that the presence of these B-cell follicle-like structures correlates with an earlier onset 
and more severe disease (Franciotta et al., 2008). The development of such ectopic follicles 
was also shown in SJL mice with relapsing EAE, but could not be detected in C57BL/6 or 
DBA-1 mice after immunization (Magliozzi et al., 2004).  
Recently, clinical trials of a B-cell ablative therapy with rituximab, an anti-CD20 monoclonal 
antibody (which efficiently depletes naïve and memory B-cells), demonstrated a significant 
reduction in new focal inflammatory brain lesions and clinical relapses in patients with RRMS 
(Hauser et al., 2008). Importantly anti-CD20 treatment is independent of secreted antibodies 
since Rituximab does not directly target plasma cells, which implicates an antibody-
independent role of B-cells in the disease activity. The three primary antibody secretion-
independent ways that B-cells potentially impact T-cell activation or regulation are by (1) 
releasing cytokines and chemokines, thus facilitating a local microenvironment favourable to 
evolving cellular autoimmune responses, (2) providing co-stimulatory signals through direct 
B-cell – T-cell interaction (CD40, OX40 or CD 80/86 mediated interactions), or (3) serving as 
antigen presenting cells (Ireland and Monson, 2011) (Pollinger et al., 2009) (Figure 32). 
B-cells are capable of producing a wide variety of pro-inflammatory and regulatory cytokines 
and growth factors that have long been appreciated for their potential to influence B- and T-
cells. Among other important cytokines, B-cells can produce TNFα and LTα, which, in 
addition to IL23, are important factors for potentiating Th17 responses (Ireland et al., 2012). 
 A recent study reports that B-cells of MS patients exhibit abnormal pro-inflammatory 
cytokine responses (including exaggerated production of LT and TNFα), when activated in 
the context of the Th1 cytokine interferon IFNγ or in presence of TLR9 ligand (CpG DNA) 
(Bar-Or et al., 2010). Furthermore, the depletion of B-cells ex vivo and in vivo (in two clinical 
trials of rituximab in RRMS) results in significantly reduced pro-inflammatory responses of 
both CD4 and CD8 T-cells. Importantly they confirmed that secreted factors produced by 
activated B-cells from RRMS patients before treatment can reconstitute the diminished T-cell 
responses observed following in vivo B-cell depletion in the same patients. This finding 
implies that the effect is mediated at least partially by B-cell derived LT and TNFα. 
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Figure 32. Antibody independent roles of B-cells in T-cell activation. (1) releasing cytokines and 
chemokines, thus facilitating a local microenvironment favourable to evolving cellular autoimmune responses, 
(2) providing co-stimulatory signals through direct B-cell – T-cell interaction (CD40, OX40 or CD 80/86 
mediated interactions), or (3) serving as antigen presenting cells. Adapted from (Ireland and Monson, 2011).  
3.1.6. Effects of LT in various EAE models/ in demyelination 
 
Increased levels of LT has been demonstrated during the course of human MS on mRNA and 
protein level (1) in the cerebrospinal fluid (CSF) of MS patients (Matusevicius et al., 1996) 
(2) in the demyelinated plaques (Raine et al., 1998) (3) and in the meninges and white matter 
lesions (Selmaj et al., 1991a) (Lassmann et al, unpublished observations). In vitro studies 
indicate that LTα has a direct cytotoxic role on oligodendrocytes (Selmaj et al., 1991b). 
The presence of LT has been reported in association of CD3+ lymphocytes and microglial 
cells in acute and chronic active MS brain lesions (Selmaj et al., 1991a), and is therefore, 
suggested to be important in the development of demyelination. In the cuprizone induced 
model of demyelination it was shown that presence of LTα − produced by activated 
astrocytes − exacerbated demyelination and that the lack of LTα did not alter the course of 
remyelination (in contrast to the lack of TNFa) or the proliferation of oligodendrocyte 
progenitors during the remyelination phase of the cuprizone model (Plant et al., 2005). 
Further, also enhanced expression of LTβR mostly on microglia during the demyelination 
phase was demonstrated (Plant et al., 2007). This result suggests that LTαβ–LTβR signalling 
between astrocytes and microglia is a primary mediator in the inflammatory demyelinating 
process that occurs during cuprizone treatment.  
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EAE has been induced in several knockout (LTα-/-, LTβ-/- and TNF/LTα-/-) mouse models to 
examine the contribution of LTβR pathway to multiple sclerosis, often with conflicting 
results. A complicating factor in several studies is that disruption of these genes causes 
developmental defects, structural and functional immune deficiencies, such as abnormal 
lymph nodes, altered splenic architecture, and abnormal immune function (Frei et al., 1997) 
(Suen et al., 1997) . In a more recent study immunodeficiency was corrected in LTα-/- mice by 
reconstitution with bone marrow cells (Sean Riminton et al., 1998). However, this “rescue” 
could be influenced by the side effects of irradiation on the integrity of the blood brain barrier 
(BBB). To dissect the role of LT in a system with a full complement of lymph nodes and 
intact lymphoid microenvironment, LTβR pathway was blocked with the fusion protein 
LTβR-Ig in the context of three different EAE models (Gommerman et al., 2003). 
Administration of LTβR-Ig prior to immunization with myelin peptides inhibited disease 
development in a rat monophasic EAE model and prevented late-stage disease relapses in a 
mouse model of relapsing EAE (Figure 33).    
 
 
Figure 33. Effect of LTβR pathway inhibition in different models of EAE. (A) Lewis rats were treated with 
either control human IgG (diamonds), or LTβR-Ig (circles) 1 day prior to immunization with MBP-peptide in 
CFA. (B) Relapses - but not acute disease - are prevented by LTβR-Ig treatment in a chronic murine EAE model. 
SJL mice were treated with control huIgG (diamonds) or LTβR-Ig (circles) 1 day prior to immunization with 
PLP139–151 in CFA. (C) LTβR-Ig treatment does not prevent EAE in a PTx-dependent model. C57BL/6 mice 
were treated with control huIgG (diamonds) or LTβR-Ig (circles) 1 day prior to immunization with MOG35–55 in 
CFA followed by injection of PTx on days 0 and 2 (Adapted from Gommerman et al., 2003).  
 
The authors also proved that disease prevention by LTβR-Ig was due to specific blockade of 
LTα1β2 binding, rather than LIGHT binding to the LTβR. In addition treatment with LTβR-Ig 
was shown to inhibit T-cell infiltration, formation of organized ectopic B-cell follicles and 
synthesis of inflammatory (CXCL10) and lymphoid (CXCL13) chemokines in the inflamed 
CNS during the course of EAE in SJL mice (Columba-Cabezas et al., 2006). 
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3.2. Scientific aims  
 
Although the above described data about the role of LT and chemokines in the CNS indicate 
an important role of LT in autoimmune diseases of the CNS, the identity of cells expressing 
LT as well as the cells receiving and integrating LT remain elusive.  
The goal of this project was to (1) generate a mouse model (GFAP-Lta,Ltb) to study the role 
of astrocyte derived LT in various diseases of the CNS (2) to investigate the contribution of 
LT induced cytokine production and tissue destruction in CNS autoimmunity as well as (3) to 
examine the role of LTβR on specific brain cells in the various models of autoimmune disease 
by using LTβRloxP/loxP mice (Cuprizone, EAE). Furthermore Tg(GFAP-Lta,Ltb) mice were 
crossed with mice bearing myelin oligodendrocyte glycoprotein (MOG)-specific TCR 
transgenic T-cells  (GFAP/TCR) to investigate if double transgenic mice will develop 
spontaneous inflammatory demyelinating disease. 
In future studies, Tg(GFAP-Lta,Ltb) mice could be used to induce primary CNS lymphoma in 
mice (PCNSL). We hypothesize, that the inflammatory environment in the CNS as the 
consequence of LT over-expression would provide an appropriate milieu for adoptively 
transferred B-lymphoma cells derived from Emu c-myc mice. 
 
3.3. Results 
 
3.3.1. Expression of receptors and ligands of the core TNF superfamily in the 
CNS 
 
Several studies attributed an important role to LT in inflammatory CNS diseases. However, 
due to the lack of specific antibodies directed against lymphotoxin and its cognate receptor, 
LTβR, the cell specific expression patterns of these molecules in the CNS remains elusive. 
Therefore, I have tested the expression of the receptors of the core TNF superfamily, TNFR1, 
TNFR2 and LTβR on purified neural cell populations (astrocytes, neurons, oligodendrocytes 
and microglia) from C57BL/6 mice by qPCR analysis (Figure 34). Purity of the cells was 
confirmed by RT-PCR analysis of neural markers compared to cortical expression of a wild 
type mouse (Astrocytes: GFAP; Oligodendrocytes: MBP; Neurons: β-tubulin III; Microglia: 
CD11b) (data not shown). The receptors, Ltβr, Tnfr1 and Tnfr2 are mainly expressed on 
oligodendrocytes and microglial cells, while Ltα and Light shows predominantly neuronal and 
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microglial expression pattern. In contrast Tnfα appears to be highly expressed on 
oligodendrocytes.   
 
 
Figure 34. Distribution of expression of TNF family ligands and receptors on different neural cell types. 
Relative mRNA transcript expression measured by RT-PCR analysis of LTβR, TNFR1, TNFR2, LTα, TNFα and 
Light on oligodendrocytes, astrocytes, neurons and microglia isolated from C57BL/6 mice. mRNA expression in 
the different cells populations was compared to mRNA isolated from the cortex of C57BL/6 mice. 
 
3.3.2. Generation of transgenic mice 
 
Earlier findings indicate that LT expression is upregulated during the course of human MS  
(Raine et al., 1998) (Selmaj et al., 1991a), furthermore studies by Plant et al., claim that the 
absence of lymphotoxin turns mice highly resistant to Cuprizone induced demyelination. In 
order to elucidate the direct role of LT in demyelination and CNS inflammation I generated 
double transgenic mice on C57BL/6N background expressing both LTα and LTβ under the 
control of the human glial fibrillary acid protein promoter (Tg(GFAP-Lta,Ltb)) (Figure 35) 
(Brenner et al., 1994) that drives the expression specifically on astrocytes. Three double 
transgenic, Tg(GFAP-Lta,Ltb) founder mice were identified expressing the respective 
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transgenes and subsequently bred to generate three independent transgenic lines ((GFAP-
Lta,Ltb)#8; (GFAP-Lta,Ltb)#23; (GFAP-Lta,Ltb)#26)). The litter size and the average weight 
of mice were normal, and mice displayed normal behaviour and growth. Since no gender 
dependent qualitative differences were found, both male and female mice were used in the 
further described studies.  
 
 
Figure 35. GFAP –Lta,Ltb transgene structure. The gfa2 promoter contains the human GFAP fragment 
spanning bp -2163 to +47 relative to the transcriptional start site (Brenner et al., 1994).The promoter has the 
natural initiating ATG at bp +15 converted to TTG so that protein synthesis initiates within lymphotoxin. 
Adapted from (Lee Y. et al., Glia 2008). BamHI restriction sites, used for the cloning strategy are indicated. 
 
The level of lymphotoxin expression was different between the three transgenic lines (Figure 
36A), thus we classified Tg(GFAP-Lta,Ltb)#8 as the low expresser,  Tg(GFAP-Lta,Ltb)#23 as 
the intermediate expresser and Tg(GFAP-Lta,Ltb)#26 as the high expresser line. In each 
transgenic line cortex, cerebellum, brain stem and spinal cord (n=2-3) were analysed for 
endogenous LT mRNA expression. Among the different brain regions analysed, the brain 
stem and the spinal cord shows the highest LT expression in the intermediate and high 
expresser transgenic lines compared to wild type littermates.  
Thorough RT-PCR analysis revealed that in Tg(GFAP-Lta,Ltb) mice transgene expression is 
restricted to the CNS, since no LT expression could be detected in other organs such as 
spleen, kidney (Figure 36B). Slightly elevated LTα expression was observed in the liver, 
which did not cause any pathological changes up to 6 months of age (data not shown).  This 
finding is in accordance to several studies, showing that GFAP-driven transgenes may also be 
active outside of the CNS. Endogenous GFAP expression has been reported for several non-
CNS tissues, albeit at levels generally much lower than in astrocytes. These include non-
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myelinating Schwann cells, fibroblasts, liver perisinusoidal stellate cells, respiratory tract 
chondrocytes and lymphocytes (Su et al., 2004). 
 
 
Figure 36. Lymphotoxin expression in three independent double transgenic lines. (A) Endogenous LT 
mRNA expression was analyzed in the cerebellum, cortex, brain stem and spinal cord samples from (GFAP-
Lta,Ltb)#8; (GFAP-Lta,Ltb)#23 and (GFAP-Lta,Ltb)#26  transgenic lines. (B) LT expression is highly specific 
to the CNS, no or very little elevated LT mRNA expression was found outside of the CNS in (GFAP-
Lta,Ltb)#23 mice  (spleen, kidney), however a slight upregulation of LTa in the liver was observed, likely due to 
the activity of the GFAP promoter on hepatic stellate cells (Ito cells).  
 
3.3.3. Astrocyte specific LT over-expression causes early onset of reactive gliosis  
 
I first investigated by immunohistochemistry whether LT overexpression on astrocytes will 
cause pathological changes in the CNS. All three double transgenic lines develop astrogliosis 
already at the age of two months visualized by GFAP staining. The severity of gliosis 
correlates with the relative amount of transgene expression (Figure 37).  
Based on the similar patterns in the observed gliosis in all three transgenic lines I could 
exclude that the phenotype of Tg(GFAP-Lta,Ltb)  mice is a transgenic artefact. Due to the 
higher transgene expression levels in Tg(GFAP-Lta,Ltb)#26 mice I focused for the further 
analyses on this transgenic line. However, the observed phenotype and functional experiments 
were also corroborated in the intermediate expresser line. Besides the astrogliosis further 
histopathological analysis from 3 months old Tg(GFAP-Lta,Ltb)#26 mice and negative 
littermates in the nucleus caudatus revealed enhanced microglia activation (Iba-1) however no 
phagocytic activity (Mac3). Pronounced astrogliosis can be observed (GFAP), in addition the 
astrocyte polarity shows a different distribution compared to wild type mice; Aquaporin 4 is 
reduced in glia limitans but enhanced in astroglial cell bodies in transgenic mice. AQP4 is a 
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water-selective membrane transport protein expressed in astrocytes, strictly distributed in a 
polarized fashion on the astrocyte endfeets. 
 
 
Figure 37. Reactive astrogliosis in Tg(GFAP-Lta,Ltb) mice. GFAP immunoreactivity reveals astrogliosis in all 
three double transgenic lines at the age of two months in the cerebellum and brain stem. The prominence of 
astroglial reaction in various Tg lines correlates with the expressed amount of LTα and LTβ (scale bar: 200 µm). 
Lower panel displays high magnification pictures about GFAP staining in the brain stem of wild type and 
Tg(GFAP-Lta,Ltb) mice (scale bar: 50 µm). 
 
Under normal conditions AQP4 is involved in brain water balance, neuroexcitation and 
astrocyte migration (Li et al., 2011). However, during EAE, within the inflammatory cuff, 
AQP4 redistributes from the endfeet membranes to the parenchymal membranes of the 
astrocyte body. The degree of both alterations was shown to correlate with the amount of 
CNS inflammation and clinical severity of EAE (Wolburg-Buchholz et al., 2009).  
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Figure 38. Detailed histological analysis of Tg(GFAP-Lta,Ltb)#26 mice. Special stainings from 3 months old 
C57BL6 and Tg(GFAP-Lta,Ltb) mice in the nucleus caudatus. Transgenic mice show enhanced microglia 
activation (Iba-1) and astrogliosis (GFAP). Macrophages are visualized by Mac-3 staining, astrocyte polarity by 
Aquaporin 4. Oligodendrocytes and myelin sheet remains unchanged (CNPase) and no axonal damage can be 
found (APP) in the Tg(GFAP-Lta,Ltb) mice (scale bar: 50 µm). 
 
 
Figure 39. T-cell infiltrates in the thalamus and cerebellum of Tg(GFAP-Lta,Ltb)mice.  Numerous 
infiltrating CD3+ cells in Tg mice compared to negative littermates (scale bar: 200 µm) . 
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In Tg(GFAP-Lta,Ltb) mice oligodendrocytes and myelin sheet remains unchanged (CNPase) 
and no dystrophic axons can be found (APP expression) (Figure 38). Furthermore infiltration 
of CD3+ lymphocytes in the CNS parenchyma can also be found starting at three month of 
age (Figure 39). Infiltrating B-cells (B220) were not observed at any time point in any of the 
analysed CNS regions (data not shown).  
The most prominent pathological changes can be seen in the small cerebellar nuclei, thalamus 
and basal ganglia whereas the cortex and white matter show the least severe phenotype. 
3.3.4. The blood brain barrier is intact in three months old transgenic mice 
 
The observed microglial activation and astrogliosis suggest a starting neuroinflammation in 
the CNS of Tg(GFAP-Lta,Ltb) mice. Inflammation in the CNS can be coupled with an 
increased permeability of the blood brain barrier (BBB). The BBB is a selective barrier that 
maintains homeostasis of the brain. Recent work has uncovered a critical role for pericytes in 
the integration of endothelial and astrocyte functions at the neurovascular unit, and in the 
regulation of the BBB (Armulik et al., 2010). The BBB acts as a 'physical barrier' because it is 
formed by the arrangement of tight junctions between adjacent endothelial cells that line 
cerebral microvessels. Small gaseous molecules such as O2 and CO2 can diffuse freely 
through the lipid membranes, and this is also a route of entry for small lipophilic agents, 
including drugs such as barbiturates and ethanol (Abbott et al., 2006). The healthy CNS 
vasculature is impermeable to the passive transport of cells, large hydrophilic molecules such 
as peptides and proteins (like serum albumin), and bioactive compounds present in the blood 
(Armulik et al., 2011). Therefore the integrity of the BBB was tested in Tg(GFAP-Lta,Ltb) 
mice. First, brain sections from 3 months old wild type and transgenic mice were stained to 
visualize endogenous serum albumin extravasation in brain parenchyma (Figure 40A). No 
immunoreactivity against albumin was found in the brain of transgenic mice suggesting the 
presence of an intact BBB. To provide further confirmation that BBB permeability is not 
altered we injected Evans blue (a dye that has a very high affinity to serum albumin) 
intravenously into wild type and Tg mice (Figure 40B). The experiment was done in 
collaboration with Prof. Marco Prinz in Freiburg. The lack of blue colour in wild type and 
Tg(GFAP-Lta,Ltb) brains and spinal cords suggests no gross alteration in BBB permeability.  
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Figure 40. Integrity of the blood-brain barrier. (A) Immunofluorescent staining of extravasated serum 
albumin in brain sections of wild type and transgenic mice. C57BL/6 mice 14 days post irradiation served as a 
positive control. Positive albumin staining (white arrows) indicates increased blood-brain barrier permeability in 
the irradiated mice, but not in Tg(GFAP-Lta,Ltb) mice. (B) Whole brains and spinal cords photographed after 
Evans blue injection. No BBB damage can be seen in wild type or transgenic mice. The blue spots on the spinal 
cord of transgenic mice indicate the presence of meningeal vessels. Mice that suffered mechanic brain injuries 
were used as positive control.  
 
3.3.5. Lymphotoxin over expression in the CNS leads to a local inflammatory 
milieu  
 
LT was shown to play an important role in CNS diseases by being directly cytotoxic to 
oligodendrocytes (Selmaj et al., 1991b). However LT can regulate the expression of 
inflammatory cytokines, homeostatic (lymphoid) chemokines and adhesion molecules, which 
are likely to contribute to the development of an inflammatory environment. To test if 
increased lymphotoxin expression on astrocytes can lead to the generation of an inflammatory 
milieu within the CNS, we investigated chemokine and cytokine expression on mRNA and 
protein level in different brain regions of the Tg(GFAP-Lta,Ltb) mice (Figure 41). Evidence 
is accumulating that lymphoid chemokines (CCL19, CCL21 and CXCL13) play pleiotropic 
roles when expressed in the CNS. During homeostasis, CCL19 and CCL21 may facilitate 
immune surveillance of the subarachnoid space via recruitment of central memory T cells. 
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Conversely, ectopic expression of these chemokines by CNS resident cells was associated 
with triggering microglial activation and/or the recruitment and organization of infiltrating 
leukocytes. These chemokines are induced de novo (CXCL13) or above baseline levels 
(CCL19 and CCL21) in response to certain CNS infections and neoplasms, as well as in the 
setting of autoimmune inflammation. In addition to regulating leukocyte entry across the 
BBB, they have been associated with the development of ectopic lymphoid structures in the 
meninges during chronic EAE and secondary progressive MS (Lalor and Segal, 2010). In 
three months old Tg(GFAP-Lta,Ltb) I found significant induction of Ccl19 and Cxcl13 
mRNA, however Ccl21 remained unchanged (Figure 41A and data not shown). The 
inflammatory chemokines CXCL9 and CXCL10 has been also demonstrated to be produced 
in many diverse pathological conditions of the CNS, such as bacterial and viral meningitis, 
multiple sclerosis, optic neuritis and Alzheimer’s disease (Muller et al., 2010). More recent 
attention has focused on the function of these chemokines in the CNS inflammation. Here I 
demonstrate that in Tg(GFAP-Lta,Ltb) mice inflammatory chemokines, like Cxcl1, Cxcl9 and 
Cxcl10 are induced upon astrocytic LT overexpression (Figure 41A). According to the widely 
held view, CNS immune surveillance is principally mediated by interactions between α4β1-
integrin bearing lymphocytes and VCAM-expressing endothelium (Engelhardt et al., 1998). 
Therefore I have examined the expression of the adhesion molecule Vcam in Tg(GFAP-
Lta,Ltb) mice. Indeed three months old transgenic mice showed an up-regulated Vcam mRNA 
expression, especially in the spinal cord. Furthermore, the highest up-regulation of mRNA 
transcripts and protein levels (Figure 41B) of the described chemokines are found in the 
cerebellum and spinal cord, which corresponds to the distribution of high LT expression. The 
levels of CXCL10 and CXCL13 up-regulation were corroborated on protein level as well, 
supporting the finding that these chemokines are elevated in a LT dependent manner. 
So far no indications of spontaneous autoimmunity or demyelination have been observed.  
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Figure 41. Cytokine and chemokine expression in certain regions of Tg(GFAP-Lta,Ltb) mice. (A) mRNA 
transcript expression of homeostatic chemokines (Cxcl13, Ccl19), inflammatory chemokines (Cxcl1, Cxcl9, 
Cxcl10, Ccl2) and adhesion molecule (Vcam) in the cortex, cerebellum and spinal cord of 3 months old high 
LTαβ expresser transgenic line, Tg(GFAP-Lta,Ltb)#26. (B) Cytokine and chemokine expression on protein 
level, measured in homogenized brain tissue from the forebrain, hindbrain, cerebellum and spinal cord. *: 
P>0.05; **: P<0.01, ***: P<0.001 
 
3.3.6. Exacerbated EAE in Tg(GFAP-Lta,Ltb) mice 
 
So far all experiments aiming to dissect the role of lymphotoxin in demyelinating diseases 
utilized either genetic ablation of ligands (LTα-/-, LTβ-/-) and receptors (LTβR-/-) of the LTβR 
signalling cascade, or applied pharmacological blocking of the LTβR with the LTβR-Ig 
fusion protein. Although in the beginning the results were slightly controversial due to the 
developmental abnormalities that LT knockout mice harbor, the utilization of LTβR led to the 
conclusion in both the cuprizone induced model of demyelination (Plant et al., 2007) and in 
different EAE models (Gommerman and Browning, 2003), that blocking LTβR-signalling 
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profoundly inhibits or delays demyelinating pathologies and reduces relapses. In order to 
assess the direct role of focal lymphotoxin expression, and the LT induced chemokine 
production in the CNS in autoimmunity, we performed active EAE experiment with 
Tg(GFAP-Lta,Ltb)#26 mice. The experiments were done in collaboration with Prof. Marco 
Prinz in Freiburg. Transgenic mice and wild type littermates were immunized with MOG35–55 
in CFA. Two independent experiments were performed with 4-7 animals per group (Figure 
42). In both experiments disease onset after immunization was significantly earlier in 
transgenic mice (6.5 and 9.5 days versus 13 and 14.5 days) compared to negative littermates, 
and the incidence was 100%.  Besides the maximum clinical score as well as the accumulated 
clinical score were significantly higher in Tg(GFAP-Lta,Ltb)#26 mice in both experiments. Of 
note, transgenic mice developed a relapse in both experiments, which was either not observed 
in wild type mice (second experiment) or the clinical score during the relapses remained 
significantly lower than in transgenic mice (first experiment). Histological examination of 
brains 55 days after immunization showed a quantitative difference in mononuclear cells (T- 
and B- lymphocytes, macrophages), however the localization of the infiltrating cells and 
demyelination was similar, mainly in the cerebellum and spinal cord (data not shown).  
 
Figure 42. Active EAE in Tg(GFAP-Lta,Ltb)#26 mice. Transgenic overexpression of LTαβ (circles) 
predisposes mice to an earlier disease onset and significantly higher maximum and accumulative clinical scores 
in two independent experiments compared to wild type littermates (squares). Furthermore all Tg(GFAP-
Lta,Ltb)#26 mice developed a relapse which was not observed in wild type animals.  
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3.3.7. Double transgenic 2D2/GFAP-LT mice display early spontaneous 
neurological symptoms 
 
Despite of the wide use of the EAE model, the factors determining onset, course, distribution, 
and cellular composition of autoimmune lesions in MS remain largely unknown. In particular, 
it is unclear which processes are involved in triggering the disease and which drive 
inflammation during the further course of the disorder. Our unawareness to these vital issues 
is largely due to the lack of suitable animal models that would develop human inflammatory 
demyelinating disease spontaneously and reproduce its essential clinical and molecular 
aspects (Krishnamoorthy et al., 2006). The important unresolved question is how self-reactive 
cells are “spontaneously” activated. Some investigators link the trigger of MS to microbial 
infection or molecular mimicry (Kurtzke, 1993), the opposite has been proposed as well, 
namely that the susceptibility to autoimmune and allergic diseases is related to the decreasing 
prevalence of infections. Here I sought to investigate if the inflammatory environment 
developed in Tg(GFAP-Lta,Ltb) mice contributes to the activation or to the migration of 
autoreactive T-cells in the CNS. Therefore I intercrossed Tg(GFAP-Lta,Ltb) mice with mice 
bearing MOG-specific T-cell receptor (TCR) transgenic T-cells (2D2). A large proportion 
(~50%) of 2D2 mice develops spontaneous optic neuritis, without evidence of clinical or 
histological signs of EAE. However, only approximately 4% of the 2D2 mice develop 
spontaneous inflammatory demyelinating disease in the CNS at the age of 2-2,5 months 
(Bettelli et al., 2003) . Surprisingly 2D2/GFAP-LTab mice showed a very early (28-35 days 
postnatal) onset of symptoms like limp tail and hind leg weakness (Figure 43A), reminiscent 
to EAE. The observed phenotype progressed within 7 days into complete hind limb paralysis 
accompanied by significant weight loss. No relapse was observed in the disease course; 
therefore animals were sacrificed when reaching experimental end point criteria (clinical 
score ≥ 3 persist for 3 days and 15% weight loss) (Figure 43B). Disease incidence was 100% 
among the double transgenic mice, conversely single transgenic 2D2 or Tg(GFAP-Lta,Ltb) 
mice remained free of clinical signs during the observation period.    
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Figure 43. Disease kinetics of spontaneous inflammatory demyelinating disease in double transgenic 
2D2/GFAP-LT mice. (A) Spontaneous incidence of early EAE-like symptoms were observed in double 
transgenic 2D2/GFAP-LT mice housed under SPF conditions (red line, n=16). The disease progressed quickly to 
severe (clinical score>3) symptoms without remission. Single transgenic 2D2 littermates did not show any 
clinical symptoms within the observed time frame (black line, n=13). (B) Relative time of survival (%) of 
2D2/GFAP-LT mice (red line n=16) compared to single transgenic littermates (black and blue lines, n=13). 
Double transgenic mice succumb to death in 100% while single transgenic littermates remain symptom free.  
 
3.3.8. Histopathological analysis of CNS lesions 
 
Since the 2D2/GFAP-LT mice spontaneously develop neurological symptoms similar to those 
observed in EAE, I examined tissue sections from the brain and spinal cord of double 
transgenic mice to assess if they also develop an inflammatory demyelinating pathology. 
2D2/GFAP-LT mice were sacrificed approximately 10 days after the first symptoms 
appeared, along with single transgenic (2D2 and Tg(GFAP-Lta,Ltb)) littermates as controls. 
Localization and cellular composition of the lesions was determined by immunohistochemical 
stainings (Figure 44). Inflammatory infiltrates were dominated by mononuclear cells. Severe 
inflammatory cell infiltrations were found in the brain stem meninges (n=13) and cerebellum 
(n=3) of double transgenic mice (Figure 44A). However, the most prominent pathological 
changes were observed in the spinal cord, especially in the lumbar region (n=16) (Figure 
44B). Although, the localization of the lesions resembles those usually found in the EAE 
model, importantly in 2D2/GFAP-LT mice high percent of the infiltrating cells are B-cells, a 
phenomenon reminiscent to human MS infiltrates, but rarely observed in EAE model in 
C57BL/6 mice. Besides the B-cells, CD3+ T-cells and Mac-3+ macrophages were also found 
in the spinal cord lesion of double transgenic mice, concomitant with profound inflammatory 
demyelination (LFB) (Figure 44B and Figure 45). Age matched single transgenic 2D2 or 
Tg(GFAP-Lta,Ltb) mice did not display any pathological alterations. 
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Figure 44. Histological analysis of the CNS from sick 2D2/GFAP-LT mice. (A) Immunohistochemical 
characterization of the infiltrates in cerebellum and brain stem meninges of double transgenic mice and 2D2 
single transgenic littermates. HE, B220+ B-cells and CD3+ T-cells are indicated (scale bar: 500 µm).  (B) Special 
stainings in the spinal cord of 2 independent double transgenic mice compared to a single transgenic 2D2 mice. 
Demyelination is visualized by LFB stainings, infiltrating macrophages (MAC-3), T-cells (CD3) and B-cells 
(B220) are indicated (scale bar: 50 µm).  
 
The lesions in 2D2/GFAP-LT mice were circumscribed rather than diffuse, and interestingly 
displayed follicle like structures in brain stem meninges (Figure 46) and in the spinal cord 
(Figure 47). A great number of human SPMS cases were reported to contain B-cell follicle 
like structures in the cerebral meninges, which were identified based on the presence of 
Ki67+/CD20+ proliferating B-cells, plasma cells, T-cells and CD35+ FDCs (Howell et al., 
2011).  To confirm the presence of such follicle-like structures in the spinal cord of 
2D2/GFAP-LT mice I analysed spinal cord cross section from 4 independent 2D2/GFAP-LT 
mice, with a clinical score of 3.  Immunohistochemistry identified a high number of B-cells, 
CD4+ T-cells, however only very few CD8+ T-cells (Figure 47). 
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Figure 45. Spinal cord cross sections in 2D2/GFAP-LT mice. Cross sections of the spinal cord from 
2D2/GFAP-LT mouse, showing the extent of demyelinated area (LFB) and inflammatory infiltrates. 
Macrophages (MAC-3), T-cells (CD3) and B-cells (B220) are indicated (scale bar: 500 µm).   
 
Figure 46. B-cell infiltrates in the brain stem meninges of 2D2/GFAP-LT mice. B220+ B-lymphocytes in two 
independent double transgenic mouse with clinical score 3 localized in the brain stem meninges. 
 
The low frequency of CD8+ T-cells is characteristic for the 2D2 transgenic mice. 2D2 mice 
show a skewing toward CD4+ T-cells in spleens, as well as the CD4/CD8 single positive ratio 
in thymus is biased toward CD4+ compartment (Bettelli et al., 2003). Furthermore I observed 
CD21/35+ germinal center B-cells as well as FDC networks in the infiltrates, which 
corroborates the development of ectopic lymphoid follicles in 2D2/GFAP-LT mice. None of 
the single transgenic parental lines displayed follicle-like infiltrates in the CNS.  
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Figure 47. Histological analysis of inflammatory infiltrates in the spinal cord of 2D2/GFAP-LT mice. 
H/E, CD4+ T-cells, CD8+ T-cells, B220+ B-cells, CD21/35+ germinal center B-cells (scale bar: 500 µm) and 
FDC-M1+ follicular dendritic cells and networks are indicated (scale bar: 100 µm).  
 
3.3.9. Quantification of immune cells within the CNS lesion in 2D2/GFAP-LT 
mice 
 
To gain a quantitative and qualitative overview of the immune cell populations in the spinal 
cord of sick 2D2/GFAP-LT mice, age matched wild type and single transgenic 2D2 and 
Tg(GFAP-Lta,Ltb) mice, we performed flow cytometry on Percoll gradient separated 
infiltrate cells. Large numbers of inflammatory cells were recovered from the spinal cords of 
sick 2D2/GFAP-LT mice in contrast to healthy 2D2 and Tg(GFAP-Lta,Ltb) single-transgenic 
animals, which yielded only very few inflammatory cells (Figure 48). Consistent with the 
histological evaluation, a drastic increase in lymphocytes, predominantly in CD4+ T-cells, B-
220+ B-cells and regulatory T-cells was observed, along with significantly elevated 
granulocyte (CD11b+Ly6G+) and inflammatory monocyte (CD11b+Ly6Chi) population. Of 
note, double transgenic animals displaying less severe (clinical score 2) symptoms were also 
analysed and included in the quantification, which most likely explains why the particular 
subsets of lymphocytes did not reach statistical significance. However, a clear trend towards 
increased numbers of CD4+ T-cells, B-220+ B-cells can be seen.  
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Figure 48. Flow cytometric analysis of CNS infiltrating mononuclear cells. (A) CNS mononuclear cells 
isolated by Percoll gradient centrifugation from sick 2D2/GFAP-LT mice, age matched wild type and single 
transgenic 2D2 and Tg(GFAP-Lta,Ltb) mice were stained with CD45, CD11b. Lymphocytic population was 
identified as R1 (CD45hi, CD11b-) and CD4, CD8, B220, CD25, FoxP3 expression was analysed in the gated R1 
population. Monocyte population was classified as R2 (CD11b+) where Ly6C and Ly6G was further analysed. 
(B) Quantification of total cell count of CD4+, CD8+, B220+ lymphocytes, Regulatory T-cells, and 
CD11b+Ly6G+ granulocytes, CD11b+Ly6Chi inflammatory monocytes and CD11b+Ly6Clow resident monocytes 
in sick 2D2/GFAP-LT mice, age matched wild type and single transgenic 2D2 and Tg(GFAP-Lta,Ltb) mice.    *: 
P<0.05;  
3.3.11. Migration of immune cells from the spleens of sick 2D2/GFAP-LT mice 
 
To investigate macroscopic alterations outside of the CNS in double transgenic mice, I first 
evaluated the size of the spleen. Interestingly spleens from 2D2/GFAP-LT appeared to be 
smaller than spleens from the single transgenic 2D2 littermates. This drastic decrease in the 
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size of the spleen was reflected by a highly significant reduction in the number of splenocyte 
measured by flow cytometry (Figure 49). This finding implies that T-cells bearing MOG 
specific T-cell receptors might migrate directly from the spleen to the CNS.  
 
 
Figure 49. Significant reduction in total number of splenocytes in double transgenic mice. The observed 
decrease in the size of the spleen in 2D2/GFAP-LT animals was corroborated by flow cytometric analysis of the 
total number of splenocytes. Double transgenic mice with clinical score display significant decrease in the 
number of splenocytes compared to 2D2 single transgenic littermate.  
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3.4. Discussion 
 
Multiple sclerosis is a complex immune mediated disease of the central nervous system. Its 
aetiology is currently unknown and its pathogenesis is only partly understood (Lassmann and 
van Horssen, 2011).  Active MS lesions display inflammatory changes suggestive of a 
combined attack by autoreactive T- and B-cells against the CNS (Franciotta et al., 2008). 
Previous studies using various knock out models of the LTβR-signalling as well as 
pharmacological blocking of LTβR (LTβR-Ig) proposed an important role for LT in 
demyelinating processes, most notably in the pathogenesis and progression of multiple 
sclerosis. To elucidate the contribution of lymphotoxin to CNS inflammation and 
demyelination I generated a transgenic mouse model with astrocyte specific overexpression of 
LTα and LTβ. Tg(GFAP-Lta,Ltb) mice develop neuroinflammation, presented as prominent 
astrogliosis and microgliosis concomitant with numerous T-cell infiltration already at the age 
of eight-twelve weeks. The blood brain barrier was shown to be intact in transgenic mice. 
Already at the age of three months significant up-regulation of pro-inflammatory (CXCL1, 
CXCL9 and CXCL10) and homeostatic chemokines (CXCL13, CCL19) and adhesion 
molecule (VCAM) was observed on mRNA and partially on protein level.  Mice were 
followed up histologically until 12 months of age. Importantly, Tg(GFAP-Lta,Ltb) mice when 
immunized with MOG 35-55 developed a significantly earlier disease onset and more severe 
disease manifestation compared to wild type littermates. Of note, within the investigated 
timeframe Tg(GFAP-Lta,Ltb) mice did not develop any signs of spontaneous demyelination 
and autoimmunity.  
Spontaneously developing organ-specific autoimmune disease models in rodents are rare. The 
goal of the new generation mouse models is not only to closely resemble human disease 
clinically and histologically but also to develop spontaneously without artificial manipulations 
such as immunization or lymphocyte transfers (Wekerle et al., 2012). So far the best example 
for such a model was the NOD mouse model, which fulfils these requirements for the study of 
human autoimmune diabetes mellitus. Furthermore the Tg(Ela1-Lta,b) mice, I presented in 
my thesis represents a novel mouse model mimicking the spontaneous development of human 
AIP. Spontaneous autoimmune disease was also reported in the CNS. Several different TCR 
transgenic models with spontaneous EAE-like symptoms have been reported over the past 
years. Most of these are based on CD4+ T cells that recognize myelin basic protein (MBP) 
(Lafaille et al., 1994) (Goverman et al., 1993), myelin proteolipid protein (PLP) (Waldner et 
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al., 2000), or MOG (Bettelli et al., 2003) (Anderson et al., 2012; Pollinger et al., 2009)  on 
different genetic backgrounds. Low frequency (<15% under conventional and 0% under SPF 
conditions) of spontaneous disease development was observed in mice with a TCR specific 
for MBP in the context of I-Au (Goverman et al., 1993) (Lafaille et al., 1994), and MOG 
specific TCR transgenic mice on C57BL/6 background (2D2) (Bettelli et al., 2003). The 
frequency increased in the absence of regulatory lymphocytes in these mice when intercrossed 
with Rag1 deficient mice (Lafaille et al., 1994). Remarkably, mice expressing PLP specific 
TCRs on CD4+ T-cells on SJL background develops spontaneous EAE in 40-67% (Waldner 
et al., 2000) on SPF background without any further intercrossing. Although these models 
have contributed greatly to our understanding on the role of CD4+ T cells in CNS 
autoimmunity, increasing evidence suggests that CD8+ T cells and B-cells are also important 
in the pathogenesis of MS. The first TCR transgenic mice that harbour both myelin-reactive 
CD4+ and CD8+ T on NOD background (1C6) (Anderson et al., 2012)  display signs of 
spontaneous disease development in approx. 1%. To study the immune response and 
development of disease in hosts that have CD8+ T and/or CD4+ cells as well as B-cells that 
recognize the same myelin antigen (MOG), 2D2 and 1C6 mice were crossed to IgHMOG 
knock-in mice. If MOG reactive CD4+ T cells (from 2D2 TCR Tg) and MOG-reactive B cells 
(from IgHMOG knock-in) coexist on the C57BL/6 background, the mice develop spontaneous 
disease with 50% incidence and exhibit a distinct pathological pattern in which lesions are 
localized mostly in the spinal cord and optic nerve (Bettelli et al., 2006)  (Krishnamoorthy et 
al., 2006). Moreover, those mice exhibit development of ectopic lymphoid follicle-like 
structures in the spinal meninges. Notably, 1C6 x IgHMOG mice developed spontaneous 
disease with 45-79% incidence with an average age of onset of 15 weeks (Anderson et al., 
2012).  
The stimuli triggering MS pathogenesis has been commonly attributed to environmental 
factors, in particular microbial infection (Ascherio and Munger, 2007). To this end, a study 
with the relapsing-remitting model of EAE (SJL/J mice with increased proportions of MOG- 
specific autoimmune CD4+ T-cells simultaneously develop a relapsing-remitting EAE) 
(Pollinger et al., 2009) has established that CNS autoimmune T-cells are activated and 
become pathogenic after interaction with the healthy, commensal gut flora (Berer et al., 
2011). Apart from activation by molecular mimicry autoreactive T-cells could also be 
stimulated by the exposure of high local concentrations of cytokines (Hohlfeld, 1997). 
Therefore, I utilized the novel Tg(GFAP-Lta,Ltb) mouse model with CNS specific 
inflammation and intercrossed with mice bearing transgenic T-cells expressing MOG specific 
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T-cell receptors (2D2). The 2D2/GFAP-LT mice developed a very early onset of spontaneous 
inflammatory demyelinating disease. The incidence of the neurological symptoms, with ataxia 
and classical paralysis was 100%. Histological and flow cytometry analysis confirmed that 
double transgenic 2D2/GFAP-LT mice develop severe inflammatory cell infiltration 
(predominantly CD4+ T-cells, B-220+ B-cells and Mac-3+ macrophages) concomitant with 
prominent demyelination primarily in the cerebellum, brain stem and spinal cord. The 
inflammatory infiltrates resemble tertiary lymphoid tissues, which can also be found mostly in 
the meninges of human MS patients (Prineas, 1979) (Howell et al., 2011). In this novel 
2D2/GFAP-LT substantial amount of infiltrating inflammatory cells are B-cells, which are 
only rarely observed in active EAE models or in the above discussed spontaneous EAE-like 
models. This allows us in the future, to investigate the antibody-independent role of B-cells in 
the disease pathogenesis.  
Here I hypothesized that auto-reactive MOG specific T-cells get activated in the peripheral 
lymphoid tissues. In response to a cytokine and chemokine gradient resulting from the 
expression of lymphotoxin and its downstream targets, these activated autoreactive T-cells 
will migrate to the CNS. Thus, astrocyte derived LT induces a local inflammatory 
environment favourable of evolving autoimmune responses. As the next step, MOG specific 
T-cells get reactivated in the CNS upon meeting their target antigen, which triggers the further 
release of cytokines and soluble mediators. These processes contribute to the disruption of the 
BBB, and stimulate chemotaxis, resulting in a second wave of inflammatory cell recruitment. 
This time also antigen specific B-cells will migrate to the CNS and elicit multifaceted 
functions, either in T-cell activation or antibody production, causing disease exacerbation. 
Factors that attract B-cells are likely the homeostatic chemokines (e.g. CXCL13 and CCL19) 
whose production is most likely triggered by LT in the GFAP/2D2 system. This would imply 
to a role for LT in disease relapses. 
The second possibility is that autoreactive T-cells get activated within the CNS. Resting auto-
reactive T-cells may leave small blood vessels in the CNS at a very low rate. In the 
2D2/GFAP-LT model the number of attracted antigen-specific T-cells is greater than in the 
single transgenic 2D2 mice, consequently the chance that a MOG-specific CD4 T-cell reaches 
the parenchyma of the brain is much higher in the 2D2/GFAP-LT transgenic mice. If they 
recognize an antigen presented by the brain’s resident antigen-presenting cells, they might 
become activated within the CNS, which results in local clonal expansion and recruitment of 
further inflammatory cells, including self-antigen specific B-cells. Due to the higher LT 
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concentration and the presence of lymphoid chemokines (CXCL13 and CCL19) the 
infiltrating cells form ectopic lymphoid follicles.  
This is the first study to our knowledge that describes the role of local CNS immunity in 
attracting myelin specific T-cells, facilitating to study the initiation and pathogenesis of a 
complex spontaneous demyelinating autoimmune disease.     
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3.5. Outlook 
 
(1) First of all, I plan to intercross the intermediate LT expresser transgenic line (GFAP-
Lta,Ltb#23) with the 2D2 transgenic mice, to elucidate the disease pathogenesis, e.g. the 
disease onset and the localization of the possible lesions. The aim is to see if lower level and 
different distribution of LT expression would alter the development of spontaneous 
inflammatory demyelinating disease.    
(2) According to the hypothesis, autoreactive T-cells in 2D2/GFAP-LT mice can also get 
activated inside of the CNS. Therefore, we would like to analyse with flow cytometry the 
activation status of CD4+ T-cells in the CNS (CD62L, CD25, CD44) in the spleen and in the 
cervical LNs (CNS draining peripheral lymph nodes). Alternatively to the hypothesis I 
proposed in my discussion, it is well possible that B-cells arise before transgenic T-cells 
infiltrate the CNS. Therefore we would like to perform a time-course analysis on day 21 and 
day 30 post natal and investigate lymphocyte subpopulations by immunohistochemistry and 
flow cytometry.  
(3) Next, I would like to determine the CD4+ T helper cell (Th) polarization pattern 
underlying the spontaneous disease in double transgenic mice. Th cells can be classified into 
subsets (Th1, Th2, Th17 and Treg) based on their distinct cytokine expression and master 
transcription factors that are required to linage commitment. Therefore, I will analyse these 
cytokines and transcription factors by RT-PCR, in the spinal cord and spleen of double 
transgenic mice as well as in 2D2 and Tg(GFAP-Lta,Ltb) single transgenic littermates for 
control.  
(4) To describe the inflammatory cells in more detail I also plan to characterize the specific B-
cell receptors and T-cell receptors on the infiltrating cells in the CNS.  
(5) Increased intrathecal production of immunoglobulins in the CSF is observed in more than 
90% of MS patients. These Igs include IgG, IgM, IgD, and IgA. Concurrent elevations of Igs 
are not observed in the serum, indicating that the immunoglobulins are produced locally 
within the CNS. Cerebrospinal IgG and IgM usually demonstrate an oligoclonal pattern when 
the proteins are separated by electrophoretic methods (Cross et al., 2001). In sick double 
transgenic mice, I will test for the presence of the various immunoglobulin subclasses and 
oligoclonal IgG in brain homogenates. Furthermore, I would like to test sera of sick 
2D2/GFAP-LT as well as 2D2 and Tg(GFAP-Lta,Ltb) mice to confirm if anti-MOG 
antibodies have undergone class switch from IgM to IgG. 
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(6) To examine the importance of B-cells in the development and course of spontaneous 
inflammatory demyelinating disease, I set out to deplete B-cells in the 2D2/GFAP-LT model 
with a monoclonal anti-mouse CD-20 antibody. Moreover, I also plan to administer LTβR-Ig 
to investigate if blocking LTβR-signalling would delay or alter the course of spontaneous 
disease development. First both treatments will be given prophylactically; Mice will be 
treated starting from day 20 (approximately 10 days before onset), on a weekly basis with 
either LTβR-Ig or anti CD-20 antibody. In case this treatment induces a beneficial effect in 
double transgenic mice, we plan to repeat the treatment in a more physiological setting, 
namely to start administering the drug once the symptoms have become clinically apparent 
(clinical score 1). Treatment efficacy will be monitored in case of anti CD-20 antibody by 
quantifying B-cells in the peripheral blood. To monitor LTβR-Ig treatment, absence of 
germinal centers and FDC-networks will be confirmed in spleens.  
(7) Furthermore, I would like to establish the passive EAE protocol (adoptive transfer of T-
cells from MOG TCR transgenic (2D2) mice, stimulated with MOG). I plan to use this model 
in Tg(GFAP-LTa,LTb) mice on Rag1-/- background. This would enable me to elucidate the 
importance of B-cells in the initiation of EAE, given that the only lymphocytes present in this 
setting will be the auto-reactive T-cells.  
(8) In order to examine the role of LTβR on specific brain cells, and to define the cell type 
that responds to LT, I intercrossed Tg(GFAP-LTa,LTb) mice to  LTβRloxP/loxP mice in 
combination with using the oligodendrocyte specific Cre-deleter line (MOGi-Cre) as well as 
the neuron specific Nestin-Cre line. Here, my aim is to investigate whether the direct cross-
talk between astrocyte derived lymphotoxin and oligodendrocytes or neurons could contribute 
to the observed astrogliosis and microgliosis in Tg(GFAP-LTa,LTb) mice.   
(9) Additionally, I would like to induce EAE in mice lacking LTβR on either 
oligodendrocytes or neurons, to test the possible importance of LTβR locally in the CNS in 
EAE development.  
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3.6. Material and Methods 
 
Generation of Tg(GFAP-Lta,Ltb) mice : The Ela promoter from the ELa1-Lta,b expression 
constructs was cut out by Not I, BamH I double digest and the remaining DNA expression 
vector cassettes purified (LTa-expression cassette; LTb expression cassette). The gfa2-lacZ 
plasmid was used as template to amplify the promoter sequence. This plasmid  is a pUC 
vector containing the human GFAP sequences from -2163 to +47 (the human gfa2 segment), 
with the initiating ATG mutated to TTG, placed in front of the standard, cytoplasmic, E. coli 
lacZ gene, which in turn is followed by a fragment of the mouse protamine-1 (mP-1) gene 
(Brenner et al., 1994).  The latter supplies an intron, stabilizing 3' UTR, and a polyadenylation 
signal.  The lacZ gene was excised by digestion with BAMH I, retaining the mP-1 segment.   
The fwd primers for both LTa and LTb were designed with a 24 base overhang to create a 
BamH I cut site. The PCR products of LTa and LTb were ligated separately to the gfa2 
promoter using a T4 DNA Ligase (New England Biolabs). The positive clones were selected 
and analyzed by sequencing (Microsynth). Bacterial colonies containing the GFAP-LTa and 
GFAP-LTb constructs were then picked, cultivated and screened by digestion with BamHI. 
After sequencing, plasmids and subsequent linearization microinjection was performed into 
pronuclei of C57BL/6N zygotes with equimolar ratio of independent, linearized constructs 
harbouring each the Lta and Ltb murine cDNA.  
Upon PCR analysis, from 35 born offspring, 3 were identified harbouring both LTa and LTb 
transgenes. All three potential founder lines expressed the transgenes on mRNA level in the 
brain and spinal cord.  
 
Evans Blue: Evans blue (400 ml 1% Evans blue dye in PBS) was intravenously administered. 
4 hours later mice were euthanized, and intracardiac perfusion was performed through the left 
ventricle with cold PBS to remove intravascular albumin-Evans blue. Brains and spinal cords 
were removed. Pictures were obtained with a Canon Power shot G6 camera. As a positive 
control, mice, in which a mechanical lesion was set in the cerebrum to disrupt the blood brain 
barrier was used. 
 
RNA isolation from CNS tissue: Mouse tissue or cells were rapidly dissected, snap frozen in 
isopentane, and stored at −80 °C. Total RNA was prepared according to the TRIzol method 
(Invitrogen). 
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Real-time polymerase chain reaction: For mRNA expression analysis Real-time PCR was 
performed using Fast Start SYBR Green Master Rox (Roche). Primers were custom made by 
Microsynth. Real-time PCR was performed on an ABI PRISM 7900 HT Fast Real-Time PCR 
System (AB). Data were generated and analyzed using SDS 2.4 and RQ manager 1.2 
software. The mRNA expression levels were normalized to the housekeeping gene Gapdh. 
 
 
Cytokine Protein array and Immunoglobulin measurement: Cytokine protein levels from 
mouse CNS tissues were measured using a multiplexed particle-based flow cytometric 
cytokine assay (Vignali et al., 2000). Kits were purchased from BioRad (Ismaning, Germany) 
and R&D Systems (Oxon, UK) and Millipore (Zug, Switzerland). The procedures closely 
followed the manufacturer’s instructions. The analysis was conducted using a conventional 
flow cytometer (Guava EasyCyte Plus, Millipore, Zug, Switzerland) Multiplexed particle-
based flow cytometric assays. Protein concentration from CNS homogenates were determined 
by BCA (explain, vendor) assay, and final cytokine concentrations were normalized to total 
protein concentrations.   
 
Induction of EAE: Female 8–10 weeks old mice from each group were immunized 
subcutaneously with 200 μg of MOG35–55 peptide emulsified in complete Freund's adjuvant 
containing 1 mg of Mycobacterium tuberculosis (H37RA, Difco Laboratories). The mice 
received intraperitonal injections of 250 ng pertussis toxin (List Laboratories) at the time of 
immunization and 48 h later. Animals were observed daily and neurological deficits were 
quantified on an arbitrary clinical scale: 1, limp tail; 2, hind limb weakness or abnormal gait; 
2.5: unilateral hind limb paralysis; 3, complete bilateral hind limb paralysis;  3.5, complete 
bilateral hind limb paralysis and partial fore limb paralysis 4, moribund, complete paralysis; 
5, death. 
 
CNS Mononuclear Cell Isolation: At the end stage of disease, mice were anesthetized, 
perfused with 20 mL of ice cold PBS. Spinal cord tissue samples were collected and 
homogenized mechanically in dissecting medium (50 ml 1x HBSS, 650 µl 45% Glucose, 750 
µl 1M HEPES). After centrifugation (300xg, 10 min) pellet was resuspended in 70% Sucrose. 
Mononuclear cells were collected from the 35%/30% interface of a Percoll gradient after 
centrifugation at 450×g for 25 min at 4°C. Collected cells were washed once with FACS 
buffer (10 ml FCS, 10 ml 5M EDTA pH8) and stored on ice for further use. 
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Flow Cytometry: Fluorescence staining of cell samples was performed using the following 
mouse specific antibodies: anti-CD45-pacific blue, anti-CD11b-FITC/APC, anti-B220-Biotin, 
anti-CD4- PerCP, anti-CD8a-PE, anti-Ly6C-PE-Cy7, anti-CD115-PE, anti-Ly6G-FITC, anti-
CD25-APC and the strepavidin-APC complex (all eBioscience). Intracellular staining of 
Foxp3 was performed with the corresponding staining kits (eBioscience) according to the 
manufacturer's protocol. Samples were acquired using a Canto II flow cytometer (BD) and 
data analyzed using FlowJo (TreeStar). 
 
 
Histology: For histological analysis, spinal cords were dissected, tissues were fixed either in 
4% buffered formalin fixed and embedded in paraffin or in snap frozen in OCT media. For 
immunohistochemical analysis of spinal cord tissues, we used monoclonal rat anti-mouse 
MAC3 (clone M3/84; BD Biosciences), monoclonal rat anti-human/mouse CD3 (clone CD3-
12; Serotec), monoclonal rat anti-mouse B220 (clone RA3-6B2; Serotec), and monoclonal 
mouse anti-amyloid precursor protein (clone 22C11; Chemicon), Luxol fast blue, anti-AQP4 
(rabbit polyclonal; Sigma, Germany) and anti-GFAP FDCM-1 (BD Biosciences cat. Nr. 
551320), anti-CD21/35 antibodies (BD Biosciences cat. Nr. 553817 rat monoclonal (7G6)). 
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